BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer. 2010;10:165-180. [PMID: 20179713 DOI: 10.1038/nrc2806] [Cited by in Crossref: 763] [Cited by in F6Publishing: 762] [Article Influence: 63.6] [Reference Citation Analysis]
Number Citing Articles
1 Xu H, Zhang F, Gao X, Zhou Q, Zhu L. Fate decisions of breast cancer stem cells in cancer progression. Front Oncol 2022;12:968306. [DOI: 10.3389/fonc.2022.968306] [Reference Citation Analysis]
2 Zapata-Mercado E, Biener G, McKenzie DM, Wimley WC, Pasquale EB, Raicu V, Hristova K. The efficacy of receptor tyrosine kinase EphA2 autophosphorylation increases with EphA2 oligomer size. J Biol Chem 2022;:102370. [PMID: 35970390 DOI: 10.1016/j.jbc.2022.102370] [Reference Citation Analysis]
3 Jiao Z, Feng X, Cui Y, Wang L, Gan J, Zhao Y, Meng Q. Expression characteristic, immune signature, and prognosis value of EFNA family identified by multi-omics integrative analysis in pan-cancer. BMC Cancer 2022;22:871. [PMID: 35945523 DOI: 10.1186/s12885-022-09951-0] [Reference Citation Analysis]
4 Miyazaki T, Chen S, Florinas S, Igarashi K, Matsumoto Y, Yamasoba T, Xu ZQ, Wu H, Gao C, Kataoka K, Christie RJ, Cabral H. A Hoechst Reporter Enables Visualization of Drug Engagement In Vitro and In Vivo: Toward Safe and Effective Nanodrug Delivery. ACS Nano 2022. [PMID: 35942986 DOI: 10.1021/acsnano.2c03170] [Reference Citation Analysis]
5 Qu B, Han Y, Liang T, Zhang C, Hou G, Gao F. Evaluation of a novel EphA2 targeting peptide for triple negative breast cancer based on radionuclide molecular imaging. Arabian Journal of Chemistry 2022. [DOI: 10.1016/j.arabjc.2022.104211] [Reference Citation Analysis]
6 Sachdeva A, Hart CA, Kim K, Tawadros T, Oliveira P, Shanks J, Brown M, Clarke N. Non-canonical EphA2 activation underpins PTEN-mediated metastatic migration and poor clinical outcome in prostate cancer. Br J Cancer. [DOI: 10.1038/s41416-022-01914-3] [Reference Citation Analysis]
7 Zhao W, Liu L, Li X, Xu S. EphA10 drives tumor progression and immune evasion by regulating the MAPK/ERK cascade in lung adenocarcinoma. Int Immunopharmacol 2022;110:109031. [PMID: 35839564 DOI: 10.1016/j.intimp.2022.109031] [Reference Citation Analysis]
8 Banerjee SL, Lessard F, Chartier FJM, Jacquet K, Osornio-Hernandez AI, Teyssier V, Ghani K, Lavoie N, Lavoie JN, Caruso M, Laprise P, Elowe S, Lambert JP, Bisson N. EPH receptor tyrosine kinases phosphorylate the PAR-3 scaffold protein to modulate downstream signaling networks. Cell Rep 2022;40:111031. [PMID: 35793621 DOI: 10.1016/j.celrep.2022.111031] [Reference Citation Analysis]
9 Bhatia S, Nguyen D, Darragh LB, Van Court B, Sharma J, Knitz MW, Piper M, Bukkapatnam S, Gadwa J, Bickett TE, Bhuvane S, Corbo S, Wu B, Lee Y, Fujita M, Joshi M, Heasley LE, Ferris RL, Rodriguez O, Albanese C, Kapoor M, Pasquale EB, Karam SD. EphB4 and ephrinB2 act in opposition in the head and neck tumor microenvironment. Nat Commun 2022;13:3535. [PMID: 35725568 DOI: 10.1038/s41467-022-31124-7] [Reference Citation Analysis]
10 Borggaard XG, Nielsen MH, Delaisse J, Andreasen CM, Andersen TL. Spatial Organization of Osteoclastic Coupling Factors and Their Receptors at Human Bone Remodeling Sites. Front Mol Biosci 2022;9:896841. [DOI: 10.3389/fmolb.2022.896841] [Reference Citation Analysis]
11 Poornima K, Francis AP, Hoda M, Eladl MA, Subramanian S, Veeraraghavan VP, El-Sherbiny M, Asseri SM, Hussamuldin ABA, Surapaneni KM, Mony U, Rajagopalan R. Implications of Three-Dimensional Cell Culture in Cancer Therapeutic Research. Front Oncol 2022;12:891673. [PMID: 35646714 DOI: 10.3389/fonc.2022.891673] [Reference Citation Analysis]
12 Liu C, He Y, Feng X, Li J, Wang J. Expression of EPHA5 in lung adenocarcinoma is associated with lymph node metastasis and EGFR mutation. APMIS 2022;130:338-45. [PMID: 35332588 DOI: 10.1111/apm.13222] [Reference Citation Analysis]
13 Wang Y, Meng T, Su S, Han L, Zhu N, Jia T. Copper‐Catalyzed Chan‐Lam Coupling of NH‐Diaryl Sulfondiimines. Adv Synth Catal 2022;364:2040-6. [DOI: 10.1002/adsc.202200279] [Reference Citation Analysis]
14 Kakarla M, ChallaSivaKanaka S, Dufficy MF, Gil V, Filipovich Y, Vickman R, Crawford SE, Hayward SW, Franco OE. Ephrin B Activate Src Family Kinases in Fibroblasts Inducing Stromal Remodeling in Prostate Cancer. Cancers (Basel) 2022;14:2336. [PMID: 35565468 DOI: 10.3390/cancers14092336] [Reference Citation Analysis]
15 Broggini T, Stange L, Lucia KE, Vajkoczy P, Czabanka M. Endothelial EphrinB2 Regulates Sunitinib Therapy Response in Murine Glioma. Life 2022;12:691. [DOI: 10.3390/life12050691] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Kurnia I, Rauf S, Hatta M, Arifuddin S, Hidayat YM, Natzir R, Kaelan C, Bukhari A, Pelupessy NU, Patelonggi IJ. Molecular Patho-mechanisms of cervical cancer (MMP1). Annals of Medicine and Surgery 2022;77:103415. [DOI: 10.1016/j.amsu.2022.103415] [Reference Citation Analysis]
17 Buhl E, Kim YA, Parsons T, Zhu B, Santa-maria I, Lefort R, Hodge JJ. Effects of Eph/ephrin signalling and human Alzheimer's disease-associated EphA1 on behaviour and neurophysiology. Neurobiology of Disease 2022. [DOI: 10.1016/j.nbd.2022.105752] [Reference Citation Analysis]
18 Pang Z, Dong X, Deng H, Wang C, Liao X, Liao C, Liao Y, Tian W, Cheng J, Chen G, Yi H, Huang L. MUC1 triggers lineage plasticity of Her2 positive mammary tumors. Oncogene. [DOI: 10.1038/s41388-022-02320-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Farghaly TA, Abbas EM, Al-soliemy AM, Sabour R, Shaaban MR. Novel sulfonyl thiazolyl-hydrazone derivatives as EGFR inhibitors: Design, synthesis, biological evaluation and molecular docking studies. Bioorganic Chemistry 2022;121:105684. [DOI: 10.1016/j.bioorg.2022.105684] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Papadakos SP, Petrogiannopoulos L, Pergaris A, Theocharis S. The EPH/Ephrin System in Colorectal Cancer. Int J Mol Sci 2022;23:2761. [PMID: 35269901 DOI: 10.3390/ijms23052761] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Cha J, Chan L, Wang Y, Chu Y, Wang C, Lee H, Xia W, Shyu W, Liu S, Yao J, Chang C, Cheng F, Liu J, Lim S, Hsu JL, Yang W, Hortobagyi GN, Lin C, Yang L, Yu D, Jeng L, Hung M. Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer. Journal of Biological Chemistry 2022. [DOI: 10.1016/j.jbc.2022.101817] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
22 Murugan S, Cheng C. Roles of Eph-Ephrin Signaling in the Eye Lens Cataractogenesis, Biomechanics, and Homeostasis. Front Cell Dev Biol 2022;10:852236. [DOI: 10.3389/fcell.2022.852236] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Fraguas-sánchez AI, Lozza I, Torres-suárez AI. Actively Targeted Nanomedicines in Breast Cancer: From Pre-Clinal Investigation to Clinic. Cancers 2022;14:1198. [DOI: 10.3390/cancers14051198] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
24 Jung M, Lee S, Moon KC. c-Met and EPHA7 Receptor Tyrosine Kinases Are Related to Prognosis in Clear Cell Renal Cell Carcinoma: Focusing on the Association with Myoferlin Expression. Cancers (Basel) 2022;14:1095. [PMID: 35205843 DOI: 10.3390/cancers14041095] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Liu W, Yu C, Li J, Fang J. The Roles of EphB2 in Cancer. Front Cell Dev Biol 2022;10:788587. [DOI: 10.3389/fcell.2022.788587] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Wolff DW, Deng Z, Bianchi-Smiraglia A, Foley CE, Han Z, Wang X, Shen S, Rosenberg MM, Moparthy S, Yun DH, Chen J, Baker BK, Roll MV, Magiera AJ, Li J, Hurley E, Feltri ML, Cox AO, Lee J, Furdui CM, Liu L, Bshara W, LaConte LEW, Kandel ES, Pasquale EB, Qu J, Hedstrom L, Nikiforov MA. Phosphorylation of guanosine monophosphate reductase triggers a GTP-dependent switch from pro- to anti-oncogenic function of EPHA4. Cell Chem Biol 2022:S2451-9456(22)00049-6. [PMID: 35148834 DOI: 10.1016/j.chembiol.2022.01.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Gai QJ, Fu Z, He J, Mao M, Yao XX, Qin Y, Lan X, Zhang L, Miao JY, Wang YX, Zhu J, Yang FC, Lu HM, Yan ZX, Chen FL, Shi Y, Ping YF, Cui YH, Zhang X, Liu X, Yao XH, Lv SQ, Bian XW, Wang Y. EPHA2 mediates PDGFA activity and functions together with PDGFRA as prognostic marker and therapeutic target in glioblastoma. Signal Transduct Target Ther 2022;7:33. [PMID: 35105853 DOI: 10.1038/s41392-021-00855-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
28 Nikas I, Giaginis C, Petrouska K, Alexandrou P, Michail A, Sarantis P, Tsourouflis G, Danas E, Pergaris A, Politis PK, Nakopoulou L, Theocharis S. EPHA2, EPHA4, and EPHA7 Expression in Triple-Negative Breast Cancer. Diagnostics 2022;12:366. [DOI: 10.3390/diagnostics12020366] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Husain A, Chiu Y, Sze KM, Ho DW, Tsui Y, Suarez EMS, Zhang VX, Chan L, Lee E, Lee JM, Cheung T, Wong CC, Chung CY, Ng IO. Ephrin-A3/EphA2 axis regulates cellular metabolic plasticity to enhance cancer stemness in hypoxic hepatocellular carcinoma. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.02.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
30 Piffko A, Uhl C, Vajkoczy P, Czabanka M, Broggini T. EphrinB2-EphB4 Signaling in Neurooncological Disease. Int J Mol Sci 2022;23:1679. [PMID: 35163601 DOI: 10.3390/ijms23031679] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Batchu S, Hakim A, Henry OS, Madzo J, Atabek U, Spitz FR, Hong YK. Transcriptome-guided resolution of tumor microenvironment interactions in pheochromocytoma and paraganglioma subtypes. J Endocrinol Invest 2022. [PMID: 35088383 DOI: 10.1007/s40618-021-01729-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Guidetti L, Castelli R, Scalvini L, Ferlenghi F, Corrado M, Giorgio C, Tognolini M, Lodola A. Protein-Protein Interaction Inhibitors Targeting the Eph-Ephrin System with a Focus on Amino Acid Conjugates of Bile Acids. Pharmaceuticals 2022;15:137. [DOI: 10.3390/ph15020137] [Reference Citation Analysis]
33 Honoré B, Andersen MD, Wilken D, Kamper P, d'Amore F, Hamilton-Dutoit S, Ludvigsen M. Classic Hodgkin Lymphoma Refractory for ABVD Treatment Is Characterized by Pathologically Activated Signal Transduction Pathways as Revealed by Proteomic Profiling. Cancers (Basel) 2022;14:247. [PMID: 35008410 DOI: 10.3390/cancers14010247] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Masaoutis C, Georgantzoglou N, Sarantis P, Theochari I, Tsoukalas N, Bobos M, Alexandrou P, Pergaris A, Rontogianni D, Theocharis S. Ephrin Receptors (Ephs) Expression in Thymic Epithelial Tumors: Prognostic Implications and Future Therapeutic Approaches. Diagnostics 2021;11:2265. [DOI: 10.3390/diagnostics11122265] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
35 Lechtenberg BC, Gehring MP, Light TP, Horne CR, Matsumoto MW, Hristova K, Pasquale EB. Regulation of the EphA2 receptor intracellular region by phosphomimetic negative charges in the kinase-SAM linker. Nat Commun 2021;12:7047. [PMID: 34857764 DOI: 10.1038/s41467-021-27343-z] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
36 Lee K, Nada H, Byun HJ, Lee CH, Elkamhawy A. Hit Identification of a Novel Quinazoline Sulfonamide as a Promising EphB3 Inhibitor: Design, Virtual Combinatorial Library, Synthesis, Biological Evaluation, and Docking Simulation Studies. Pharmaceuticals (Basel) 2021;14:1247. [PMID: 34959648 DOI: 10.3390/ph14121247] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
37 Nakajima K, Ino Y, Naito C, Nara S, Shimasaki M, Ishimoto U, Iwasaki T, Doi N, Esaki M, Kishi Y, Shimada K, Hiraoka N. Neoadjuvant therapy alters the collagen architecture of pancreatic cancer tissue via Ephrin-A5. Br J Cancer 2021. [PMID: 34824448 DOI: 10.1038/s41416-021-01639-9] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
38 Márquez-Ortiz RA, Contreras-Zárate MJ, Tesic V, Alvarez-Eraso KLF, Kwak G, Littrell Z, Costello JC, Sreekanth V, Ormond DR, Karam SD, Kabos P, Cittelly DM. IL13Rα2 Promotes Proliferation and Outgrowth of Breast Cancer Brain Metastases. Clin Cancer Res 2021;27:6209-21. [PMID: 34544797 DOI: 10.1158/1078-0432.CCR-21-0361] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
39 Wang Z, Meng F, Zhong Z. Emerging targeted drug delivery strategies toward ovarian cancer. Adv Drug Deliv Rev 2021;178:113969. [PMID: 34509574 DOI: 10.1016/j.addr.2021.113969] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
40 Yang Y, Nian S, Li L, Wen X, Liu Q, Zhang B, Lan Y, Yuan Q, Ye Y. Fully human recombinant antibodies against EphA2 from a multi-tumor patient immune library suitable for tumor-targeted therapy. Bioengineered 2021. [PMID: 34709992 DOI: 10.1080/21655979.2021.1996807] [Reference Citation Analysis]
41 Nishimura T, Fujii K, Nakamura H, Naruki S, Sakai H, Kimura H, Miyazawa T, Takagi M, Furuya N, Marko-Varga G, Kato H, Saji H. Protein co-expression network-based profiles revealed from laser-microdissected cancerous cells of lung squamous-cell carcinomas. Sci Rep 2021;11:20209. [PMID: 34642392 DOI: 10.1038/s41598-021-99695-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
42 M Gagné L, Morin N, Lavoie N, Bisson N, Lambert JP, Mallette FA, Huot MÉ. Tyrosine phosphorylation of DEPTOR functions as a molecular switch to activate mTOR signaling. J Biol Chem 2021;297:101291. [PMID: 34634301 DOI: 10.1016/j.jbc.2021.101291] [Reference Citation Analysis]
43 Xu Y, Robev D, Saha N, Wang B, Dalva MB, Xu K, Himanen JP, Nikolov DB. The Ephb2 Receptor Uses Homotypic, Head-to-Tail Interactions within Its Ectodomain as an Autoinhibitory Control Mechanism. Int J Mol Sci 2021;22:10473. [PMID: 34638814 DOI: 10.3390/ijms221910473] [Reference Citation Analysis]
44 Yi C, Zhang X, Li H, Chen G, Zeng B, Li Y, Wang C, He Y, Chen X, Huang Z, Yu D. EPHB4 Regulates the Proliferation and Metastasis of Oral Squamous Cell Carcinoma through the HMGB1/NF-κB Signalling Pathway. J Cancer 2021;12:5999-6011. [PMID: 34539874 DOI: 10.7150/jca.59331] [Reference Citation Analysis]
45 Liang LY, Roy M, Horne CR, Sandow JJ, Surudoi M, Dagley LF, Young SN, Dite T, Babon JJ, Janes PW, Patel O, Murphy JM, Lucet IS. The intracellular domains of the EphB6 and EphA10 receptor tyrosine pseudokinases function as dynamic signalling hubs. Biochem J 2021;478:3351-71. [PMID: 34431498 DOI: 10.1042/BCJ20210572] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
46 Yeung W, Kwon A, Taujale R, Bunn C, Venkat A, Kannan N. Evolution of functional diversity in the holozoan tyrosine kinome. Mol Biol Evol 2021:msab272. [PMID: 34515793 DOI: 10.1093/molbev/msab272] [Reference Citation Analysis]
47 Lin Z, Wu Z, Luo W. Chimeric Antigen Receptor T-Cell Therapy: The Light of Day for Osteosarcoma. Cancers (Basel) 2021;13:4469. [PMID: 34503279 DOI: 10.3390/cancers13174469] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
48 Lin J, Zeng C, Zhang J, Song Z, Qi N, Liu X, Zhang Z, Li A, Chen F. EFNA4 promotes cell proliferation and tumor metastasis in hepatocellular carcinoma through a PIK3R2/GSK3β/β-catenin positive feedback loop. Mol Ther Nucleic Acids 2021;25:328-41. [PMID: 34484860 DOI: 10.1016/j.omtn.2021.06.002] [Reference Citation Analysis]
49 Zhao J, Stevens CH, Boyd AW, Ooi L, Bartlett PF. Role of EphA4 in Mediating Motor Neuron Death in MND. Int J Mol Sci 2021;22:9430. [PMID: 34502339 DOI: 10.3390/ijms22179430] [Reference Citation Analysis]
50 Rusnati M, Paiardi G, Tobia C, Urbinati C, Lodola A, D'Ursi P, Corrado M, Castelli R, Wade RC, Tognolini M, Chiodelli P. Cholenic acid derivative UniPR1331 impairs tumor angiogenesis via blockade of VEGF/VEGFR2 in addition to Eph/ephrin. Cancer Gene Ther 2021. [PMID: 34426652 DOI: 10.1038/s41417-021-00379-5] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
51 Sato A, Rahman NIA, Shimizu A, Ogita H. Cell-to-cell contact-mediated regulation of tumor behavior in the tumor microenvironment. Cancer Sci 2021;112:4005-12. [PMID: 34420253 DOI: 10.1111/cas.15114] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
52 Mancarella C, Morrione A, Scotlandi K. Unraveling the IGF System Interactome in Sarcomas Exploits Novel Therapeutic Options. Cells 2021;10:2075. [PMID: 34440844 DOI: 10.3390/cells10082075] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Furukawa T, Kimura H, Torimoto H, Yagi Y, Kawashima H, Arimitsu K, Yasui H. A Putative Single-Photon Emission CT Imaging Tracer for Erythropoietin-Producing Hepatocellular A2 Receptor. ACS Med Chem Lett 2021;12:1238-44. [PMID: 34413953 DOI: 10.1021/acsmedchemlett.1c00030] [Reference Citation Analysis]
54 Şen S, Lux CJ, Erber R. A Potential Role of Semaphorin 3A during Orthodontic Tooth Movement. Int J Mol Sci 2021;22:8297. [PMID: 34361063 DOI: 10.3390/ijms22158297] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
55 Harly C, Joyce SP, Domblides C, Bachelet T, Pitard V, Mannat C, Pappalardo A, Couzi L, Netzer S, Massara L, Obre E, Hawchar O, Lartigue L, Claverol S, Cano C, Moreau JF, Mahouche I, Soubeyran I, Rossignol R, Viollet B, Willcox CR, Mohammed F, Willcox BE, Faustin B, Déchanet-Merville J. Human γδ T cell sensing of AMPK-dependent metabolic tumor reprogramming through TCR recognition of EphA2. Sci Immunol 2021;6:eaba9010. [PMID: 34330813 DOI: 10.1126/sciimmunol.aba9010] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
56 Piffko A, Broggini T, Harms C, Adams RH, Vajkoczy P, Czabanka M. Ligand-Dependent and Ligand-Independent Effects of Ephrin-B2-EphB4 Signaling in Melanoma Metastatic Spine Disease. Int J Mol Sci 2021;22:8028. [PMID: 34360793 DOI: 10.3390/ijms22158028] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
57 Lee TH, Heo JH, Jeong JY, Lee GH, Park DS, Kim TH. Low Expression of EphB2, EphB3, and EphB4 in Bladder Cancer: Novel Potential Indicators of Muscular Invasion. Yonsei Med J 2021;62:679-90. [PMID: 34296545 DOI: 10.3349/ymj.2021.62.8.679] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
58 Renuse S, Madamsetty VS, Mun DG, Madugundu AK, Singh S, Udainiya S, Mangalaparthi KK, Kim MS, Liu R, Kumar SR, Krasnoperov V, Truty M, Graham RP, Gill PS, Mukhopadhyay D, Pandey A. Tyrosine Phosphoproteomics of Patient-Derived Xenografts Reveals Ephrin Type-B Receptor 4 Tyrosine Kinase as a Therapeutic Target in Pancreatic Cancer. Cancers (Basel) 2021;13:3404. [PMID: 34298619 DOI: 10.3390/cancers13143404] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
59 Keskin T, Rucci B, Cornaz-Buros S, Martin P, Fusco C, Broye L, Cisarova K, Perez EM, Letovanec I, La Rosa S, Cherix S, Diezi M, Renella R, Provero P, Suvà ML, Stamenkovic I, Riggi N. A live single-cell reporter assay links intratumor heterogeneity to metastatic proclivity in Ewing sarcoma. Sci Adv 2021;7:eabf9394. [PMID: 34215585 DOI: 10.1126/sciadv.abf9394] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
60 Zhang X. The Expression Profile and Prognostic Values of EPHA Family Members in Breast Cancer. Front Oncol 2021;11:619949. [PMID: 34221956 DOI: 10.3389/fonc.2021.619949] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Udompholkul P, Baggio C, Gambini L, Sun Y, Zhao M, Hoffman RM, Pellecchia M. Effective Tumor Targeting by EphA2-Agonist-Biotin-Streptavidin Conjugates. Molecules 2021;26:3687. [PMID: 34204178 DOI: 10.3390/molecules26123687] [Reference Citation Analysis]
62 Light TP, Gomez-Soler M, Wang Z, Karl K, Zapata-Mercado E, Gehring MP, Lechtenberg BC, Pogorelov TV, Hristova K, Pasquale EB. A cancer mutation promotes EphA4 oligomerization and signaling by altering the conformation of the SAM domain. J Biol Chem 2021;297:100876. [PMID: 34139238 DOI: 10.1016/j.jbc.2021.100876] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
63 Sun X, Zhan M, Sun X, Liu W, Meng X. C1GALT1 in health and disease. Oncol Lett 2021;22:589. [PMID: 34149900 DOI: 10.3892/ol.2021.12850] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
64 Melrose J, Hayes AJ, Bix G. The CNS/PNS Extracellular Matrix Provides Instructive Guidance Cues to Neural Cells and Neuroregulatory Proteins in Neural Development and Repair. Int J Mol Sci 2021;22:5583. [PMID: 34070424 DOI: 10.3390/ijms22115583] [Cited by in Crossref: 1] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
65 Itoh T, Hatano R, Horimoto Y, Yamada T, Song D, Otsuka H, Shirakawa Y, Mastuoka S, Iwao N, Aune TM, Dang NH, Kaneko Y, Okumura K, Morimoto C, Ohnuma K. IL-26 mediates epidermal growth factor receptor-tyrosine kinase inhibitor resistance through endoplasmic reticulum stress signaling pathway in triple-negative breast cancer cells. Cell Death Dis 2021;12:520. [PMID: 34021125 DOI: 10.1038/s41419-021-03787-5] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
66 Peng J, Zhang D. Coexpression of EphA10 and Gli3 promotes breast cancer cell proliferation, invasion and migration. J Investig Med 2021;69:1215-21. [PMID: 33990369 DOI: 10.1136/jim-2021-001836] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
67 Ji Y, Gao L, Zhang C, Sun X, Dai L, Ji Z, Zhang J, Zhang Z, Cao W, Zhao Y, Zhang L. Identification of the hub genes and prognostic indicators of gastric cancer and correlation of indicators with tumor-infiltrating immune cell levels. J Cancer 2021;12:4025-38. [PMID: 34093807 DOI: 10.7150/jca.52105] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
68 Volz C, Breid S, Selenz C, Zaplatina A, Golfmann K, Meder L, Dietlein F, Borchmann S, Chatterjee S, Siobal M, Schöttle J, Florin A, Koker M, Nill M, Ozretić L, Uhlenbrock N, Smith S, Büttner R, Miao H, Wang B, Reinhardt HC, Rauh D, Hallek M, Acker-Palmer A, Heukamp LC, Ullrich RT. Inhibition of Tumor VEGFR2 Induces Serine 897 EphA2-Dependent Tumor Cell Invasion and Metastasis in NSCLC. Cell Rep 2020;31:107568. [PMID: 32348765 DOI: 10.1016/j.celrep.2020.107568] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
69 Lee HH, Wang YN, Yang WH, Xia W, Wei Y, Chan LC, Wang YH, Jiang Z, Xu S, Yao J, Qiu Y, Hsu YH, Hwang WL, Yan M, Cha JH, Hsu JL, Shen J, Ye Y, Wu X, Hou MF, Tseng LM, Wang SC, Pan MR, Yang CH, Wang YL, Yamaguchi H, Pang D, Hortobagyi GN, Yu D, Hung MC. Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation. Nat Commun 2021;12:2788. [PMID: 33986289 DOI: 10.1038/s41467-021-23075-2] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
70 Alam J, Ogawa K. Expression and localisation of ephrin-B1 and EphB4 in steroidogenic cells in the naturally cycling mouse ovary. Reprod Biol 2021;21:100511. [PMID: 33991765 DOI: 10.1016/j.repbio.2021.100511] [Reference Citation Analysis]
71 Wirth D, McCall A, Hristova K. Neural network strategies for plasma membrane selection in fluorescence microscopy images. Biophys J 2021;120:2374-85. [PMID: 33961865 DOI: 10.1016/j.bpj.2021.04.030] [Reference Citation Analysis]
72 Mao L, Yuan W, Cai K, Lai C, Huang C, Xu Y, Zhong S, Yang C, Wang R, Zeng P, Huang H, Chen Z, Chen Z. EphA2-YES1-ANXA2 pathway promotes gastric cancer progression and metastasis. Oncogene 2021;40:3610-23. [PMID: 33941853 DOI: 10.1038/s41388-021-01786-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
73 Jukonen J, Moyano-Galceran L, Höpfner K, Pietilä EA, Lehtinen L, Huhtinen K, Gucciardo E, Hynninen J, Hietanen S, Grénman S, Ojala PM, Carpén O, Lehti K. Aggressive and recurrent ovarian cancers upregulate ephrinA5, a non-canonical effector of EphA2 signaling duality. Sci Rep 2021;11:8856. [PMID: 33893375 DOI: 10.1038/s41598-021-88382-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
74 Liang Z, Wang X, Dong K, Li X, Qin C, Zhou H. Expression Pattern and Prognostic Value of EPHA/EFNA in Breast Cancer by Bioinformatics Analysis: Revealing Its Importance in Chemotherapy. Biomed Res Int 2021;2021:5575704. [PMID: 33977106 DOI: 10.1155/2021/5575704] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
75 Gao Z, Han X, Zhu Y, Zhang H, Tian R, Wang Z, Cui Y, Wang Z, Niu R, Zhang F. Drug-resistant cancer cell-derived exosomal EphA2 promotes breast cancer metastasis via the EphA2-Ephrin A1 reverse signaling. Cell Death Dis 2021;12:414. [PMID: 33879771 DOI: 10.1038/s41419-021-03692-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
76 Paul MD, Hristova K. Interactions between Ligand-Bound EGFR and VEGFR2. J Mol Biol 2021;433:167006. [PMID: 33891904 DOI: 10.1016/j.jmb.2021.167006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
77 Kindberg AA, Srivastava V, Muncie JM, Weaver VM, Gartner ZJ, Bush JO. EPH/EPHRIN regulates cellular organization by actomyosin contractility effects on cell contacts. J Cell Biol 2021;220:e202005216. [PMID: 33798261 DOI: 10.1083/jcb.202005216] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
78 Sun W, Wang H, Hu H, Ma X, Zhang H, Chen J, Du Y, He R, Cui Z, Peng Q, Wang C. Cutting Edge: EPHB2 Is a Coreceptor for Fungal Recognition and Phosphorylation of Syk in the Dectin-1 Signaling Pathway. J Immunol 2021;206:1419-23. [PMID: 33685996 DOI: 10.4049/jimmunol.2001373] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
79 Pacenta HL, Allen-Rhoades W, Langenau D, Houghton PJ, Keller C, Heske CM, Deel MD, Linardic CM, Shern JF, Stewart E, Turpin B, Harrison DJ, Khan J, Mascarenhas L, Skapek SX, Meyer WH, Hawkins DS, Chen EY, Amatruda JF, Hingorani P, Laetsch TW. Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children's Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force. J Clin Med 2021;10:1416. [PMID: 33915882 DOI: 10.3390/jcm10071416] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
80 Porębska N, Poźniak M, Matynia A, Żukowska D, Zakrzewska M, Otlewski J, Opaliński Ł. Galectins as modulators of receptor tyrosine kinases signaling in health and disease. Cytokine Growth Factor Rev 2021;60:89-106. [PMID: 33863623 DOI: 10.1016/j.cytogfr.2021.03.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Zhao Y, Cai C, Zhang M, Shi L, Wang J, Zhang H, Ma P, Li S. Ephrin-A2 promotes prostate cancer metastasis by enhancing angiogenesis and promoting EMT. J Cancer Res Clin Oncol 2021;147:2013-23. [PMID: 33772606 DOI: 10.1007/s00432-021-03618-2] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
82 Fitsiou E, Soto-Gamez A, Demaria M. Biological functions of therapy-induced senescence in cancer. Semin Cancer Biol 2021:S1044-579X(21)00071-7. [PMID: 33775830 DOI: 10.1016/j.semcancer.2021.03.021] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
83 Han X, Zhu Y, Shen L, Zhou Y, Pang L, Zhou W, Gu H, Han K, Yang Y, Jiang C, Xie J, Zhang C, Ding L. PTIP Inhibits Cell Invasion in Esophageal Squamous Cell Carcinoma via Modulation of EphA2 Expression. Front Oncol 2021;11:629916. [PMID: 33833989 DOI: 10.3389/fonc.2021.629916] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
84 Ahmed MS, Wang P, Nguyen NUN, Nakada Y, Menendez-Montes I, Ismail M, Bachoo R, Henkemeyer M, Sadek HA, Kandil ES. Identification of tetracycline combinations as EphB1 tyrosine kinase inhibitors for treatment of neuropathic pain. Proc Natl Acad Sci U S A 2021;118:e2016265118. [PMID: 33627480 DOI: 10.1073/pnas.2016265118] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
85 Oner E, Kotmakci M, Baird AM, Gray SG, Debelec Butuner B, Bozkurt E, Kantarci AG, Finn SP. Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small-molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids. J Nanobiotechnology 2021;19:71. [PMID: 33685469 DOI: 10.1186/s12951-021-00781-z] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
86 Wang Y, Ling L, Tian F, Won Kim SH, Ho S, Bikle DD. Ablation of Ephrin B2 in Col2 Expressing Cells Delays Fracture Repair. Endocrinology 2020;161:bqaa179. [PMID: 32987403 DOI: 10.1210/endocr/bqaa179] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
87 Großkopf AK, Schlagowski S, Fricke T, Ensser A, Desrosiers RC, Hahn AS. Plxdc family members are novel receptors for the rhesus monkey rhadinovirus (RRV). PLoS Pathog 2021;17:e1008979. [PMID: 33657166 DOI: 10.1371/journal.ppat.1008979] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
88 Kaminskyy VO, Hååg P, Novak M, Végvári Á, Arapi V, Lewensohn R, Viktorsson K. EPHA2 Interacts with DNA-PKcs in Cell Nucleus and Controls Ionizing Radiation Responses in Non-Small Cell Lung Cancer Cells. Cancers (Basel) 2021;13:1010. [PMID: 33671073 DOI: 10.3390/cancers13051010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
89 Zhang M, Lin L, Wang C, Zhu J. Double inhibition and activation mechanisms of Ephexin family RhoGEFs. Proc Natl Acad Sci U S A 2021;118:e2024465118. [PMID: 33597305 DOI: 10.1073/pnas.2024465118] [Reference Citation Analysis]
90 Wallaschek N, Reuter S, Silkenat S, Wolf K, Niklas C, Kayisoglu Ö, Aguilar C, Wiegering A, Germer CT, Kircher S, Rosenwald A, Shannon-Lowe C, Bartfeld S. Ephrin receptor A2, the epithelial receptor for Epstein-Barr virus entry, is not available for efficient infection in human gastric organoids. PLoS Pathog 2021;17:e1009210. [PMID: 33596248 DOI: 10.1371/journal.ppat.1009210] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
91 Huang C, Chen Z, He Y, He Z, Ban Z, Zhu Y, Ding L, Yang C, Jeong JH, Yuan W, Yang L. EphA2 promotes tumorigenicity of cervical cancer by up-regulating CDK6. J Cell Mol Med 2021;25:2967-75. [PMID: 33586348 DOI: 10.1111/jcmm.16337] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
92 Cioce M, Fazio VM. EphA2 and EGFR: Friends in Life, Partners in Crime. Can EphA2 Be a Predictive Biomarker of Response to Anti-EGFR Agents? Cancers (Basel) 2021;13:700. [PMID: 33572284 DOI: 10.3390/cancers13040700] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
93 Eyvazi S, Khamaneh AM, Tarhriz V, Bandehpour M, Hejazi MS, Sadat ATE, Sepehri B. CpG Islands Methylation Analysis of CDH11, EphA5, and HS3ST2 Genes in Gastric Adenocarcinoma Patients. J Gastrointest Cancer. 2019;. [PMID: 31407253 DOI: 10.1007/s12029-019-00290-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
94 Zhang Z, Wu HX, Lin WH, Wang ZX, Yang LP, Zeng ZL, Luo HY. EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers. BMC Med 2021;19:26. [PMID: 33526018 DOI: 10.1186/s12916-020-01899-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
95 Wang H, Hou W, Perera A, Bettler C, Beach JR, Ding X, Li J, Denning MF, Dhanarajan A, Cotler SJ, Joyce C, Yin J, Ahmed F, Roberts LR, Qiu W. Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling. Cell Rep 2021;34:108765. [PMID: 33626345 DOI: 10.1016/j.celrep.2021.108765] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Nagare RP, Sneha S, Sidhanth C, Roopa S, Murhekar K, Shirley S, Swaminathan R, Sridevi V, Ganesan TS. Expression of cancer stem cell markers CD24, EPHA1 and CD9 and their correlation with clinical outcome in epithelial ovarian tumours. Cancer Biomark 2020;28:397-408. [PMID: 32224528 DOI: 10.3233/CBM-201463] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
97 Pensold D, Gehrmann J, Pitschelatow G, Walberg A, Braunsteffer K, Reichard J, Ravaei A, Linde J, Lampert A, Costa IG, Zimmer-Bensch G. The Expression of the Cancer-Associated lncRNA Snhg15 Is Modulated by EphrinA5-Induced Signaling. Int J Mol Sci 2021;22:1332. [PMID: 33572758 DOI: 10.3390/ijms22031332] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Manzoli R, Badenetti L, Rubin M, Moro E. Lysosomal Function and Axon Guidance: Is There a Meaningful Liaison? Biomolecules 2021;11:191. [PMID: 33573025 DOI: 10.3390/biom11020191] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
99 Qu F, Song Y, Wu Y, Huang Y, Zhong Q, Zhang Y, Fan Z, Xu C. The protective role of Ephrin-B2/EphB4 signaling in osteogenic differentiation under inflammatory environment. Exp Cell Res 2021;400:112505. [PMID: 33516666 DOI: 10.1016/j.yexcr.2021.112505] [Reference Citation Analysis]
100 Chen YL, Yen YC, Jang CW, Wang SH, Huang HT, Chen CH, Hsiao JR, Chang JY, Chen YW. Ephrin A4-ephrin receptor A10 signaling promotes cell migration and spheroid formation by upregulating NANOG expression in oral squamous cell carcinoma cells. Sci Rep 2021;11:644. [PMID: 33436772 DOI: 10.1038/s41598-020-80060-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
101 Anderton M, van der Meulen E, Blumenthal MJ, Schäfer G. The Role of the Eph Receptor Family in Tumorigenesis. Cancers (Basel) 2021;13:E206. [PMID: 33430066 DOI: 10.3390/cancers13020206] [Cited by in Crossref: 6] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
102 Martinelli E, Ciardiello D, Martini G, Troiani T, Cardone C, Vitiello PP, Normanno N, Rachiglio AM, Maiello E, Latiano T, De Vita F, Ciardiello F. Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives. Ann Oncol 2020;31:30-40. [PMID: 31912793 DOI: 10.1016/j.annonc.2019.10.007] [Cited by in Crossref: 29] [Cited by in F6Publishing: 58] [Article Influence: 29.0] [Reference Citation Analysis]
103 Zhang H, Cui Z, Cheng D, Du Y, Guo X, Gao R, Chen J, Sun W, He R, Ma X, Peng Q, Martin BN, Yan W, Rong Y, Wang C. RNF186 regulates EFNB1 (ephrin B1)-EPHB2-induced autophagy in the colonic epithelial cells for the maintenance of intestinal homeostasis. Autophagy 2020;:1-18. [PMID: 33280498 DOI: 10.1080/15548627.2020.1851496] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
104 Stefanski KM, Russell CM, Westerfield JM, Lamichhane R, Barrera FN. PIP2 promotes conformation-specific dimerization of the EphA2 membrane region. J Biol Chem 2021;296:100149. [PMID: 33277361 DOI: 10.1074/jbc.RA120.016423] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
105 Leonard CE, Baydyuk M, Stepler MA, Burton DA, Donoghue MJ. EphA7 isoforms differentially regulate cortical dendrite development. PLoS One 2020;15:e0231561. [PMID: 33275600 DOI: 10.1371/journal.pone.0231561] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
106 Scalia P, Giordano A, Martini C, Williams SJ. Isoform- and Paralog-Switching in IR-Signaling: When Diabetes Opens the Gates to Cancer. Biomolecules 2020;10:E1617. [PMID: 33266015 DOI: 10.3390/biom10121617] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
107 Kim A, Seong KM, Choi YY, Shim S, Park S, Lee SS. Inhibition of EphA2 by Dasatinib Suppresses Radiation-Induced Intestinal Injury. Int J Mol Sci 2020;21:E9096. [PMID: 33265912 DOI: 10.3390/ijms21239096] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
108 Zhang BN, Liu Y, Yang Q, Leung PY, Wang C, Wong TCB, Tham CC, Chan SO, Pang CP, Chen LJ, Dekker J, Zhao H, Chu WK. rad21 Is Involved in Corneal Stroma Development by Regulating Neural Crest Migration. Int J Mol Sci 2020;21:E7807. [PMID: 33096935 DOI: 10.3390/ijms21207807] [Reference Citation Analysis]
109 Kamoun W, Swindell E, Pien C, Luus L, Cain J, Pham M, Kandela I, Huang ZR, Tipparaju SK, Koshkaryev A, Askoxylakis V, Kirpotin DB, Bloom T, Mino-Kenudson M, Marks JD, Zalutskaya A, Bshara W, Morrison C, Drummond DC. Targeting EphA2 in Bladder Cancer Using a Novel Antibody-Directed Nanotherapeutic. Pharmaceutics 2020;12:E996. [PMID: 33092175 DOI: 10.3390/pharmaceutics12100996] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
110 Srivastava S, Pang KM, Iida M, Nelson MS, Liu J, Nam A, Wang J, Mambetsariev I, Pillai R, Mohanty A, McDaniel N, Behal A, Kulkarni P, Wheeler DL, Salgia R. Activation of EPHA2-ROBO1 Heterodimer by SLIT2 Attenuates Non-canonical Signaling and Proliferation in Squamous Cell Carcinomas. iScience 2020;23:101692. [PMID: 33196021 DOI: 10.1016/j.isci.2020.101692] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
111 McCullough D, Atofanei C, Knight E, Trim SA, Trim CM. Kinome scale profiling of venom effects on cancer cells reveals potential new venom activities. Toxicon 2020;185:129-46. [PMID: 32682827 DOI: 10.1016/j.toxicon.2020.07.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
112 Arcas A, Wilkinson DG, Nieto MÁ. The Evolutionary History of Ephs and Ephrins: Toward Multicellular Organisms. Mol Biol Evol 2020;37:379-94. [PMID: 31589243 DOI: 10.1093/molbev/msz222] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
113 Li H, Wang H, Sokulsky L, Liu S, Yang R, Liu X, Zhou L, Li J, Huang C, Li F, Lei X, Jia H, Cheng J, Li F, Yang M, Zhang G. Single-cell transcriptomic analysis reveals key immune cell phenotypes in the lungs of patients with asthma exacerbation. J Allergy Clin Immunol 2021;147:941-54. [PMID: 33039479 DOI: 10.1016/j.jaci.2020.09.032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
114 Salem AF, Gambini L, Billet S, Sun Y, Oshiro H, Zhao M, Hoffman RM, Bhowmick NA, Pellecchia M. Prostate Cancer Metastases Are Strongly Inhibited by Agonistic Epha2 Ligands in an Orthotopic Mouse Model. Cancers (Basel) 2020;12:E2854. [PMID: 33023262 DOI: 10.3390/cancers12102854] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
115 Zhang R, Han D, Li L, Luo W, Liu J, Qian L. EphA5 Silencing Increases the Radiosensitivity of ESCC Cells Through ATM-Dependent Pathway. Cancer Manag Res 2020;12:9539-49. [PMID: 33061640 DOI: 10.2147/CMAR.S261182] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
116 Wang X, Wang Z. Identification of the soluble EphA7-interacting protein Nicalin as a regulator of EphA7 expression. Mol Cell Biochem 2021;476:213-20. [PMID: 32914261 DOI: 10.1007/s11010-020-03898-1] [Reference Citation Analysis]
117 Chen BS, Wang KY, Yu SQ, Zhang CB, Li GZ, Wang ZL, Bao ZS. Whole-transcriptome sequencing profiling identifies functional and prognostic signatures in patients with PTPRZ1-MET fusion-negative secondary glioblastoma multiforme. Oncol Lett 2020;20:187. [PMID: 32952656 DOI: 10.3892/ol.2020.12049] [Reference Citation Analysis]
118 Zhang C, Smalley I, Emmons MF, Sharma R, Izumi V, Messina J, Koomen JM, Pasquale EB, Forsyth PA, Smalley KSM. Noncanonical EphA2 Signaling Is a Driver of Tumor-Endothelial Cell Interactions and Metastatic Dissemination in BRAF Inhibitor‒Resistant Melanoma. J Invest Dermatol 2021;141:840-851.e4. [PMID: 32890629 DOI: 10.1016/j.jid.2020.08.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
119 Hsu K, Middlemiss S, Saletta F, Gottschalk S, McCowage GB, Kramer B. Chimeric Antigen Receptor-modified T cells targeting EphA2 for the immunotherapy of paediatric bone tumours. Cancer Gene Ther 2021;28:321-34. [PMID: 32873870 DOI: 10.1038/s41417-020-00221-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
120 Xiang YP, Xiao T, Li QG, Lu SS, Zhu W, Liu YY, Qiu JY, Song ZH, Huang W, Yi H, Tang YY, Xiao ZQ. Y772 phosphorylation of EphA2 is responsible for EphA2-dependent NPC nasopharyngeal carcinoma growth by Shp2/Erk-1/2 signaling pathway. Cell Death Dis 2020;11:709. [PMID: 32848131 DOI: 10.1038/s41419-020-02831-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
121 Song W, Kim LC, Han W, Hou Y, Edwards DN, Wang S, Blackwell TS, Cheng F, Brantley-Sieders DM, Chen J. Phosphorylation of PLCγ1 by EphA2 Receptor Tyrosine Kinase Promotes Tumor Growth in Lung Cancer. Mol Cancer Res 2020;18:1735-43. [PMID: 32753469 DOI: 10.1158/1541-7786.MCR-20-0075] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
122 Orahoske CM, Li Y, Petty A, Salem FM, Hanna J, Zhang W, Su B, Wang B. Dimeric small molecule agonists of EphA2 receptor inhibit glioblastoma cell growth. Bioorg Med Chem 2020;28:115656. [PMID: 32828423 DOI: 10.1016/j.bmc.2020.115656] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
123 Azad T, Rezaei R, Surendran A, Singaravelu R, Boulton S, Dave J, Bell JC, Ilkow CS. Hippo Signaling Pathway as a Central Mediator of Receptors Tyrosine Kinases (RTKs) in Tumorigenesis. Cancers (Basel) 2020;12:E2042. [PMID: 32722184 DOI: 10.3390/cancers12082042] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
124 Alshamrani AA. Roles of microRNAs in Ovarian Cancer Tumorigenesis: Two Decades Later, What Have We Learned? Front Oncol 2020;10:1084. [PMID: 32850313 DOI: 10.3389/fonc.2020.01084] [Cited by in Crossref: 8] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
125 Pyo A, You SH, Sik Kim H, Young Kim J, Min JJ, Kim DY, Hong Y. Production of 64Cu-labeled monobody for imaging of human EphA2-expressing tumors. Bioorg Med Chem Lett 2020;30:127262. [PMID: 32527560 DOI: 10.1016/j.bmcl.2020.127262] [Reference Citation Analysis]
126 Wu JE, Wu YY, Tung CH, Tsai YT, Chen HY, Chen YL, Hong TM. DNA methylation maintains the CLDN1-EPHB6-SLUG axis to enhance chemotherapeutic efficacy and inhibit lung cancer progression. Theranostics 2020;10:8903-23. [PMID: 32754286 DOI: 10.7150/thno.45785] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
127 London M, Gallo E. Critical role of EphA3 in cancer and current state of EphA3 drug therapeutics. Mol Biol Rep 2020;47:5523-33. [PMID: 32621117 DOI: 10.1007/s11033-020-05571-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
128 Li S, Zhai J, Xu B, Liu J, Chu W, Wang D, Geng X, Chen Z, Du Y. Erythropoietin-producing hepatocellular receptor A7 restrains estrogen negative feedback of luteinizing hormone via ephrin A5 in the hypothalamus of female rats. American Journal of Physiology-Endocrinology and Metabolism 2020;319:E81-90. [DOI: 10.1152/ajpendo.00046.2020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
129 Gofur MR, Alam J, Ogawa K. Expression and localisation of ephrin-B1, EphB2, and EphB4 in the mouse testis during postnatal development. Reprod Biol 2020;20:321-32. [PMID: 32620380 DOI: 10.1016/j.repbio.2020.06.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
130 Verschueren E, Husain B, Yuen K, Sun Y, Paduchuri S, Senbabaoglu Y, Lehoux I, Arena TA, Wilson B, Lianoglou S, Bakalarski C, Franke Y, Chan P, Wong AW, Gonzalez LC, Mariathasan S, Turley SJ, Lill JR, Martinez-Martin N. The Immunoglobulin Superfamily Receptome Defines Cancer-Relevant Networks Associated with Clinical Outcome. Cell 2020;182:329-344.e19. [PMID: 32589946 DOI: 10.1016/j.cell.2020.06.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
131 Kaur K, Singh N, Dhawan RK. Potential role of EphrinA2 receptors in postconditioning induced cardioprotection in rats. Eur J Pharmacol 2020;883:173231. [PMID: 32589885 DOI: 10.1016/j.ejphar.2020.173231] [Reference Citation Analysis]
132 Fattet L, Jung HY, Matsumoto MW, Aubol BE, Kumar A, Adams JA, Chen AC, Sah RL, Engler AJ, Pasquale EB, Yang J. Matrix Rigidity Controls Epithelial-Mesenchymal Plasticity and Tumor Metastasis via a Mechanoresponsive EPHA2/LYN Complex. Dev Cell 2020;54:302-316.e7. [PMID: 32574556 DOI: 10.1016/j.devcel.2020.05.031] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 12.0] [Reference Citation Analysis]
133 Bhatia S, Bukkapatnam S, Van Court B, Phan A, Oweida A, Gadwa J, Mueller AC, Piper M, Darragh L, Nguyen D, Gilani A, Knitz M, Bickett T, Green A, Venkataraman S, Vibhakar R, Cittelly D, Karam SD. The effects of ephrinB2 signaling on proliferation and invasion in glioblastoma multiforme. Mol Carcinog 2020;59:1064-75. [PMID: 32567728 DOI: 10.1002/mc.23237] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
134 Paul MD, Grubb HN, Hristova K. Quantifying the strength of heterointeractions among receptor tyrosine kinases from different subfamilies: Implications for cell signaling. J Biol Chem 2020;295:9917-33. [PMID: 32467228 DOI: 10.1074/jbc.RA120.013639] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
135 Buraschi S, Neill T, Xu SQ, Palladino C, Belfiore A, Iozzo RV, Morrione A. Progranulin/EphA2 axis: A novel oncogenic mechanism in bladder cancer. Matrix Biol 2020;93:10-24. [PMID: 32417448 DOI: 10.1016/j.matbio.2020.03.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
136 Gehring MP, Pasquale EB. Protein kinase C phosphorylates the EphA2 receptor on serine 892 in the regulatory linker connecting the kinase and SAM domains. Cell Signal 2020;73:109668. [PMID: 32413552 DOI: 10.1016/j.cellsig.2020.109668] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
137 Salem AF, Gambini L, Udompholkul P, Baggio C, Pellecchia M. Therapeutic Targeting of Pancreatic Cancer via EphA2 Dimeric Agonistic Agents. Pharmaceuticals (Basel) 2020;13:E90. [PMID: 32397624 DOI: 10.3390/ph13050090] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
138 Janes PW, Vail ME, Gan HK, Scott AM. Antibody Targeting of Eph Receptors in Cancer. Pharmaceuticals (Basel) 2020;13:E88. [PMID: 32397088 DOI: 10.3390/ph13050088] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
139 Wang L, Peng Q, Sai B, Zheng L, Xu J, Yin N, Feng X, Xiang J. Ligand-independent EphB1 signaling mediates TGF-β-activated CDH2 and promotes lung cancer cell invasion and migration. J Cancer 2020;11:4123-31. [PMID: 32368295 DOI: 10.7150/jca.44576] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
140 Li QG, Xiao T, Zhu W, Yu ZZ, Huang XP, Yi H, Lu SS, Tang YY, Huang W, Xiao ZQ. HDAC7 promotes the oncogenicity of nasopharyngeal carcinoma cells by miR-4465-EphA2 signaling axis. Cell Death Dis 2020;11:322. [PMID: 32376822 DOI: 10.1038/s41419-020-2521-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
141 Yang J, Gong Y, Jiang Q, Liu L, Li S, Zhou Q, Huang F, Liu Z. Circular RNA Expression Profiles in Nasopharyngeal Carcinoma by Sequence Analysis. Front Oncol 2020;10:601. [PMID: 32426279 DOI: 10.3389/fonc.2020.00601] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
142 Andolfo I, Lasorsa VA, Manna F, Rosato BE, Formicola D, Iolascon A, Capasso M. Kinome multigenic panel identified novel druggable EPHB4-V871I somatic variant in high-risk neuroblastoma. J Cell Mol Med 2020;24:6459-71. [PMID: 32336043 DOI: 10.1111/jcmm.15297] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
143 Gupta C, Sali A, Ma B, Jackovich A, Sadeghi S, Quinn D, Gill P, Gill I. EphrinB2 expression in prostate adenocarcinoma: Implications for targeted therapy. Pathol Res Pract 2020;216:152967. [PMID: 32362422 DOI: 10.1016/j.prp.2020.152967] [Reference Citation Analysis]
144 Nagare RP, Sneha S, Krishnapriya S, Ramachandran B, Murhekar K, Vasudevan S, Shabna A, Ganesan TS. ALDH1A1+ ovarian cancer stem cells co-expressing surface markers CD24, EPHA1 and CD9 form tumours in vivo. Exp Cell Res 2020;392:112009. [PMID: 32305326 DOI: 10.1016/j.yexcr.2020.112009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
145 Mo J, Zhao X, Dong X, Liu T, Zhao N, Zhang D, Wang W, Zhang Y, Sun B. Effect of EphA2 knockdown on melanoma metastasis depends on intrinsic ephrinA1 level. Cell Oncol (Dordr) 2020;43:655-67. [PMID: 32291572 DOI: 10.1007/s13402-020-00511-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
146 Jang BG, Kim HS, Bae JM, Kim WH, Hyun CL, Kang GH. Expression Profile and Prognostic Significance of EPHB3 in Colorectal Cancer. Biomolecules 2020;10:E602. [PMID: 32294981 DOI: 10.3390/biom10040602] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
147 Giorgio C, Zanotti I, Lodola A, Tognolini M. Ephrin or not? Six tough questions on Eph targeting. Expert Opin Ther Targets 2020;24:403-15. [PMID: 32197575 DOI: 10.1080/14728222.2020.1745187] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
148 Chen CT, Liao LZ, Lu CH, Huang YH, Lin YK, Lin JH, Chow LP. Quantitative phosphoproteomic analysis identifies the potential therapeutic target EphA2 for overcoming sorafenib resistance in hepatocellular carcinoma cells. Exp Mol Med 2020;52:497-513. [PMID: 32203105 DOI: 10.1038/s12276-020-0404-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
149 Li C, Lanman NA, Kong Y, He D, Mao F, Farah E, Zhang Y, Liu J, Wang C, Wei Q, Liu X. Inhibition of the erythropoietin-producing receptor EPHB4 antagonizes androgen receptor overexpression and reduces enzalutamide resistance. J Biol Chem 2020;295:5470-83. [PMID: 32184358 DOI: 10.1074/jbc.RA119.011385] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
150 Li M, Nishio SY, Naruse C, Riddell M, Sapski S, Katsuno T, Hikita T, Mizapourshafiyi F, Smith FM, Cooper LT, Lee MG, Asano M, Boettger T, Krueger M, Wietelmann A, Graumann J, Day BW, Boyd AW, Offermanns S, Kitajiri SI, Usami SI, Nakayama M. Digenic inheritance of mutations in EPHA2 and SLC26A4 in Pendred syndrome. Nat Commun 2020;11:1343. [PMID: 32165640 DOI: 10.1038/s41467-020-15198-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
151 Shrestha S, Byrne DP, Harris JA, Kannan N, Eyers PA. Cataloguing the dead: breathing new life into pseudokinase research. FEBS J 2020;287:4150-69. [PMID: 32053275 DOI: 10.1111/febs.15246] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
152 Hester SC, Kuriakose M, Nguyen CD, Mallidi S. Role of Ultrasound and Photoacoustic Imaging in Photodynamic Therapy for Cancer. Photochem Photobiol 2020;96:260-79. [PMID: 31919853 DOI: 10.1111/php.13217] [Cited by in Crossref: 13] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
153 Colapietro A, Gravina GL, Petragnano F, Fasciani I, Scicchitano BM, Beirinckx F, Pujuguet P, Saniere L, Van der Aar E, Musio D, De Felice F, Mattei V, Martellucci S, Maggio R, Tombolini V, Festuccia C, Marampon F. Antitumorigenic Effects of Inhibiting Ephrin Receptor Kinase Signaling by GLPG1790 against Colorectal Cancer Cell Lines In Vitro and In Vivo. J Oncol 2020;2020:9342732. [PMID: 32184826 DOI: 10.1155/2020/9342732] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
154 Vincenzi M, Mercurio FA, Leone M. Sam Domains in Multiple Diseases. Curr Med Chem 2020;27:450-76. [PMID: 30306850 DOI: 10.2174/0929867325666181009114445] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
155 Leite M, Marques MS, Melo J, Pinto MT, Cavadas B, Aroso M, Gomez-Lazaro M, Seruca R, Figueiredo C. Helicobacter Pylori Targets the EPHA2 Receptor Tyrosine Kinase in Gastric Cells Modulating Key Cellular Functions. Cells 2020;9:E513. [PMID: 32102381 DOI: 10.3390/cells9020513] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
156 Yin J, Li Z, Ye L, Birkin E, Li L, Xu R, Chen G, Ji J, Zhang Z, Jiang WG, Cui Y. EphB2 represents an independent prognostic marker in patients with gastric cancer and promotes tumour cell aggressiveness. J Cancer 2020;11:2778-87. [PMID: 32226496 DOI: 10.7150/jca.38098] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
157 Zhu F, Dai SN, Xu DL, Hou CQ, Liu TT, Chen QY, Wu JL, Miao Y. EFNB2 facilitates cell proliferation, migration, and invasion in pancreatic ductal adenocarcinoma via the p53/p21 pathway and EMT. Biomed Pharmacother 2020;125:109972. [PMID: 32036221 DOI: 10.1016/j.biopha.2020.109972] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
158 Incerti M, Russo S, Corrado M, Giorgio C, Ballabeni V, Chiodelli P, Rusnati M, Scalvini L, Callegari D, Castelli R, Vacondio F, Ferlenghi F, Tognolini M, Lodola A. Optimization of EphA2 antagonists based on a lithocholic acid core led to the identification of UniPR505, a new 3α-carbamoyloxy derivative with antiangiogenetic properties. Eur J Med Chem 2020;189:112083. [PMID: 32000051 DOI: 10.1016/j.ejmech.2020.112083] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
159 Xiong C, Wen Y, Zhao J, Yin D, Xu L, Chelariu-Raicu A, Yao C, Leng X, Liu J, Chaudhari RR, Zhang S, Sood AK, Li C. Targeting Forward and Reverse EphB4/EFNB2 Signaling by a Peptide with Dual Functions. Sci Rep 2020;10:520. [PMID: 31949258 DOI: 10.1038/s41598-020-57477-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
160 Rezaie E, Amani J, Bidmeshki Pour A, Mahmoodzadeh Hosseini H. A new scfv-based recombinant immunotoxin against EPHA2-overexpressing breast cancer cells; High in vitro anti-cancer potency. Eur J Pharmacol 2020;870:172912. [PMID: 31926992 DOI: 10.1016/j.ejphar.2020.172912] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
161 Gianni-Barrera R, Di Maggio N, Melly L, Burger MG, Mujagic E, Gürke L, Schaefer DJ, Banfi A. Therapeutic vascularization in regenerative medicine. Stem Cells Transl Med 2020;9:433-44. [PMID: 31922362 DOI: 10.1002/sctm.19-0319] [Cited by in Crossref: 26] [Cited by in F6Publishing: 33] [Article Influence: 13.0] [Reference Citation Analysis]
162 Wang J, Zheng X, Peng Q, Zhang X, Qin Z. Eph receptors: the bridge linking host and virus. Cell Mol Life Sci 2020;77:2355-65. [PMID: 31893311 DOI: 10.1007/s00018-019-03409-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
163 Milewska M, Domoradzki T, Majewska A, Błaszczyk M, Gajewska M, Hulanicka M, Grzelkowska-Kowalczyk K. Interleukin-6 affects pacsin3, ephrinA4 expression and cytoskeletal proteins in differentiating primary skeletal myoblasts through transcriptional and post-transcriptional mechanisms. Cell Tissue Res 2020;380:155-72. [PMID: 31820147 DOI: 10.1007/s00441-019-03133-4] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
164 Scalia P, Williams SJ, Giordano A. Core Element Cloning, Cis-Element Mapping and Serum Regulation of the Human EphB4 Promoter: A Novel TATA-Less Inr/MTE/DPE-Like Regulated Gene. Genes (Basel) 2019;10:E997. [PMID: 31810288 DOI: 10.3390/genes10120997] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
165 Liu YL, Horning AM, Lieberman B, Kim M, Lin CK, Hung CN, Chou CW, Wang CM, Lin CL, Kirma NB, Liss MA, Vasisht R, Perillo EP, Blocher K, Horng H, Taverna JA, Ruan J, Yankeelov TE, Dunn AK, Huang TH, Yeh HC, Chen CL. Spatial EGFR Dynamics and Metastatic Phenotypes Modulated by Upregulated EphB2 and Src Pathways in Advanced Prostate Cancer. Cancers (Basel) 2019;11:E1910. [PMID: 31805710 DOI: 10.3390/cancers11121910] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
166 Day BW, Lathia JD, Bruce ZC, D'Souza RCJ, Baumgartner U, Ensbey KS, Lim YC, Stringer BW, Akgül S, Offenhäuser C, Li Y, Jamieson PR, Smith FM, Jurd CLR, Robertson T, Inglis PL, Lwin Z, Jeffree RL, Johns TG, Bhat KPL, Rich JN, Campbell KP, Boyd AW. The dystroglycan receptor maintains glioma stem cells in the vascular niche. Acta Neuropathol 2019;138:1033-52. [PMID: 31463571 DOI: 10.1007/s00401-019-02069-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
167 Luxán G, Stewen J, Díaz N, Kato K, Maney SK, Aravamudhan A, Berkenfeld F, Nagelmann N, Drexler HC, Zeuschner D, Faber C, Schillers H, Hermann S, Wiseman J, Vaquerizas JM, Pitulescu ME, Adams RH. Endothelial EphB4 maintains vascular integrity and transport function in adult heart. Elife 2019;8:e45863. [PMID: 31782728 DOI: 10.7554/eLife.45863] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 3.7] [Reference Citation Analysis]
168 Mercurio FA, Di Natale C, Pirone L, Vincenzi M, Marasco D, De Luca S, Pedone EM, Leone M. Exploring the Ability of Cyclic Peptides to Target SAM Domains: A Computational and Experimental Study. ChemBioChem 2020;21:702-11. [DOI: 10.1002/cbic.201900444] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
169 Mitra D, Bhattacharyya S, Alam N, Sen S, Mitra S, Mandal S, Vignesh S, Majumder B, Murmu N. Phosphorylation of EphA2 receptor and vasculogenic mimicry is an indicator of poor prognosis in invasive carcinoma of the breast. Breast Cancer Res Treat 2020;179:359-70. [PMID: 31686261 DOI: 10.1007/s10549-019-05482-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
170 Seano G, Jain RK. Vessel co-option in glioblastoma: emerging insights and opportunities. Angiogenesis 2020;23:9-16. [PMID: 31679081 DOI: 10.1007/s10456-019-09691-z] [Cited by in Crossref: 30] [Cited by in F6Publishing: 48] [Article Influence: 10.0] [Reference Citation Analysis]
171 Paul MD, Hristova K. The transition model of RTK activation: A quantitative framework for understanding RTK signaling and RTK modulator activity. Cytokine Growth Factor Rev 2019;49:23-31. [PMID: 31711797 DOI: 10.1016/j.cytogfr.2019.10.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
172 Chen X, Cao Y, Sedhom W, Lu L, Liu Y, Wang H, Oka M, Bornstein S, Said S, Song J, Lu SL. Distinct roles of PIK3CA in the enrichment and maintenance of cancer stem cells in head and neck squamous cell carcinoma. Mol Oncol 2020;14:139-58. [PMID: 31600013 DOI: 10.1002/1878-0261.12584] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
173 Ghosal S, Das S, Pang Y, Gonzales MK, Huynh TT, Yang Y, Taieb D, Crona J, Shankavaram UT, Pacak K. Long intergenic noncoding RNA profiles of pheochromocytoma and paraganglioma: A novel prognostic biomarker. Int J Cancer 2020;146:2326-35. [PMID: 31469413 DOI: 10.1002/ijc.32654] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
174 Saha N, Robev D, Himanen JP, Nikolov DB. ADAM proteases: Emerging role and targeting of the non-catalytic domains. Cancer Lett 2019;467:50-7. [PMID: 31593799 DOI: 10.1016/j.canlet.2019.10.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
175 Magic Z, Sandström J, Perez-Tenorio G. Ephrin‑B2 inhibits cell proliferation and motility in vitro and predicts longer metastasis‑free survival in breast cancer. Int J Oncol 2019;55:1275-86. [PMID: 31638179 DOI: 10.3892/ijo.2019.4892] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
176 Ishigaki H, Minami T, Morimura O, Kitai H, Horio D, Koda Y, Fujimoto E, Negi Y, Nakajima Y, Niki M, Kanemura S, Shibata E, Mikami K, Takahashi R, Yokoi T, Kuribayashi K, Kijima T. EphA2 inhibition suppresses proliferation of small-cell lung cancer cells through inducing cell cycle arrest. Biochem Biophys Res Commun 2019;519:846-53. [PMID: 31558317 DOI: 10.1016/j.bbrc.2019.09.076] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
177 Alibardi L. Immunodetection of ephrin receptors in the regenerating tail of the lizard Podarcis muralis suggests stimulation of differentiation and muscle segmentation. Zool Res 2019;40:416-26. [PMID: 31111695 DOI: 10.24272/j.issn.2095-8137.2019.046] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
178 Franco M, Carmena A. Eph signaling in mitotic spindle orientation: what´s your angle here? Cell Cycle 2019;18:2590-7. [PMID: 31475621 DOI: 10.1080/15384101.2019.1658479] [Reference Citation Analysis]
179 Kovalski JR, Shanderson RL, Khavari PA. Ras functional proximity proteomics establishes mTORC2 as new direct ras effector. Oncotarget 2019;10:5126-35. [PMID: 31497244 DOI: 10.18632/oncotarget.27025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
180 Huang C, Yuan W, Lai C, Zhong S, Yang C, Wang R, Mao L, Chen Z. EphA2-to-YAP pathway drives gastric cancer growth and therapy resistance. Int J Cancer. 2020;146:1937-1949. [PMID: 31376289 DOI: 10.1002/ijc.32609] [Cited by in Crossref: 16] [Cited by in F6Publishing: 26] [Article Influence: 5.3] [Reference Citation Analysis]
181 Lahaie S, Morales D, Bagci H, Hamoud N, Castonguay CE, Kazan JM, Desrochers G, Klar A, Gingras AC, Pause A, Côté JF, Kania A. The endosomal sorting adaptor HD-PTP is required for ephrin-B:EphB signalling in cellular collapse and spinal motor axon guidance. Sci Rep 2019;9:11945. [PMID: 31420572 DOI: 10.1038/s41598-019-48421-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
182 Liang LY, Patel O, Janes PW, Murphy JM, Lucet IS. Eph receptor signalling: from catalytic to non-catalytic functions. Oncogene 2019;38:6567-84. [PMID: 31406248 DOI: 10.1038/s41388-019-0931-2] [Cited by in Crossref: 34] [Cited by in F6Publishing: 43] [Article Influence: 11.3] [Reference Citation Analysis]
183 Caiazza F, Oficjalska K, Tosetto M, Phelan JJ, Noonan S, Martin P, Killick K, Breen L, O'Neill F, Nolan B, Furney S, Power R, Fennelly D, Craik CS, O'Sullivan J, Sheahan K, Doherty GA, Ryan EJ. KH-Type Splicing Regulatory Protein Controls Colorectal Cancer Cell Growth and Modulates the Tumor Microenvironment. Am J Pathol 2019;189:1916-32. [PMID: 31404541 DOI: 10.1016/j.ajpath.2019.07.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
184 Hjaltelin JX, Izarzugaza JMG, Jensen LJ, Russo F, Westergaard D, Brunak S. Identification of hyper-rewired genomic stress non-oncogene addiction genes across 15 cancer types. NPJ Syst Biol Appl 2019;5:27. [PMID: 31396397 DOI: 10.1038/s41540-019-0104-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
185 Huang ZR, Tipparaju SK, Kirpotin DB, Pien C, Kornaga T, Noble CO, Koshkaryev A, Tran J, Kamoun WS, Drummond DC. Formulation optimization of an ephrin A2 targeted immunoliposome encapsulating reversibly modified taxane prodrugs. J Control Release 2019;310:47-57. [PMID: 31400383 DOI: 10.1016/j.jconrel.2019.08.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
186 Dolan M, Mastri M, Tracz A, Christensen JG, Chatta G, Ebos JML. Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance. PLoS One 2019;14:e0220101. [PMID: 31369645 DOI: 10.1371/journal.pone.0220101] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
187 Linder H, Zhang Y. Iterative integrated imputation for missing data and pathway models with applications to breast cancer subtypes. CSAM 2019;26:411-30. [DOI: 10.29220/csam.2019.26.4.411] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
188 Di W, Weinan X, Xin L, Zhiwei Y, Xinyue G, Jinxue T, Mingqi L. Long noncoding RNA SNHG14 facilitates colorectal cancer metastasis through targeting EZH2-regulated EPHA7. Cell Death Dis 2019;10:514. [PMID: 31273190 DOI: 10.1038/s41419-019-1707-x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 59] [Article Influence: 14.7] [Reference Citation Analysis]
189 Darling TK, Lamb TJ. Emerging Roles for Eph Receptors and Ephrin Ligands in Immunity. Front Immunol 2019;10:1473. [PMID: 31333644 DOI: 10.3389/fimmu.2019.01473] [Cited by in Crossref: 47] [Cited by in F6Publishing: 62] [Article Influence: 15.7] [Reference Citation Analysis]
190 Scalia P, Pandini G, Carnevale V, Giordano A, Williams SJ. Identification of a novel EphB4 phosphodegron regulated by the autocrine IGFII/IRA axis in malignant mesothelioma. Oncogene 2019;38:5987-6001. [PMID: 31270394 DOI: 10.1038/s41388-019-0854-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
191 Hampton-O'Neil LA, Severn CE, Cross SJ, Gurung S, Nobes CD, Toye AM. Ephrin/Eph receptor interaction facilitates macrophage recognition of differentiating human erythroblasts. Haematologica 2020;105:914-24. [PMID: 31197068 DOI: 10.3324/haematol.2018.215160] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
192 Teramoto K, Katoh H. The cystine/glutamate antiporter xCT is a key regulator of EphA2 S897 phosphorylation under glucose-limited conditions. Cell Signal 2019;62:109329. [PMID: 31152846 DOI: 10.1016/j.cellsig.2019.05.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
193 Mu X, Huang O, Jiang M, Xie Z, Chen D, Zhang X. Prognostic value of ephrin B receptors in breast cancer: An online survival analysis using the microarray data of 3,554 patients. Oncol Lett 2019;18:742-50. [PMID: 31289549 DOI: 10.3892/ol.2019.10363] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
194 Brenca M, Stacchiotti S, Fassetta K, Sbaraglia M, Janjusevic M, Racanelli D, Polano M, Rossi S, Brich S, Dagrada GP, Collini P, Colombo C, Gronchi A, Astolfi A, Indio V, Pantaleo MA, Picci P, Casali PG, Dei Tos AP, Pilotti S, Maestro R. NR4A3 fusion proteins trigger an axon guidance switch that marks the difference between EWSR1 and TAF15 translocated extraskeletal myxoid chondrosarcomas. J Pathol 2019;249:90-101. [PMID: 31020999 DOI: 10.1002/path.5284] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
195 Gomez-Soler M, Petersen Gehring M, Lechtenberg BC, Zapata-Mercado E, Hristova K, Pasquale EB. Engineering nanomolar peptide ligands that differentially modulate EphA2 receptor signaling. J Biol Chem 2019;294:8791-805. [PMID: 31015204 DOI: 10.1074/jbc.RA119.008213] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
196 Chen Z, Liu Z, Zhang M, Huang W, Li Z, Wang S, Zhang C, Dong B, Gao J, Shen L. EPHA2 blockade reverses acquired resistance to afatinib induced by EPHA2-mediated MAPK pathway activation in gastric cancer cells and avatar mice. Int J Cancer 2019;145:2440-9. [PMID: 30957241 DOI: 10.1002/ijc.32313] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
197 Sereena MC, Sebastian D. Evaluation of Anticancer and Anti-hemolytic Activity of Azurin, a Novel Bacterial Protein from Pseudomonas aeruginosa SSj. Int J Pept Res Ther 2020;26:459-66. [DOI: 10.1007/s10989-019-09851-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
198 Su SA, Xie Y, Zhang Y, Xi Y, Cheng J, Xiang M. Essential roles of EphrinB2 in mammalian heart: from development to diseases. Cell Commun Signal 2019;17:29. [PMID: 30909943 DOI: 10.1186/s12964-019-0337-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
199 Horton JL, Virag J. Use of Multifactorial Treatments to Address the Challenge of Translating Experimental Myocardial Infarct Reduction Strategies. Int J Mol Sci 2019;20:E1449. [PMID: 30909376 DOI: 10.3390/ijms20061449] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
200 Inagaki Y, Tokunaga T, Yanai M, Wu D, Huang J, Nagase H, Fukuda N, Ozaki T, Soma M, Fujiwara K. Silencing of EPHB2 promotes the epithelial-mesenchymal transition of skin squamous cell carcinoma-derived A431 cells. Oncol Lett 2019;17:3735-42. [PMID: 30881495 DOI: 10.3892/ol.2019.10019] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
201 Wolfram J, Ferrari M. Clinical Cancer Nanomedicine. Nano Today 2019;25:85-98. [PMID: 31360214 DOI: 10.1016/j.nantod.2019.02.005] [Cited by in Crossref: 144] [Cited by in F6Publishing: 193] [Article Influence: 48.0] [Reference Citation Analysis]
202 Sun F, Suttapitugsakul S, Wu R. Enzymatic Tagging of Glycoproteins on the Cell Surface for Their Global and Site-Specific Analysis with Mass Spectrometry. Anal Chem 2019;91:4195-203. [PMID: 30794380 DOI: 10.1021/acs.analchem.9b00441] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
203 Mercurio FA, Di Natale C, Pirone L, Marasco D, Calce E, Vincenzi M, Pedone EM, De Luca S, Leone M. Design and analysis of EphA2-SAM peptide ligands: A multi-disciplinary screening approach. Bioorganic Chemistry 2019;84:434-43. [DOI: 10.1016/j.bioorg.2018.12.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
204 Garrido-Laguna I, Krop I, Burris HA 3rd, Hamilton E, Braiteh F, Weise AM, Abu-Khalaf M, Werner TL, Pirie-Shepherd S, Zopf CJ, Lakshminarayanan M, Holland JS, Baffa R, Hong DS. First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors. Int J Cancer 2019;145:1798-808. [PMID: 30680712 DOI: 10.1002/ijc.32154] [Cited by in Crossref: 10] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
205 Pan Y, Lu S, Lei L, Lamberto I, Wang Y, Pasquale EB, Wang Y. Genetically Encoded FRET Biosensor for Visualizing EphA4 Activity in Different Compartments of the Plasma Membrane. ACS Sens 2019;4:294-300. [PMID: 30608127 DOI: 10.1021/acssensors.8b00465] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
206 Suo G, Shen F, Sun B, Song H, Xu M, Wu Y. Abnormal expression of ephrin-A5 affects brain development of congenital hypothyroidism rats. Neuroreport 2018;29:877-82. [PMID: 29762250 DOI: 10.1097/WNR.0000000000001047] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
207 Chen J, Zhang X, Schaller S, Jardetzky TS, Longnecker R. Ephrin Receptor A4 is a New Kaposi's Sarcoma-Associated Herpesvirus Virus Entry Receptor. mBio 2019;10:e02892-18. [PMID: 30782663 DOI: 10.1128/mBio.02892-18] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
208 Lan C, Li J, Huang X, Heindl A, Wang Y, Yan S, Yuan Y. Stromal cell ratio based on automated image analysis as a predictor for platinum-resistant recurrent ovarian cancer. BMC Cancer 2019;19:159. [PMID: 30777045 DOI: 10.1186/s12885-019-5343-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
209 Ieguchi K, Maru Y. Roles of EphA1/A2 and ephrin-A1 in cancer. Cancer Sci 2019;110:841-8. [PMID: 30657619 DOI: 10.1111/cas.13942] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]
210 Kaibori Y, Saito Y, Nakayama Y. EphA2 phosphorylation at Ser897 by the Cdk1/MEK/ERK/RSK pathway regulates M-phase progression via maintenance of cortical rigidity. FASEB J 2019;33:5334-49. [PMID: 30668924 DOI: 10.1096/fj.201801519RR] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
211 Zhang P, Ming Y, Ye Q, Niu Y. Comprehensive circRNA expression profile during ischemic postconditioning attenuating hepatic ischemia/reperfusion injury. Sci Rep 2019;9:264. [PMID: 30670716 DOI: 10.1038/s41598-018-36443-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
212 Zhong B, Li Y, Idippily N, Petty A, Su B, Wang B. A quantitative LC-MS/MS method for determination of a small molecule agonist of EphA2 in mouse plasma and brain tissue. Biomed Chromatogr 2019;33:e4461. [PMID: 30548501 DOI: 10.1002/bmc.4461] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
213 Toyama M, Hamaoka Y, Katoh H. EphA3 is up-regulated by epidermal growth factor and promotes formation of glioblastoma cell aggregates. Biochem Biophys Res Commun 2019;508:715-21. [PMID: 30528229 DOI: 10.1016/j.bbrc.2018.12.002] [Reference Citation Analysis]
214 Zuo S, Dai G, Ren X. Identification of a 6-gene signature predicting prognosis for colorectal cancer. Cancer Cell Int. 2019;19:6. [PMID: 30627052 DOI: 10.1186/s12935-018-0724-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 41] [Article Influence: 8.3] [Reference Citation Analysis]
215 Fiore L, Medori M, Spelzini G, Carreño CO, Carri NG, Sanchez V, Scicolone G. Regulation of axonal EphA4 forward signaling is involved in the effect of EphA3 on chicken retinal ganglion cell axon growth during retinotectal mapping. Experimental Eye Research 2019;178:46-60. [DOI: 10.1016/j.exer.2018.09.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
216 Paul MD, Hristova K. The RTK Interactome: Overview and Perspective on RTK Heterointeractions. Chem Rev 2019;119:5881-921. [PMID: 30589534 DOI: 10.1021/acs.chemrev.8b00467] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
217 Li JY, Xiao T, Yi HM, Yi H, Feng J, Zhu JF, Huang W, Lu SS, Zhou YH, Li XH, Xiao ZQ. S897 phosphorylation of EphA2 is indispensable for EphA2-dependent nasopharyngeal carcinoma cell invasion, metastasis and stem properties. Cancer Lett 2019;444:162-74. [PMID: 30583071 DOI: 10.1016/j.canlet.2018.12.011] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
218 Offenhäuser C, Al-Ejeh F, Puttick S, Ensbey KS, Bruce ZC, Jamieson PR, Smith FM, Stringer BW, Carrington B, Fuchs AV, Bell CA, Jeffree R, Rose S, Thurecht KJ, Boyd AW, Day BW. EphA3 Pay-Loaded Antibody Therapeutics for the Treatment of Glioblastoma. Cancers (Basel) 2018;10:E519. [PMID: 30562956 DOI: 10.3390/cancers10120519] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
219 An E, Brognard J. Orange is the new black: Kinases are the new master regulators of tumor suppression. IUBMB Life 2019;71:738-48. [PMID: 30548122 DOI: 10.1002/iub.1981] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
220 Radford K, Taylor RC, Hall JG, Gick B. Aerodigestive and communicative behaviors in anencephalic and hydranencephalic infants. Birth Defects Research 2018. [DOI: 10.1002/bdr2.1424] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
221 Yu SN, Liu GF, Li LY, Zhao GQ, Liu L, Li XF. Analgesic effects of microRNA-129-5p against bone cancer pain through the EphB1/EphrinB2 signaling pathway in mice. J Cell Biochem 2019;120:2876-85. [PMID: 29236320 DOI: 10.1002/jcb.26605] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
222 Ahmed F, Hristova K. Dimerization of the Trk receptors in the plasma membrane: effects of their cognate ligands. Biochem J 2018;475:3669-85. [PMID: 30366959 DOI: 10.1042/BCJ20180637] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
223 Peng Q, Chen L, Wu W, Wang J, Zheng X, Chen Z, Jiang Q, Han J, Wei L, Wang L, Huang J, Ma J. EPH receptor A2 governs a feedback loop that activates Wnt/β-catenin signaling in gastric cancer. Cell Death Dis 2018;9:1146. [PMID: 30451837 DOI: 10.1038/s41419-018-1164-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
224 Chen P, Zhong Q, Li Z, Zhang Y, Huang Z. Expression and clinical significance of basic transcription factor 3 in nasopharyngeal carcinoma. Oncol Lett 2019;17:789-96. [PMID: 30655831 DOI: 10.3892/ol.2018.9699] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
225 Li X, Sui J, Xing J, Cao F, Wang H, Fu C, Wang H. Basic transcription factor 3 expression silencing attenuates colon cancer cell proliferation and migration in vitro. Oncol Lett 2019;17:113-8. [PMID: 30655745 DOI: 10.3892/ol.2018.9613] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
226 Liu ST, Zhong SM, Li XY, Gao F, Li F, Zhang ML, Zhu K, Sun XH, Wang X, Miao Y, Yang XL, Wang Z. EphrinB/EphB forward signaling in Müller cells causes apoptosis of retinal ganglion cells by increasing tumor necrosis factor alpha production in rat experimental glaucomatous model. Acta Neuropathol Commun 2018;6:111. [PMID: 30355282 DOI: 10.1186/s40478-018-0618-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
227 Madeo M, Colbert PL, Vermeer DW, Lucido CT, Cain JT, Vichaya EG, Grossberg AJ, Muirhead D, Rickel AP, Hong Z, Zhao J, Weimer JM, Spanos WC, Lee JH, Dantzer R, Vermeer PD. Cancer exosomes induce tumor innervation. Nat Commun 2018;9:4284. [PMID: 30327461 DOI: 10.1038/s41467-018-06640-0] [Cited by in Crossref: 72] [Cited by in F6Publishing: 94] [Article Influence: 18.0] [Reference Citation Analysis]
228 Liu L, Wang X, Ge W. EphA8 is a Prognostic Factor for Oral Tongue Squamous Cell Carcinoma. Med Sci Monit 2018;24:7213-22. [PMID: 30300334 DOI: 10.12659/MSM.910909] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
229 Li S, Zhai J, Liu J, Di F, Sun Y, Li W, Chen ZJ, Du Y. Erythropoietin-producing hepatocellular A7 triggering ovulation indicates a potential beneficial role for polycystic ovary syndrome. EBioMedicine 2018;36:539-52. [PMID: 30292674 DOI: 10.1016/j.ebiom.2018.09.046] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
230 Lee J, Liu Z, Sa JK, Shin S, Wang J, Bordyuh M, Cho HJ, Elliott O, Chu T, Choi SW, Rosenbloom DIS, Lee I, Shin YJ, Kang HJ, Kim D, Kim SY, Sim M, Kim J, Lee T, Seo YJ, Shin H, Lee M, Kim SH, Kwon Y, Oh J, Song M, Kim M, Kong D, Choi JW, Seol HJ, Lee J, Kim ST, Park JO, Kim K, Song S, Lee J, Kim H, Lee JE, Choi MG, Seo SW, Shim YM, Zo JI, Jeong BC, Yoon Y, Ryu GH, Kim NKD, Bae JS, Park W, Lee J, Verhaak RGW, Iavarone A, Lee J, Rabadan R, Nam D. Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. Nat Genet 2018;50:1399-411. [DOI: 10.1038/s41588-018-0209-6] [Cited by in Crossref: 78] [Cited by in F6Publishing: 84] [Article Influence: 19.5] [Reference Citation Analysis]
231 Zhang T, Li J, Ma X, Yang Y, Sun W, Jin W, Wang L, He Y, Yang F, Yi Z, Hua Y, Liu M, Chen Y, Cai Z. Inhibition of HDACs-EphA2 Signaling Axis with WW437 Demonstrates Promising Preclinical Antitumor Activity in Breast Cancer. EBioMedicine 2018;31:276-86. [PMID: 29759486 DOI: 10.1016/j.ebiom.2018.05.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
232 Zhao Y, Yin L, Zhang H, Lan T, Li S, Ma P. Eph/ephrin family anchored on exosome facilitate communications between cells. Cell Biol Int 2018;42:1458-62. [PMID: 29624789 DOI: 10.1002/cbin.10968] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
233 Berrou E, Soukaseum C, Favier R, Adam F, Elaib Z, Kauskot A, Bordet JC, Ballerini P, Loyau S, Feng M, Dias K, Muheidli A, Girault S, Nurden AT, Turro E, Ouwehand WH, Denis CV, Jandrot-Perrus M, Rosa JP, Nurden P, Bryckaert M. A mutation of the human EPHB2 gene leads to a major platelet functional defect. Blood 2018;132:2067-77. [PMID: 30213874 DOI: 10.1182/blood-2018-04-845644] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
234 Spit M, Koo BK, Maurice MM. Tales from the crypt: intestinal niche signals in tissue renewal, plasticity and cancer. Open Biol 2018;8:180120. [PMID: 30209039 DOI: 10.1098/rsob.180120] [Cited by in Crossref: 47] [Cited by in F6Publishing: 54] [Article Influence: 11.8] [Reference Citation Analysis]
235 Jamshidi-Parsian A, Griffin RJ, Kore RA, Todorova VK, Makhoul I. Tumor-endothelial cell interaction in an experimental model of human hepatocellular carcinoma. Exp Cell Res 2018;372:16-24. [PMID: 30205087 DOI: 10.1016/j.yexcr.2018.09.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
236 Park SL, Patel YM, Loo LWM, Mullen DJ, Offringa IA, Maunakea A, Stram DO, Siegmund K, Murphy SE, Tiirikainen M, Le Marchand L. Association of internal smoking dose with blood DNA methylation in three racial/ethnic populations. Clin Epigenetics 2018;10:110. [PMID: 30139389 DOI: 10.1186/s13148-018-0543-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
237 Gong W, Qie S, Huang P, Xi J. Deletion of long noncoding RNA EFNA3 aggravates hypoxia-induced injury in PC-12 cells by upregulation of miR-101a. J Cell Biochem 2019;120:836-47. [PMID: 30125989 DOI: 10.1002/jcb.27444] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
238 Muhammad BA, Almozyan S, Babaei-Jadidi R, Onyido EK, Saadeddin A, Kashfi SH, Spencer-Dene B, Ilyas M, Lourdusamy A, Behrens A, Nateri AS. FLYWCH1, a Novel Suppressor of Nuclear β-Catenin, Regulates Migration and Morphology in Colorectal Cancer. Mol Cancer Res 2018;16:1977-90. [PMID: 30097457 DOI: 10.1158/1541-7786.MCR-18-0262] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
239 Kadife E, Ware TMB, Luwor RB, Chan STF, Nurgali K, Senior PV. Effects of EphB4 receptor expression on colorectal cancer cells, tumor growth, vascularization and composition. Acta Oncol 2018;57:1043-56. [PMID: 29368976 DOI: 10.1080/0284186X.2018.1429650] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
240 Stallaert W, Brüggemann Y, Sabet O, Baak L, Gattiglio M, Bastiaens PIH. Contact inhibitory Eph signaling suppresses EGF-promoted cell migration by decoupling EGFR activity from vesicular recycling. Sci Signal 2018;11:eaat0114. [DOI: 10.1126/scisignal.aat0114] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
241 Nikas I, Ryu HS, Theocharis S. Viewing the Eph receptors with a focus on breast cancer heterogeneity. Cancer Lett 2018;434:160-71. [PMID: 30055288 DOI: 10.1016/j.canlet.2018.07.030] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
242 Gofur MR, Ogawa K. Compartments with predominant ephrin‐B1 and EphB2/B4 expression are present alternately along the excurrent duct system in the adult mouse testis and epididymis. Andrology 2019;7:888-901. [DOI: 10.1111/andr.12523] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
243 Dong M, Spelke DP, Lee YK, Chung JK, Yu CH, Schaffer DV, Groves JT. Spatiomechanical Modulation of EphB4-Ephrin-B2 Signaling in Neural Stem Cell Differentiation. Biophys J 2018;115:865-73. [PMID: 30075851 DOI: 10.1016/j.bpj.2018.06.031] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
244 Townsend MH, Shrestha G, Robison RA, O'Neill KL. The expansion of targetable biomarkers for CAR T cell therapy. J Exp Clin Cancer Res 2018;37:163. [PMID: 30031396 DOI: 10.1186/s13046-018-0817-0] [Cited by in Crossref: 42] [Cited by in F6Publishing: 51] [Article Influence: 10.5] [Reference Citation Analysis]
245 Tröster A, Heinzlmeir S, Berger BT, Gande SL, Saxena K, Sreeramulu S, Linhard V, Nasiri AH, Bolte M, Müller S, Kuster B, Médard G, Kudlinzki D, Schwalbe H. NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. ChemMedChem 2018;13:1629-33. [PMID: 29928781 DOI: 10.1002/cmdc.201800398] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
246 Kori M, Yalcin Arga K. Potential biomarkers and therapeutic targets in cervical cancer: Insights from the meta-analysis of transcriptomics data within network biomedicine perspective. PLoS One 2018;13:e0200717. [PMID: 30020984 DOI: 10.1371/journal.pone.0200717] [Cited by in Crossref: 41] [Cited by in F6Publishing: 46] [Article Influence: 10.3] [Reference Citation Analysis]
247 Jang BG, Kim HS, Chang WY, Bae JM, Kang GH. Prognostic Significance of EPHB2 Expression in Colorectal Cancer Progression. J Pathol Transl Med 2018;52:298-306. [PMID: 30016858 DOI: 10.4132/jptm.2018.06.29] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
248 Gianni-Barrera R, Butschkau A, Uccelli A, Certelli A, Valente P, Bartolomeo M, Groppa E, Burger MG, Hlushchuk R, Heberer M, Schaefer DJ, Gürke L, Djonov V, Vollmar B, Banfi A. PDGF-BB regulates splitting angiogenesis in skeletal muscle by limiting VEGF-induced endothelial proliferation. Angiogenesis 2018;21:883-900. [PMID: 30014172 DOI: 10.1007/s10456-018-9634-5] [Cited by in Crossref: 50] [Cited by in F6Publishing: 64] [Article Influence: 12.5] [Reference Citation Analysis]
249 Li X, Zhang Y, Zheng L, Liu M, Chen CD, Jiang H. UTX is an escape from X-inactivation tumor-suppressor in B cell lymphoma. Nat Commun 2018;9:2720. [PMID: 30006524 DOI: 10.1038/s41467-018-05084-w] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 6.3] [Reference Citation Analysis]
250 Uhl C, Markel M, Broggini T, Nieminen M, Kremenetskaia I, Vajkoczy P, Czabanka M. EphB4 mediates resistance to antiangiogenic therapy in experimental glioma. Angiogenesis 2018;21:873-81. [PMID: 29987450 DOI: 10.1007/s10456-018-9633-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
251 Wu Q, Xu L, Wang C, Fan W, Yan H, Li Q. MicroRNA-124-3p represses cell growth and cell motility by targeting EphA2 in glioma. Biochem Biophys Res Commun 2018;503:2436-42. [PMID: 29969628 DOI: 10.1016/j.bbrc.2018.06.173] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
252 Taylor H, Campbell J, Nobes CD. Ephs and ephrins. Curr Biol 2017;27:R90-5. [PMID: 28171762 DOI: 10.1016/j.cub.2017.01.003] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 11.8] [Reference Citation Analysis]
253 Alfaro D, Zapata AG. Eph/Ephrin-mediated stimulation of human bone marrow mesenchymal stromal cells correlates with changes in cell adherence and increased cell death. Stem Cell Res Ther 2018;9:172. [PMID: 29941036 DOI: 10.1186/s13287-018-0912-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
254 Hensel J, Wetterwald A, Temanni R, Keller I, Riether C, van der Pluijm G, Cecchini MG, Thalmann GN. Osteolytic cancer cells induce vascular/axon guidance processes in the bone/bone marrow stroma. Oncotarget 2018;9:28877-96. [DOI: 10.18632/oncotarget.25608] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
255 Wu X, Zahari MS, Renuse S, Sahasrabuddhe NA, Chaerkady R, Kim MS, Fackler MJ, Stampfer M, Gabrielson E, Sukumar S, Pandey A. Quantitative phosphoproteomic analysis reveals reciprocal activation of receptor tyrosine kinases between cancer epithelial cells and stromal fibroblasts. Clin Proteomics 2018;15:21. [PMID: 29946230 DOI: 10.1186/s12014-018-9197-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
256 Hong HN, Won YJ, Shim JH, Kim HJ, Han SH, Kim BS, Kim HS. Cancer-associated fibroblasts promote gastric tumorigenesis through EphA2 activation in a ligand-independent manner. J Cancer Res Clin Oncol 2018;144:1649-63. [PMID: 29948146 DOI: 10.1007/s00432-018-2683-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
257 Chavent M, Karia D, Kalli AC, Domański J, Duncan AL, Hedger G, Stansfeld PJ, Seiradake E, Jones EY, Sansom MSP. Interactions of the EphA2 Kinase Domain with PIPs in Membranes: Implications for Receptor Function. Structure 2018;26:1025-1034.e2. [PMID: 29887500 DOI: 10.1016/j.str.2018.05.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
258 Bhatia S, Sharma J, Bukkapatnam S, Oweida A, Lennon S, Phan A, Milner D, Uyanga N, Jimeno A, Raben D, Somerset H, Heasley L, Karam SD. Inhibition of EphB4-Ephrin-B2 Signaling Enhances Response to Cetuximab-Radiation Therapy in Head and Neck Cancers. Clin Cancer Res 2018;24:4539-50. [PMID: 29848571 DOI: 10.1158/1078-0432.CCR-18-0327] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
259 Yang WH, Cha JH, Xia W, Lee HH, Chan LC, Wang YN, Hsu JL, Ren G, Hung MC. Juxtacrine Signaling Inhibits Antitumor Immunity by Upregulating PD-L1 Expression. Cancer Res 2018;78:3761-8. [PMID: 29789418 DOI: 10.1158/0008-5472.CAN-18-0040] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
260 Wang Y, Shang Y, Li J, Chen W, Li G, Wan J, Liu W, Zhang M. Specific Eph receptor-cytoplasmic effector signaling mediated by SAM-SAM domain interactions. Elife 2018;7:e35677. [PMID: 29749928 DOI: 10.7554/eLife.35677] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
261 Hamaoka Y, Negishi M, Katoh H. Tyrosine kinase activity of EphA2 promotes its S897 phosphorylation and glioblastoma cell proliferation. Biochemical and Biophysical Research Communications 2018;499:920-6. [DOI: 10.1016/j.bbrc.2018.04.020] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
262 Worku T, Wang K, Ayers D, Wu D, Ur Rehman Z, Zhou H, Yang L. Regulatory roles of ephrinA5 and its novel signaling pathway in mouse primary granulosa cell apoptosis and proliferation. Cell Cycle 2018;17:892-902. [PMID: 29619874 DOI: 10.1080/15384101.2018.1456297] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
263 Malik VA, Di Benedetto B. The Blood-Brain Barrier and the EphR/Ephrin System: Perspectives on a Link Between Neurovascular and Neuropsychiatric Disorders. Front Mol Neurosci 2018;11:127. [PMID: 29706868 DOI: 10.3389/fnmol.2018.00127] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
264 Kim SH, Lee WH, Kim SW, Je HU, Lee JC, Chang HW, Kim YM, Kim K, Kim SY, Han MW. EphA3 maintains radioresistance in head and neck cancers through epithelial mesenchymal transition. Cell Signal 2018;47:122-30. [PMID: 29653204 DOI: 10.1016/j.cellsig.2018.04.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
265 Kadota T, Fujita Y, Yoshioka Y, Araya J, Kuwano K, Ochiya T. Emerging role of extracellular vesicles as a senescence-associated secretory phenotype: Insights into the pathophysiology of lung diseases. Molecular Aspects of Medicine 2018;60:92-103. [DOI: 10.1016/j.mam.2017.11.005] [Cited by in Crossref: 67] [Cited by in F6Publishing: 63] [Article Influence: 16.8] [Reference Citation Analysis]
266 Caivano A, La Rocca F, Laurenzana I, Annese T, Tamma R, Famigliari U, Simeon V, Trino S, De Luca L, Villani O, Berardi S, Basile A, Vacca A, Saglio G, Del Vecchio L, Musto P, Cilloni D. Epha3 acts as proangiogenic factor in multiple myeloma. Oncotarget 2017;8:34298-309. [PMID: 28415715 DOI: 10.18632/oncotarget.16100] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
267 Gu X, Xiao Q, Ruan Q, Shu Y, Dongre A, Iyer R, Humphreys WG, Lai Y. Comparative untargeted proteomic analysis of ADME proteins and tumor antigens for tumor cell lines. Acta Pharm Sin B 2018;8:252-60. [PMID: 29719786 DOI: 10.1016/j.apsb.2017.10.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
268 Kou CJ, Kandpal RP. Differential Expression Patterns of Eph Receptors and Ephrin Ligands in Human Cancers. Biomed Res Int 2018;2018:7390104. [PMID: 29682554 DOI: 10.1155/2018/7390104] [Cited by in Crossref: 18] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
269 Salem AF, Wang S, Billet S, Chen JF, Udompholkul P, Gambini L, Baggio C, Tseng HR, Posadas EM, Bhowmick NA, Pellecchia M. Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide-Drug Conjugate. J Med Chem 2018;61:2052-61. [PMID: 29470068 DOI: 10.1021/acs.jmedchem.7b01837] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
270 Fokas E, Kamlah F, Hänze J, Engenhart-Cabillic R, Rose F, An HX. EphA2 blockade enhances the anti-endothelial effect of radiation and inhibits irradiated tumor cell-induced migration of endothelial cells. Thorac Cancer 2010;1:153-62. [PMID: 27755819 DOI: 10.1111/j.1759-7714.2010.00029.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
271 Ma T, Liu X, Cen Z, Xin C, Guo M, Zou C, Song W, Xie R, Wang K, Zhou H, Zhang J, Wang Z, Bian C, Cui K, Li J, Wei YQ, Li J, Zhou X. MicroRNA-302b negatively regulates IL-1β production in response to MSU crystals by targeting IRAK4 and EphA2. Arthritis Res Ther 2018;20:34. [PMID: 29482609 DOI: 10.1186/s13075-018-1528-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
272 Singh DR, Kanvinde P, King C, Pasquale EB, Hristova K. The EphA2 receptor is activated through induction of distinct, ligand-dependent oligomeric structures. Commun Biol 2018;1:15. [PMID: 30271902 DOI: 10.1038/s42003-018-0017-7] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 10.0] [Reference Citation Analysis]
273 Paul JM, Toosi B, Vizeacoumar FS, Bhanumathy KK, Li Y, Gerger C, El Zawily A, Freywald T, Anderson DH, Mousseau D, Kanthan R, Zhang Z, Vizeacoumar FJ, Freywald A. Targeting synthetic lethality between the SRC kinase and the EPHB6 receptor may benefit cancer treatment. Oncotarget 2016;7:50027-42. [PMID: 27418135 DOI: 10.18632/oncotarget.10569] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
274 Zhao J, Zhao F, Wang X, Fan X, Wu G. Secondary nuclear targeting of mesoporous silica nano-particles for cancer-specific drug delivery based on charge inversion. Oncotarget 2016;7:70100-12. [PMID: 27661121 DOI: 10.18632/oncotarget.12149] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
275 Efazat G, Novak M, Kaminskyy VO, De Petris L, Kanter L, Juntti T, Bergman P, Zhivotovsky B, Lewensohn R, Hååg P, Viktorsson K. Ephrin B3 interacts with multiple EphA receptors and drives migration and invasion in non-small cell lung cancer. Oncotarget 2016;7:60332-47. [PMID: 27533087 DOI: 10.18632/oncotarget.11219] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
276 Zhou D, Ren K, Wang J, Ren H, Yang W, Wang W, Li Q, Liu X, Tang F. Erythropoietin-producing hepatocellular A6 overexpression is a novel biomarker of poor prognosis in patients with breast cancer. Oncol Lett 2018;15:5257-63. [PMID: 29552165 DOI: 10.3892/ol.2018.7919] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
277 Salgia R, Kulkarni P, Gill PS. EphB4: A promising target for upper aerodigestive malignancies. Biochim Biophys Acta Rev Cancer 2018;1869:128-37. [PMID: 29369779 DOI: 10.1016/j.bbcan.2018.01.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
278 Liu X, Xu Y, Jin Q, Wang W, Zhang S, Wang X, Zhang Y, Xu X, Huang J. EphA8 is a prognostic marker for epithelial ovarian cancer. Oncotarget 2016;7:20801-9. [PMID: 26989075 DOI: 10.18632/oncotarget.8018] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
279 Xu D, Yuan L, Liu X, Li M, Zhang F, Gu XY, Zhang D, Yang Y, Cui B, Tong J, Zhou J, Yu Z. EphB6 overexpression and Apc mutation together promote colorectal cancer. Oncotarget 2016;7:31111-21. [PMID: 27145271 DOI: 10.18632/oncotarget.9080] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
280 Yamamoto R, Osawa T, Sasaki Y, Yamamoto S, Anai M, Izumi K, Matsumura Y, Sakai J, Aburatani H, Mizokami A, Kodama T, Tanaka T. Overexpression of p54nrb/NONO induces differential EPHA6 splicing and contributes to castration-resistant prostate cancer growth. Oncotarget 2018;9:10510-24. [PMID: 29535823 DOI: 10.18632/oncotarget.24063] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
281 Kapinova A, Kubatka P, Zubor P, Golubnitschaja O, Dankova Z, Uramova S, Pilchova I, Caprnda M, Opatrilova R, Richnavsky J, Kruzliak P, Danko J. The hypoxia-responsive long non-coding RNAs may impact on the tumor biology and subsequent management of breast cancer. Biomed Pharmacother 2018;99:51-8. [PMID: 29324312 DOI: 10.1016/j.biopha.2017.12.104] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
282 Tanabe S, Aoyagi K, Yokozaki H, Sasaki H; 1 Division of Risk Assessment, Biological Safety Research Center, National Institute of Health Sciences, Kawasaki, Japan, 2 Department of Clinical Genomics, National Cancer Center Research Institute, Tokyo, Japan, 3 Department of Pathology, Kobe University of Graduate School of Medicine, Kobe, Japan, 4 Department of Translational Oncology, National Cancer Center Research Institute, Tokyo, Japan. . AIMS Cell and Tissue Engineering 2018;2:58-77. [DOI: 10.3934/celltissue.2018.2.58] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
283 Bennett TM, M'Hamdi O, Hejtmancik JF, Shiels A. Germ-line and somatic EPHA2 coding variants in lens aging and cataract. PLoS One 2017;12:e0189881. [PMID: 29267365 DOI: 10.1371/journal.pone.0189881] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
284 Montagnani V, Benelli M, Apollo A, Pescucci C, Licastro D, Urso C, Gerlini G, Borgognoni L, Luzzatto L, Stecca B. Thin and thick primary cutaneous melanomas reveal distinct patterns of somatic copy number alterations. Oncotarget 2016;7:30365-78. [PMID: 27095580 DOI: 10.18632/oncotarget.8758] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
285 Locke C, Machida K, Tucker CL, Wu Y, Yu J. Optogenetic activation of EphB2 receptor in dendrites induced actin polymerization by activating Arg kinase. Biol Open 2017;6:1820-30. [PMID: 29158322 DOI: 10.1242/bio.029900] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
286 Quinn BA, Wang S, Barile E, Das SK, Emdad L, Sarkar D, De SK, Morvaridi SK, Stebbins JL, Pandol SJ, Fisher PB, Pellecchia M. Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine. Oncotarget 2016;7:17103-10. [PMID: 26959746 DOI: 10.18632/oncotarget.7931] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
287 Javaherian S, D'Arcangelo E, Slater B, Londono C, Xu B, McGuigan AP. Modulation of cellular polarization and migration by ephrin/Eph signal-mediated boundary formation. Integr Biol (Camb) 2017;9:934-46. [PMID: 29120470 DOI: 10.1039/c7ib00176b] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
288 Cantisani MC, Parascandolo A, Perälä M, Allocca C, Fey V, Sahlberg N, Merolla F, Basolo F, Laukkanen MO, Kallioniemi OP, Santoro M, Castellone MD. A loss-of-function genetic screening identifies novel mediators of thyroid cancer cell viability. Oncotarget 2016;7:28510-22. [PMID: 27058903 DOI: 10.18632/oncotarget.8577] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
289 Daoud A, Gopal U, Kaur J, Isaacs JS. Molecular and functional crosstalk between extracellular Hsp90 and ephrin A1 signaling. Oncotarget 2017;8:106807-19. [PMID: 29290990 DOI: 10.18632/oncotarget.22370] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
290 Edwards DN, Ngwa VM, Wang S, Shiuan E, Brantley-Sieders DM, Kim LC, Reynolds AB, Chen J. The receptor tyrosine kinase EphA2 promotes glutamine metabolism in tumors by activating the transcriptional coactivators YAP and TAZ. Sci Signal 2017;10:eaan4667. [PMID: 29208682 DOI: 10.1126/scisignal.aan4667] [Cited by in Crossref: 42] [Cited by in F6Publishing: 48] [Article Influence: 8.4] [Reference Citation Analysis]
291 Husa AM, Magić Ž, Larsson M, Fornander T, Pérez-Tenorio G. EPH/ephrin profile and EPHB2 expression predicts patient survival in breast cancer. Oncotarget 2016;7:21362-80. [PMID: 26870995 DOI: 10.18632/oncotarget.7246] [Cited by in Crossref: 16] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
292 Sasabe E, Tomomura A, Tomita R, Sento S, Kitamura N, Yamamoto T. Ephrin-B2 reverse signaling regulates progression and lymph node metastasis of oral squamous cell carcinoma. PLoS One 2017;12:e0188965. [PMID: 29190834 DOI: 10.1371/journal.pone.0188965] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
293 Rupp T, Langlois B, Koczorowska MM, Radwanska A, Sun Z, Hussenet T, Lefebvre O, Murdamoothoo D, Arnold C, Klein A, Biniossek ML, Hyenne V, Naudin E, Velazquez-Quesada I, Schilling O, Van Obberghen-Schilling E, Orend G. Tenascin-C Orchestrates Glioblastoma Angiogenesis by Modulation of Pro- and Anti-angiogenic Signaling.Cell Rep. 2016;17:2607-2619. [PMID: 27926865 DOI: 10.1016/j.celrep.2016.11.012] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 8.4] [Reference Citation Analysis]
294 Gumus E, Kaloglu C, Sari I, Yilmaz M, Cetin A. Effects of vitrification and transplantation on follicular development and expression of EphrinB1 and PDGFA in mouse ovaries. Cryobiology 2018;80:101-13. [PMID: 29154909 DOI: 10.1016/j.cryobiol.2017.11.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
295 El Zawily A, McEwen E, Toosi B, Vizeacoumar FS, Freywald T, Vizeacoumar FJ, Freywald A. The EphB6 receptor is overexpressed in pediatric T cell acute lymphoblastic leukemia and increases its sensitivity to doxorubicin treatment. Sci Rep 2017;7:14767. [PMID: 29116180 DOI: 10.1038/s41598-017-15200-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
296 Haghiralsadat F, Amoabediny G, Naderinezhad S, Nazmi K, De Boer JP, Zandieh-doulabi B, Forouzanfar T, Helder MN. EphA2 Targeted Doxorubicin-Nanoliposomes for Osteosarcoma Treatment. Pharm Res 2017;34:2891-900. [DOI: 10.1007/s11095-017-2272-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
297 Evergren E, Cobbe N, McMahon HT. Eps15R and clathrin regulate EphB2-mediated cell repulsion. Traffic 2018;19:44-57. [PMID: 28972287 DOI: 10.1111/tra.12531] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
298 Weghorn D, Sunyaev S. Bayesian inference of negative and positive selection in human cancers. Nat Genet 2017;49:1785-8. [DOI: 10.1038/ng.3987] [Cited by in Crossref: 48] [Cited by in F6Publishing: 33] [Article Influence: 9.6] [Reference Citation Analysis]
299 Hachim IY, Villatoro M, Canaff L, Hachim MY, Boudreault J, Haiub H, Ali S, Lebrun JJ. Transforming Growth Factor-beta Regulation of Ephrin Type-A Receptor 4 Signaling in Breast Cancer Cellular Migration. Sci Rep 2017;7:14976. [PMID: 29101386 DOI: 10.1038/s41598-017-14549-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
300 Arabzadeh A, McGregor K, Breton V, Van Der Kraak L, Akavia UD, Greenwood CMT, Beauchemin N. EphA2 signaling is impacted by carcinoembryonic antigen cell adhesion molecule 1-L expression in colorectal cancer liver metastasis in a cell context-dependent manner. Oncotarget 2017;8:104330-46. [PMID: 29262644 DOI: 10.18632/oncotarget.22236] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
301 Goichberg P. Current Understanding of the Pathways Involved in Adult Stem and Progenitor Cell Migration for Tissue Homeostasis and Repair. Stem Cell Rev Rep 2016;12:421-37. [PMID: 27209167 DOI: 10.1007/s12015-016-9663-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
302 Cho HJ, Hwang YS, Yoon J, Lee M, Lee HG, Daar IO. EphrinB1 promotes cancer cell migration and invasion through the interaction with RhoGDI1. Oncogene 2018;37:861-72. [PMID: 29059157 DOI: 10.1038/onc.2017.386] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
303 Berry V, Pontikos N, Albarca-Aguilera M, Plagnol V, Massouras A, Prescott D, Moore AT, Arno G, Cheetham ME, Michaelides M. A recurrent splice-site mutation in EPHA2 causing congenital posterior nuclear cataract. Ophthalmic Genet 2018;39:236-41. [PMID: 29039721 DOI: 10.1080/13816810.2017.1381977] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
304 Royet A, Broutier L, Coissieux MM, Malleval C, Gadot N, Maillet D, Gratadou-Hupon L, Bernet A, Nony P, Treilleux I, Honnorat J, Liebl D, Pelletier L, Berger F, Meyronet D, Castets M, Mehlen P. Ephrin-B3 supports glioblastoma growth by inhibiting apoptosis induced by the dependence receptor EphA4. Oncotarget 2017;8:23750-9. [PMID: 28423606 DOI: 10.18632/oncotarget.16077] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
305 Petty A, Idippily N, Bobba V, Geldenhuys WJ, Zhong B, Su B, Wang B. Design and synthesis of small molecule agonists of EphA2 receptor. Eur J Med Chem 2018;143:1261-76. [PMID: 29128116 DOI: 10.1016/j.ejmech.2017.10.026] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
306 Megiorni F, Gravina GL, Camero S, Ceccarelli S, Del Fattore A, Desiderio V, Papaccio F, McDowell HP, Shukla R, Pizzuti A, Beirinckx F, Pujuguet P, Saniere L, der Aar EV, Maggio R, De Felice F, Marchese C, Dominici C, Tombolini V, Festuccia C, Marampon F. Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells. J Hematol Oncol 2017;10:161. [PMID: 28985758 DOI: 10.1186/s13045-017-0530-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
307 Chen Y, Zhang H, Zhang Y. Targeting receptor tyrosine kinase EphB4 in cancer therapy. Semin Cancer Biol 2019;56:37-46. [PMID: 28993206 DOI: 10.1016/j.semcancer.2017.10.002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 5.2] [Reference Citation Analysis]
308 Graves PR, Din SU, Ashamalla M, Ashamalla H, Gilbert TSK, Graves LM. Ionizing radiation induces EphA2 S897 phosphorylation in a MEK/ERK/RSK-dependent manner. Int J Radiat Biol 2017;93:929-36. [PMID: 28705041 DOI: 10.1080/09553002.2017.1355580] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
309 Okumura F, Joo-Okumura A, Obara K, Petersen A, Nishikimi A, Fukui Y, Nakatsukasa K, Kamura T. Ubiquitin ligase SPSB4 diminishes cell repulsive responses mediated by EphB2. Mol Biol Cell 2017;28:3532-41. [PMID: 28931592 DOI: 10.1091/mbc.E17-07-0450] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
310 Mercurio FA, Costantini S, Di Natale C, Pirone L, Guariniello S, Scognamiglio PL, Marasco D, Pedone EM, Leone M. Structural investigation of a C-terminal EphA2 receptor mutant: Does mutation affect the structure and interaction properties of the Sam domain? Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 2017;1865:1095-104. [DOI: 10.1016/j.bbapap.2017.06.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
311 Mukai M, Suruga N, Saeki N, Ogawa K. EphA receptors and ephrin-A ligands are upregulated by monocytic differentiation/maturation and promote cell adhesion and protrusion formation in HL60 monocytes. BMC Cell Biol 2017;18:28. [PMID: 28851287 DOI: 10.1186/s12860-017-0144-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
312 Ivey JW, Latouche EL, Richards ML, Lesser GJ, Debinski W, Davalos RV, Verbridge SS. Enhancing Irreversible Electroporation by Manipulating Cellular Biophysics with a Molecular Adjuvant. Biophys J 2017;113:472-80. [PMID: 28746857 DOI: 10.1016/j.bpj.2017.06.014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
313 Randolph ME, Cleary MM, Bajwa Z, Svalina MN, Young MC, Mansoor A, Kaur P, Bult CJ, Goros MW, Michalek JE, Xiang S, Keck J, Krasnoperov V, Gill P, Keller C. EphB4/EphrinB2 therapeutics in Rhabdomyosarcoma. PLoS One 2017;12:e0183161. [PMID: 28817624 DOI: 10.1371/journal.pone.0183161] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
314 Yu C, Fu C, Hung L, Wang C, Chiang N, Wang Y, Shan Y, Lee G. Screening of peptide specific to cholangiocarcinoma cancer cells using an integrated microfluidic system and phage display technology. Microfluid Nanofluid 2017;21. [DOI: 10.1007/s10404-017-1983-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
315 Kim MA, Yoon HS, Park SH, Kim DY, Pyo A, Kim HS, Min JJ, Hong Y. Engineering of monobody conjugates for human EphA2-specific optical imaging. PLoS One 2017;12:e0180786. [PMID: 28686661 DOI: 10.1371/journal.pone.0180786] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
316 Kuramitsu S, Yamamichi A, Ohka F, Motomura K, Hara M, Natsume A. Adoptive immunotherapy for the treatment of glioblastoma: progress and possibilities. Immunotherapy 2016;8:1393-404. [PMID: 28000534 DOI: 10.2217/imt-2016-0076] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
317 Takasugi M, Okada R, Takahashi A, Virya Chen D, Watanabe S, Hara E. Small extracellular vesicles secreted from senescent cells promote cancer cell proliferation through EphA2. Nat Commun 2017;8:15729. [PMID: 28585531 DOI: 10.1038/ncomms15728] [Cited by in Crossref: 144] [Cited by in F6Publishing: 172] [Article Influence: 28.8] [Reference Citation Analysis]
318 Gugliotta G, Castagnetti F, Breccia M, Albano F, Iurlo A, Intermesoli T, Abruzzese E, Levato L, D'Adda M, Pregno P, Cavazzini F, Stagno F, Martino B, La Barba G, Sorà F, Tiribelli M, Bigazzi C, Binotto G, Bonifacio M, Caracciolo C, Soverini S, Foà R, Cavo M, Martinelli G, Pane F, Saglio G, Baccarani M, Rosti G; Gruppo Italiano Malattie Ematologiche dell’Adulto - Chronic Myeloid Leukemia Working Party. Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia. Haematologica 2017;102:1530-6. [PMID: 28572163 DOI: 10.3324/haematol.2017.169532] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
319 Jacobson O, Li Q, Chen H, Niu G, Kiesewetter DO, Xu L, Cook K, Yang G, Dall'Acqua W, Tsui P, Peng L, Chen X. PET-Guided Evaluation and Optimization of Internalized Antibody-Drug Conjugates Targeting Erythropoietin-Producing Hepatoma A2 Receptor. J Nucl Med 2017;58:1838-44. [PMID: 28546337 DOI: 10.2967/jnumed.117.192245] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
320 Li Y, Ohira M, Zhou Y, Xiong T, Luo W, Yang C, Li X, Gao Z, Zhou R, Nakamura Y, Kamijo T, Kaneko Y, Taketani T, Ueyama J, Tajiri T, Zhang H, Wang J, Yang H, Yin Y, Nakagawara A. Genomic analysis-integrated whole-exome sequencing of neuroblastomas identifies genetic mutations in axon guidance pathway. Oncotarget 2017;8:56684-97. [PMID: 28915622 DOI: 10.18632/oncotarget.18079] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
321 Hwang YS, Daar IO. A frog's view of EphrinB signaling. Genesis 2017;55. [PMID: 28095646 DOI: 10.1002/dvg.23002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
322 Kiessling S, O'Callaghan EK, Freyburger M, Cermakian N, Mongrain V. The cell adhesion molecule EphA4 is involved in circadian clock functions. Genes Brain Behav 2018;17:82-92. [PMID: 28425198 DOI: 10.1111/gbb.12387] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
323 Nasri B, Inokuchi M, Ishikawa T, Uetake H, Takagi Y, Otsuki S, Kojima K, Kawano T. High expression of EphA3 (erythropoietin-producing hepatocellular A3) in gastric cancer is associated with metastasis and poor survival. BMC Clin Pathol 2017;17:8. [PMID: 28465671 DOI: 10.1186/s12907-017-0047-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
324 Lin CY, Lee YE, Tian YF, Sun DP, Sheu MJ, Lin CY, Li CF, Lee SW, Lin LC, Chang IW, Wang CT, He HL. High Expression of EphA4 Predicted Lesser Degree of Tumor Regression after Neoadjuvant Chemoradiotherapy in Rectal Cancer. J Cancer 2017;8:1089-96. [PMID: 28529623 DOI: 10.7150/jca.17471] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
325 Ding L, Shen Y, Ni J, Ou Y, Ou Y, Liu H. EphA4 promotes cell proliferation and cell adhesion-mediated drug resistance via the AKT pathway in multiple myeloma. Tumour Biol 2017;39:1010428317694298. [PMID: 28351297 DOI: 10.1177/1010428317694298] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
326 Ghosh D, Funk CC, Caballero J, Shah N, Rouleau K, Earls JC, Soroceanu L, Foltz G, Cobbs CS, Price ND, Hood L. A Cell-Surface Membrane Protein Signature for Glioblastoma. Cell Syst 2017;4:516-529.e7. [PMID: 28365151 DOI: 10.1016/j.cels.2017.03.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
327 Zhao C, Wang A, Lu F, Chen H, Fu P, Zhao X, Chen H. Overexpression of junctional adhesion molecule-A and EphB2 predicts poor survival in lung adenocarcinoma patients. Tumour Biol 2017;39:1010428317691000. [PMID: 28231727 DOI: 10.1177/1010428317691000] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
328 Shi X, Hapiak V, Zheng J, Muller-Greven J, Bowman D, Lingerak R, Buck M, Wang BC, Smith AW. A role of the SAM domain in EphA2 receptor activation. Sci Rep 2017;7:45084. [PMID: 28338017 DOI: 10.1038/srep45084] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
329 Yadav SS, Li J, Stockert JA, Herzog B, O'Connor J, Garzon-Manco L, Parsons R, Tewari AK, Yadav KK. Induction of Neuroendocrine Differentiation in Prostate Cancer Cells by Dovitinib (TKI-258) and its Therapeutic Implications. Transl Oncol 2017;10:357-66. [PMID: 28342996 DOI: 10.1016/j.tranon.2017.01.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
330 Zhang X, Maity T, Kashyap MK, Bansal M, Venugopalan A, Singh S, Awasthi S, Marimuthu A, Charles Jacob HK, Belkina N, Pitts S, Cultraro CM, Gao S, Kirkali G, Biswas R, Chaerkady R, Califano A, Pandey A, Guha U. Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response. Mol Cell Proteomics 2017;16:891-910. [PMID: 28331001 DOI: 10.1074/mcp.M117.067439] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 6.6] [Reference Citation Analysis]
331 Ventrella R, Kaplan N, Getsios S. Asymmetry at cell-cell interfaces direct cell sorting, boundary formation, and tissue morphogenesis. Exp Cell Res 2017;358:58-64. [PMID: 28322822 DOI: 10.1016/j.yexcr.2017.03.024] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
332 Mateo-Lozano S, Bazzocco S, Rodrigues P, Mazzolini R, Andretta E, Dopeso H, Fernández Y, Del Llano E, Bilic J, Suárez-López L, Macaya I, Cartón-García F, Nieto R, Jimenez-Flores LM, de Marcondes PG, Nuñez Y, Afonso E, Cacci K, Hernández-Losa J, Landolfi S, Abasolo I, Ramón Y Cajal S, Mariadason JM, Schwartz S Jr, Matsui T, Arango D. Loss of the EPH receptor B6 contributes to colorectal cancer metastasis. Sci Rep 2017;7:43702. [PMID: 28262839 DOI: 10.1038/srep43702] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
333 Arend KC, Lenarcic EM, Vincent HA, Rashid N, Lazear E, McDonald IM, Gilbert TS, East MP, Herring LE, Johnson GL, Graves LM, Moorman NJ. Kinome Profiling Identifies Druggable Targets for Novel Human Cytomegalovirus (HCMV) Antivirals. Mol Cell Proteomics 2017;16:S263-76. [PMID: 28237943 DOI: 10.1074/mcp.M116.065375] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
334 Wei W, Wang H, Ji S. Paradoxes of the EphB1 receptor in malignant brain tumors. Cancer Cell Int 2017;17:21. [PMID: 28194092 DOI: 10.1186/s12935-017-0384-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
335 Andretta E, Cartón-García F, Martínez-Barriocanal Á, de Marcondes PG, Jimenez-Flores LM, Macaya I, Bazzocco S, Bilic J, Rodrigues P, Nieto R, Landolfi S, Ramon Y Cajal S, Schwartz S, Brown A, Dopeso H, Arango D. Investigation of the role of tyrosine kinase receptor EPHA3 in colorectal cancer. Sci Rep 2017;7:41576. [PMID: 28169277 DOI: 10.1038/srep41576] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
336 Messina-Baas O, Cuevas-Covarrubias SA. Inherited Congenital Cataract: A Guide to Suspect the Genetic Etiology in the Cataract Genesis. Mol Syndromol 2017;8:58-78. [PMID: 28611546 DOI: 10.1159/000455752] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 5.4] [Reference Citation Analysis]
337 Stammes MA, Prevoo HA, Ter Horst MC, Groot SA, Van de Velde CJ, Chan AB, de Geus-Oei LF, Kuppen PJ, Vahrmeijer AL, Pasquale EB, Sier CF. Evaluation of EphA2 and EphB4 as Targets for Image-Guided Colorectal Cancer Surgery. Int J Mol Sci 2017;18:E307. [PMID: 28165374 DOI: 10.3390/ijms18020307] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
338 Liu X, Liu X, Liu W, Luo M, Tao H, Wu D, Zhao Y, Zou L. HOXA9 transcriptionally regulates the EPHB4 receptor to modulate trophoblast migration and invasion. Placenta 2017;51:38-48. [PMID: 28292467 DOI: 10.1016/j.placenta.2017.01.127] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
339 Incerti M, Russo S, Callegari D, Pala D, Giorgio C, Zanotti I, Barocelli E, Vicini P, Vacondio F, Rivara S, Castelli R, Tognolini M, Lodola A. Metadynamics for Perspective Drug Design: Computationally Driven Synthesis of New Protein-Protein Interaction Inhibitors Targeting the EphA2 Receptor. J Med Chem 2017;60:787-96. [PMID: 28005388 DOI: 10.1021/acs.jmedchem.6b01642] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 4.2] [Reference Citation Analysis]
340 Donakonda S, Sinha S, Dighe SN, Rao MRS. System analysis identifies distinct and common functional networks governed by transcription factor ASCL1, in glioma and small cell lung cancer. Mol BioSyst 2017;13:1481-94. [DOI: 10.1039/c6mb00851h] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
341 Rudno-Rudzińska J, Kielan W, Frejlich E, Kotulski K, Hap W, Kurnol K, Dzierżek P, Zawadzki M, Hałoń A. A review on Eph/ephrin, angiogenesis and lymphangiogenesis in gastric, colorectal and pancreatic cancers. Chin J Cancer Res 2017;29:303-12. [PMID: 28947862 DOI: 10.21147/j.issn.1000-9604.2017.04.03] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
342 Hegde S, Srivastava O. Different gene knockout/transgenic mouse models manifesting persistent fetal vasculature: Are integrins to blame for this pathological condition? Life Sci 2017;171:30-8. [PMID: 28039002 DOI: 10.1016/j.lfs.2016.12.019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
343 Farshchian M, Nissinen L, Grénman R, Kähäri VM. Dasatinib promotes apoptosis of cutaneous squamous carcinoma cells by regulating activation of ERK1/2. Exp Dermatol 2017;26:89-92. [PMID: 27305645 DOI: 10.1111/exd.13109] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
344 Nguyen TM, Arthur A, Zannettino AC, Gronthos S. EphA5 and EphA7 forward signaling enhances human hematopoietic stem and progenitor cell maintenance, migration, and adhesion via Rac1 activation. Exp Hematol 2017;48:72-8. [PMID: 27988259 DOI: 10.1016/j.exphem.2016.12.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
345 Nguyen TM, Arthur A, Gronthos S. The role of Eph/ephrin molecules in stromal–hematopoietic interactions. Int J Hematol 2016;103:145-54. [PMID: 26475284 DOI: 10.1007/s12185-015-1886-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
346 Zhang L, Borthakur S, Buck M. Dissociation of a Dynamic Protein Complex Studied by All-Atom Molecular Simulations. Biophys J 2016;110:877-86. [PMID: 26910424 DOI: 10.1016/j.bpj.2015.12.036] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
347 Bhatia S, Hirsch K, Sharma J, Oweida A, Griego A, Keysar S, Jimeno A, Raben D, Krasnoperov V, Gill PS, Pasquale EB, Wang XJ, Karam SD. Enhancing radiosensitization in EphB4 receptor-expressing Head and Neck Squamous Cell Carcinomas. Sci Rep 2016;6:38792. [PMID: 27941840 DOI: 10.1038/srep38792] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
348 Charmsaz S, Al-Ejeh F, Yeadon TM, Miller KJ, Smith FM, Stringer BW, Moore AS, Lee FT, Cooper LT, Stylianou C, Yarranton GT, Woronicz J, Scott AM, Lackmann M, Boyd AW. EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia. Leukemia 2017;31:1779-87. [PMID: 27922598 DOI: 10.1038/leu.2016.371] [Cited by in Crossref: 17] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
349 Li M, Yang C, Liu X, Yuan L, Zhang F, Wang M, Miao D, Gu X, Jiang S, Cui B, Tong J, Yu Z. EphA3 promotes malignant transformation of colorectal epithelial cells by upregulating oncogenic pathways. Cancer Letters 2016;383:195-203. [DOI: 10.1016/j.canlet.2016.10.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
350 Yu SR, Huang XJ, Zhang YP. Gastric cancer related genes. Shijie Huaren Xiaohua Zazhi 2016; 24(32): 4381-4388 [DOI: 10.11569/wcjd.v24.i32.4381] [Reference Citation Analysis]
351 Komura D, Isagawa T, Kishi K, Suzuki R, Sato R, Tanaka M, Katoh H, Yamamoto S, Tatsuno K, Fukayama M, Aburatani H, Ishikawa S. CASTIN: a system for comprehensive analysis of cancer-stromal interactome. BMC Genomics 2016;17:899. [PMID: 27829362 DOI: 10.1186/s12864-016-3207-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
352 Shiuan E, Chen J. Eph Receptor Tyrosine Kinases in Tumor Immunity. Cancer Res 2016;76:6452-7. [PMID: 27811149 DOI: 10.1158/0008-5472.CAN-16-1521] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
353 Oweida A, Bhatia S, Hirsch K, Calame D, Griego A, Keysar S, Pitts T, Sharma J, Eckhardt G, Jimeno A, Wang XJ, Parkash G, Califano J, Karam SD. Ephrin-B2 overexpression predicts for poor prognosis and response to therapy in solid tumors. Mol Carcinog 2017;56:1189-96. [PMID: 27649287 DOI: 10.1002/mc.22574] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
354 Morales D, Kania A. Cooperation and crosstalk in axon guidance cue integration: Additivity, synergy, and fine-tuning in combinatorial signaling. Dev Neurobiol 2017;77:891-904. [PMID: 27739221 DOI: 10.1002/dneu.22463] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
355 Singh DR, Ahmed F, Paul MD, Gedam M, Pasquale EB, Hristova K. The SAM domain inhibits EphA2 interactions in the plasma membrane. Biochim Biophys Acta Mol Cell Res 2017;1864:31-8. [PMID: 27776928 DOI: 10.1016/j.bbamcr.2016.10.011] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
356 Wiedemann E, Jellinghaus S, Ende G, Augstein A, Sczech R, Wielockx B, Weinert S, Strasser RH, Poitz DM. Regulation of endothelial migration and proliferation by ephrin-A1. Cell Signal 2017;29:84-95. [PMID: 27742560 DOI: 10.1016/j.cellsig.2016.10.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
357 de Marcondes PG, Morgado-Díaz JA. The Role of EphA4 Signaling in Radiation-Induced EMT-Like Phenotype in Colorectal Cancer Cells. J Cell Biochem 2017;118:442-5. [PMID: 27632701 DOI: 10.1002/jcb.25738] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
358 Shen SP, Liu WT, Lin Y, Li YT, Chang CH, Chang FW, Wang LM, Teng SW, Hsuan Y. EphA2 is a biomarker of hMSCs derived from human placenta and umbilical cord. Taiwan J Obstet Gynecol 2015;54:749-56. [PMID: 26700997 DOI: 10.1016/j.tjog.2015.10.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
359 Takano H, Nakamura T, Tsuchikawa T, Kushibiki T, Hontani K, Inoko K, Takahashi M, Sato S, Abe H, Takeuchi S, Sato N, Hiraoka K, Nishihara H, Shichinohe T, Hirano S. Inhibition of Eph receptor A4 by 2,5-dimethylpyrrolyl benzoic acid suppresses human pancreatic cancer growing orthotopically in nude mice. Oncotarget 2015;6:41063-76. [PMID: 26516928 DOI: 10.18632/oncotarget.5729] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
360 Boonstra MC, de Geus SW, Prevoo HA, Hawinkels LJ, van de Velde CJ, Kuppen PJ, Vahrmeijer AL, Sier CF. Selecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane Proteins. Biomark Cancer 2016;8:119-33. [PMID: 27721658 DOI: 10.4137/BIC.S38542] [Cited by in Crossref: 52] [Cited by in F6Publishing: 61] [Article Influence: 8.7] [Reference Citation Analysis]
361 Li S, Ma Y, Xie C, Wu Z, Kang Z, Fang Z, Su B, Guan M. EphA6 promotes angiogenesis and prostate cancer metastasis and is associated with human prostate cancer progression. Oncotarget 2015;6:22587-97. [PMID: 26041887 DOI: 10.18632/oncotarget.4088] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 4.2] [Reference Citation Analysis]
362 Konda N, Saeki N, Nishino S, Ogawa K. Truncated EphA2 likely potentiates cell adhesion via integrins as well as infiltration and/or lodgment of a monocyte/macrophage cell line in the red pulp and marginal zone of the mouse spleen, where ephrin-A1 is prominently expressed in the vasculature. Histochem Cell Biol 2017;147:317-39. [PMID: 27665280 DOI: 10.1007/s00418-016-1494-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
363 Saeki N, Nishino S, Shimizu T, Ogawa K. EphA2 promotes cell adhesion and spreading of monocyte and monocyte/macrophage cell lines on integrin ligand-coated surfaces. Cell Adh Migr 2015;9:469-82. [PMID: 26565750 DOI: 10.1080/19336918.2015.1107693] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
364 Lee H, Noh H, Mun J, Gu C, Sever S, Park S. Anks1a regulates COPII-mediated anterograde transport of receptor tyrosine kinases critical for tumorigenesis. Nat Commun 2016;7:12799. [PMID: 27619642 DOI: 10.1038/ncomms12799] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
365 Gaitanos TN, Koerner J, Klein R. Tiam-Rac signaling mediates trans-endocytosis of ephrin receptor EphB2 and is important for cell repulsion. J Cell Biol 2016;214:735-52. [PMID: 27597758 DOI: 10.1083/jcb.201512010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
366 Sedgwick AE, D'Souza-Schorey C. Wnt Signaling in Cell Motility and Invasion: Drawing Parallels between Development and Cancer. Cancers (Basel) 2016;8:E80. [PMID: 27589803 DOI: 10.3390/cancers8090080] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 6.2] [Reference Citation Analysis]
367 Francica P, Aebersold DM, Medová M. Senescence as biologic endpoint following pharmacological targeting of receptor tyrosine kinases in cancer. Biochem Pharmacol 2017;126:1-12. [PMID: 27574725 DOI: 10.1016/j.bcp.2016.08.022] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
368 Jurek A, Genander M, Kundu P, Catchpole T, He X, Strååt K, Sabelström H, Xu NJ, Pettersson S, Henkemeyer M, Frisén J. Eph receptor interclass cooperation is required for the regulation of cell proliferation. Exp Cell Res 2016;348:10-22. [PMID: 27565439 DOI: 10.1016/j.yexcr.2016.08.017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
369 Voiculescu V, Calenic B, Ghita M, Lupu M, Caruntu A, Moraru L, Voiculescu S, Ion A, Greabu M, Ishkitiev N, Caruntu C. From Normal Skin to Squamous Cell Carcinoma: A Quest for Novel Biomarkers. Dis Markers 2016;2016:4517492. [PMID: 27642215 DOI: 10.1155/2016/4517492] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 5.2] [Reference Citation Analysis]
370 McCall JL, Gehring D, Clymer BK, Fisher KW, Das B, Kelly DL, Kim H, White MA, Lewis RE. KSR1 and EPHB4 Regulate Myc and PGC1β To Promote Survival of Human Colon Tumors. Mol Cell Biol 2016;36:2246-61. [PMID: 27273865 DOI: 10.1128/MCB.00087-16] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
371 Kung A, Chen YC, Schimpl M, Ni F, Zhu J, Turner M, Molina H, Overman R, Zhang C. Development of Specific, Irreversible Inhibitors for a Receptor Tyrosine Kinase EphB3. J Am Chem Soc 2016;138:10554-60. [PMID: 27478969 DOI: 10.1021/jacs.6b05483] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
372 Li Y, Buckhaults P, Cui X, Tollefsbol TO. Combinatorial epigenetic mechanisms and efficacy of early breast cancer inhibition by nutritive botanicals. Epigenomics 2016;8:1019-37. [PMID: 27478970 DOI: 10.2217/epi-2016-0024] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
373 Peuckert C, Aresh B, Holenya P, Adams D, Sreedharan S, Porthin A, Andersson L, Pettersson H, Wölfl S, Klein R, Oxburgh L, Kullander K. Multimodal Eph/Ephrin signaling controls several phases of urogenital development. Kidney International 2016;90:373-88. [DOI: 10.1016/j.kint.2016.04.021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
374 Depner C, Zum Buttel H, Böğürcü N, Cuesta AM, Aburto MR, Seidel S, Finkelmeier F, Foss F, Hofmann J, Kaulich K, Barbus S, Segarra M, Reifenberger G, Garvalov BK, Acker T, Acker-Palmer A. EphrinB2 repression through ZEB2 mediates tumour invasion and anti-angiogenic resistance. Nat Commun 2016;7:12329. [PMID: 27470974 DOI: 10.1038/ncomms12329] [Cited by in Crossref: 33] [Cited by in F6Publishing: 40] [Article Influence: 5.5] [Reference Citation Analysis]
375 Lee HY, Mohammed KA, Goldberg EP, Kaye F, Najmunnisa N. Silencing Receptor EphA2 Enhanced Sensitivity to Lipoplatin™ in Lung Tumor and MPM Cells. Cancer Invest 2016;34:293-304. [PMID: 27438907 DOI: 10.1080/07357907.2016.1201678] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
376 De Luca I, Di Salle A, Alessio N, Margarucci S, Simeone M, Galderisi U, Calarco A, Peluso G. Positively charged polymers modulate the fate of human mesenchymal stromal cells via ephrinB2/EphB4 signaling. Stem Cell Res 2016;17:248-55. [PMID: 27591481 DOI: 10.1016/j.scr.2016.07.005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
377 Nissinen L, Farshchian M, Riihilä P, Kähäri VM. New perspectives on role of tumor microenvironment in progression of cutaneous squamous cell carcinoma. Cell Tissue Res 2016;365:691-702. [PMID: 27411692 DOI: 10.1007/s00441-016-2457-z] [Cited by in Crossref: 33] [Cited by in F6Publishing: 41] [Article Influence: 5.5] [Reference Citation Analysis]
378 Riedl SJ, Pasquale EB. Targeting the Eph System with Peptides and Peptide Conjugates. Curr Drug Targets 2015;16:1031-47. [PMID: 26212263 DOI: 10.2174/1389450116666150727115934] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
379 Noh H, Lee H, Park E, Park S. Proper closure of the optic fissure requires ephrin A5-EphB2-JNK signaling. Development 2016;143:461-72. [PMID: 26839344 DOI: 10.1242/dev.129478] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
380 Barquilla A, Lamberto I, Noberini R, Heynen-Genel S, Brill LM, Pasquale EB. Protein kinase A can block EphA2 receptor-mediated cell repulsion by increasing EphA2 S897 phosphorylation. Mol Biol Cell 2016;27:2757-70. [PMID: 27385333 DOI: 10.1091/mbc.E16-01-0048] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 6.3] [Reference Citation Analysis]
381 Krusche B, Ottone C, Clements MP, Johnstone ER, Goetsch K, Lieven H, Mota SG, Singh P, Khadayate S, Ashraf A, Davies T, Pollard SM, De Paola V, Roncaroli F, Martinez-Torrecuadrada J, Bertone P, Parrinello S. EphrinB2 drives perivascular invasion and proliferation of glioblastoma stem-like cells. Elife 2016;5:e14845. [PMID: 27350048 DOI: 10.7554/eLife.14845] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 8.5] [Reference Citation Analysis]
382 Pasquale EB. Exosomes expand the sphere of influence of Eph receptors and ephrins. J Cell Biol 2016;214:5-7. [PMID: 27354377 DOI: 10.1083/jcb.201606074] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
383 Huang YC, Lin SJ, Lin KM, Chou YC, Lin CW, Yu SC, Chen CL, Shen TL, Chen CK, Lu J, Chen MR, Tsai CH. Regulation of EBV LMP1-triggered EphA4 downregulation in EBV-associated B lymphoma and its impact on patients' survival. Blood 2016;128:1578-89. [PMID: 27338098 DOI: 10.1182/blood-2016-02-702530] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
384 Alonso-Martin S, Rochat A, Mademtzoglou D, Morais J, de Reyniès A, Auradé F, Chang TH, Zammit PS, Relaix F. Gene Expression Profiling of Muscle Stem Cells Identifies Novel Regulators of Postnatal Myogenesis. Front Cell Dev Biol 2016;4:58. [PMID: 27446912 DOI: 10.3389/fcell.2016.00058] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
385 de Marcondes PG, Bastos LG, de-Freitas-Junior JC, Rocha MR, Morgado-Díaz JA. EphA4-mediated signaling regulates the aggressive phenotype of irradiation survivor colorectal cancer cells. Tumour Biol 2016;37:12411-22. [PMID: 27323967 DOI: 10.1007/s13277-016-5120-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
386 Huang WL, Li Z, Lin TY, Wang SW, Wu FJ, Luo CW. Thyrostimulin-TSHR signaling promotes the proliferation of NIH:OVCAR-3 ovarian cancer cells via trans-regulation of the EGFR pathway. Sci Rep 2016;6:27471. [PMID: 27273257 DOI: 10.1038/srep27471] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
387 Rundle CH, Xing W, Lau KW, Mohan S. Bidirectional ephrin signaling in bone. Osteoporos Sarcopenia 2016;2:65-76. [PMID: 30775469 DOI: 10.1016/j.afos.2016.05.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
388 Singh DR, Pasquale EB, Hristova K. A small peptide promotes EphA2 kinase-dependent signaling by stabilizing EphA2 dimers. Biochim Biophys Acta 2016;1860:1922-8. [PMID: 27281300 DOI: 10.1016/j.bbagen.2016.06.004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
389 Yang D, Jin C, Ma H, Huang M, Shi GP, Wang J, Xiang M. EphrinB2/EphB4 pathway in postnatal angiogenesis: a potential therapeutic target for ischemic cardiovascular disease. Angiogenesis 2016;19:297-309. [PMID: 27216867 DOI: 10.1007/s10456-016-9514-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 35] [Article Influence: 4.8] [Reference Citation Analysis]
390 Reinartz S, Finkernagel F, Adhikary T, Rohnalter V, Schumann T, Schober Y, Nockher WA, Nist A, Stiewe T, Jansen JM, Wagner U, Müller-Brüsselbach S, Müller R. A transcriptome-based global map of signaling pathways in the ovarian cancer microenvironment associated with clinical outcome. Genome Biol 2016;17:108. [PMID: 27215396 DOI: 10.1186/s13059-016-0956-6] [Cited by in Crossref: 52] [Cited by in F6Publishing: 61] [Article Influence: 8.7] [Reference Citation Analysis]
391 Martinez-Martin N, Ramani SR, Hackney JA, Tom I, Wranik BJ, Chan M, Wu J, Paluch MT, Takeda K, Hass PE, Clark H, Gonzalez LC. The extracellular interactome of the human adenovirus family reveals diverse strategies for immunomodulation. Nat Commun 2016;7:11473. [PMID: 27145901 DOI: 10.1038/ncomms11473] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 5.3] [Reference Citation Analysis]
392 Bard F, Chia J. Cracking the Glycome Encoder: Signaling, Trafficking, and Glycosylation. Trends in Cell Biology 2016;26:379-88. [DOI: 10.1016/j.tcb.2015.12.004] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 9.7] [Reference Citation Analysis]
393 Hamaoka Y, Negishi M, Katoh H. EphA2 is a key effector of the MEK/ERK/RSK pathway regulating glioblastoma cell proliferation. Cell Signal 2016;28:937-45. [PMID: 27132626 DOI: 10.1016/j.cellsig.2016.04.009] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 6.0] [Reference Citation Analysis]
394 Li L, Xu N, Zhang JF, Xu LL, Zhou X, Huang BT, Li YL, Liu XL. EphB4/ephrinB2 Contributes to Imatinib Resistance in Chronic Myeloid Leukemia Involved in Cytoskeletal Proteins. Int J Med Sci 2016;13:365-73. [PMID: 27226777 DOI: 10.7150/ijms.14989] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
395 San Jose-Eneriz E, Agirre X, Rodríguez-Otero P, Prosper F. Epigenetic regulation of cell signaling pathways in acute lymphoblastic leukemia. Epigenomics 2013;5:525-38. [PMID: 24059799 DOI: 10.2217/epi.13.56] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
396 Dines M, Lamprecht R. The Role of Ephs and Ephrins in Memory Formation. Int J Neuropsychopharmacol 2016;19:pyv106. [PMID: 26371183 DOI: 10.1093/ijnp/pyv106] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
397 Wang Y, Yu H, Shan Y, Tao C, Wu F, Yu Z, Guo P, Huang J, Li J, Zhu Q, Yu F, Song Q, Shi H, Zhou M, Chen G. EphA1 activation promotes the homing of endothelial progenitor cells to hepatocellular carcinoma for tumor neovascularization through the SDF-1/CXCR4 signaling pathway. J Exp Clin Cancer Res 2016;35:65. [PMID: 27066828 DOI: 10.1186/s13046-016-0339-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
398 Lv J, Xia Q, Wang J, Shen Q, Zhang J, Zhou X. EphB4 promotes the proliferation, invasion, and angiogenesis of human colorectal cancer. Exp Mol Pathol 2016;100:402-8. [PMID: 27072105 DOI: 10.1016/j.yexmp.2016.03.011] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
399 Tatsukawa R, Koga K, Aoki M, Koshikawa N, Imafuku S, Nakayama J, Nabeshima K. Immunohistochemical demonstration of EphA2 processing by MT1-MMP in invasive cutaneous squamous cell carcinoma. Virchows Arch 2016;469:25-34. [PMID: 27056569 DOI: 10.1007/s00428-016-1934-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
400 Takyar FM, Tonna S, Ho PW, Crimeen-Irwin B, Baker EK, Martin TJ, Sims NA. EphrinB2/EphB4 inhibition in the osteoblast lineage modifies the anabolic response to parathyroid hormone. J Bone Miner Res 2013;28:912-25. [PMID: 23165727 DOI: 10.1002/jbmr.1820] [Cited by in Crossref: 83] [Cited by in F6Publishing: 69] [Article Influence: 13.8] [Reference Citation Analysis]
401 Kuwano M, Sonoda K, Murakami Y, Watari K, Ono M. Overcoming drug resistance to receptor tyrosine kinase inhibitors: Learning from lung cancer. Pharmacol Ther 2016;161:97-110. [PMID: 27000770 DOI: 10.1016/j.pharmthera.2016.03.002] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 6.7] [Reference Citation Analysis]
402 Bakst RL, Wong RJ. Mechanisms of Perineural Invasion. J Neurol Surg B Skull Base. 2016;77:96-106. [PMID: 27123385 DOI: 10.1055/s-0036-1571835] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 7.3] [Reference Citation Analysis]
403 Bhatia S, Baig NA, Timofeeva O, Pasquale EB, Hirsch K, MacDonald TJ, Dritschilo A, Lee YC, Henkemeyer M, Rood B, Jung M, Wang XJ, Kool M, Rodriguez O, Albanese C, Karam SD. Knockdown of EphB1 receptor decreases medulloblastoma cell growth and migration and increases cellular radiosensitization. Oncotarget 2015;6:8929-46. [PMID: 25879388 DOI: 10.18632/oncotarget.3369] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
404 Naudin C, Sirvent A, Leroy C, Larive R, Simon V, Pannequin J, Bourgaux JF, Pierre J, Robert B, Hollande F, Roche S. SLAP displays tumour suppressor functions in colorectal cancer via destabilization of the SRC substrate EPHA2. Nat Commun 2014;5:3159. [PMID: 24457997 DOI: 10.1038/ncomms4159] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
405 Jing X, Sonoki T, Miyajima M, Sawada T, Terada N, Takemura S, Sakaguchi K. EphA4-deleted microenvironment regulates cancer development and leukemoid reaction of the isografted 4T1 murine breast cancer via reduction of an IGF1 signal. Cancer Med 2016;5:1214-27. [PMID: 26923183 DOI: 10.1002/cam4.670] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
406 Xavier GM, Miletich I, Cobourne MT. Ephrin Ligands and Eph Receptors Show Regionally Restricted Expression in the Developing Palate and Tongue. Front Physiol 2016;7:60. [PMID: 26941654 DOI: 10.3389/fphys.2016.00060] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
407 Roque CG, Wong HH, Lin JQ, Holt CE. Tumor protein Tctp regulates axon development in the embryonic visual system. Development 2016;143:1134-48. [PMID: 26903505 DOI: 10.1242/dev.131060] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
408 Locard-Paulet M, Lim L, Veluscek G, McMahon K, Sinclair J, van Weverwijk A, Worboys JD, Yuan Y, Isacke CM, Jørgensen C. Phosphoproteomic analysis of interacting tumor and endothelial cells identifies regulatory mechanisms of transendothelial migration. Sci Signal 2016;9:ra15. [PMID: 26861043 DOI: 10.1126/scisignal.aac5820] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 4.7] [Reference Citation Analysis]
409 Youngblood VM, Kim LC, Edwards DN, Hwang Y, Santapuram PR, Stirdivant SM, Lu P, Ye F, Brantley-Sieders DM, Chen J. The Ephrin-A1/EPHA2 Signaling Axis Regulates Glutamine Metabolism in HER2-Positive Breast Cancer. Cancer Res 2016;76:1825-36. [PMID: 26833123 DOI: 10.1158/0008-5472.CAN-15-0847] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 5.3] [Reference Citation Analysis]
410 Amero P, Esposito CL, Rienzo A, Moscato F, Catuogno S, de Franciscis V. Identification of an Interfering Ligand Aptamer for EphB2/3 Receptors. Nucleic Acid Ther 2016;26:102-10. [PMID: 26824783 DOI: 10.1089/nat.2015.0580] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
411 Hordijk PL. Recent insights into endothelial control of leukocyte extravasation. Cell Mol Life Sci 2016;73:1591-608. [PMID: 26794844 DOI: 10.1007/s00018-016-2136-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
412 Kania A, Klein R. Mechanisms of ephrin-Eph signalling in development, physiology and disease. Nat Rev Mol Cell Biol 2016;17:240-56. [PMID: 26790531 DOI: 10.1038/nrm.2015.16] [Cited by in Crossref: 301] [Cited by in F6Publishing: 298] [Article Influence: 50.2] [Reference Citation Analysis]
413 Tonna S, Poulton IJ, Taykar F, Ho PW, Tonkin B, Crimeen-Irwin B, Tatarczuch L, McGregor NE, Mackie EJ, Martin TJ, Sims NA. Chondrocytic ephrin B2 promotes cartilage destruction by osteoclasts in endochondral ossification. Development 2016;143:648-57. [PMID: 26755702 DOI: 10.1242/dev.125625] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
414 Yamada T, Yoshii T, Yasuda H, Okawa A, Sotome S. Dexamethasone Regulates EphA5, a Potential Inhibitory Factor with Osteogenic Capability of Human Bone Marrow Stromal Cells. Stem Cells Int 2016;2016:1301608. [PMID: 27057165 DOI: 10.1155/2016/1301608] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
415 Amato KR, Wang S, Tan L, Hastings AK, Song W, Lovly CM, Meador CB, Ye F, Lu P, Balko JM, Colvin DC, Cates JM, Pao W, Gray NS, Chen J. EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer. Cancer Res 2016;76:305-18. [PMID: 26744526 DOI: 10.1158/0008-5472.CAN-15-0717] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 9.8] [Reference Citation Analysis]
416 Popov C, Kohler J, Docheva D. Activation of EphA4 and EphB2 Reverse Signaling Restores the Age-Associated Reduction of Self-Renewal, Migration, and Actin Turnover in Human Tendon Stem/Progenitor Cells. Front Aging Neurosci. 2016;7:246. [PMID: 26779014 DOI: 10.3389/fnagi.2015.00246] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
417 Feng Y, Tian J, Krylova I, Xu T, Xie HQ, Guo TL, Zhao B. Chronic TCDD exposure results in the dysregulation of gene expression in splenic B-lymphocytes and in the impairments in T-cell and B-cell differentiation in mouse model. J Environ Sci (China) 2016;39:218-27. [PMID: 26899660 DOI: 10.1016/j.jes.2015.11.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
418 Yasmin T, Ali MT, Haque S, Hossain M. Interaction of Quercetin of Onion with Axon Guidance Protein Receptor, NRP-1 Plays Important Role in Cancer Treatment: An In Silico Approach. Interdiscip Sci 2017;9:184-91. [PMID: 26706905 DOI: 10.1007/s12539-015-0137-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
419 Chavent M, Seiradake E, Jones EY, Sansom MS. Structures of the EphA2 Receptor at the Membrane: Role of Lipid Interactions. Structure 2016;24:337-47. [PMID: 26724997 DOI: 10.1016/j.str.2015.11.008] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.1] [Reference Citation Analysis]
420 Potratz J, Tillmanns A, Berning P, Korsching E, Schaefer C, Lechtape B, Schleithoff C, Unland R, Schäfer KL, Müller-Tidow C, Jürgens H, Dirksen U. Receptor tyrosine kinase gene expression profiles of Ewing sarcomas reveal ROR1 as a potential therapeutic target in metastatic disease. Mol Oncol 2016;10:677-92. [PMID: 26739507 DOI: 10.1016/j.molonc.2015.12.009] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
421 Taki S, Kamada H, Inoue M, Nagano K, Mukai Y, Higashisaka K, Yoshioka Y, Tsutsumi Y, Tsunoda S. A Novel Bispecific Antibody against Human CD3 and Ephrin Receptor A10 for Breast Cancer Therapy. PLoS One 2015;10:e0144712. [PMID: 26678395 DOI: 10.1371/journal.pone.0144712] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
422 Vleeshouwer-Neumann T, Phelps M, Bammler TK, MacDonald JW, Jenkins I, Chen EY. Histone Deacetylase Inhibitors Antagonize Distinct Pathways to Suppress Tumorigenesis of Embryonal Rhabdomyosarcoma. PLoS One 2015;10:e0144320. [PMID: 26636678 DOI: 10.1371/journal.pone.0144320] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
423 Son AI, Hashimoto-Torii K, Rakic P, Levitt P, Torii M. EphA4 has distinct functionality from EphA7 in the corticothalamic system during mouse brain development. J Comp Neurol 2016;524:2080-92. [PMID: 26587807 DOI: 10.1002/cne.23933] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
424 Chen L, Yang J, Huang T, Kong X, Lu L, Cai YD. Mining for novel tumor suppressor genes using a shortest path approach. J Biomol Struct Dyn 2016;34:664-75. [PMID: 26209080 DOI: 10.1080/07391102.2015.1042915] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
425 Colbert PL, Vermeer DW, Wieking BG, Lee JH, Vermeer PD. EphrinB1: novel microtubule associated protein whose expression affects taxane sensitivity. Oncotarget 2015;6:953-68. [PMID: 25436983 DOI: 10.18632/oncotarget.2823] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
426 Yang J, Li D, Fan Q, Cai L, Qiu X, Zhou P, Lu Y. The Polymorphisms with Cataract Susceptibility Impair the EPHA2 Receptor Stability and Its Cytoprotective Function. J Ophthalmol 2015;2015:401894. [PMID: 26664742 DOI: 10.1155/2015/401894] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
427 Li S, Wu Z, Chen Y, Kang Z, Wang H, He P, Zhang X, Hu T, Zhang Q, Cai Y, Xu X, Guan M. Diagnostic and prognostic value of tissue and circulating levels of Ephrin-A2 in prostate cancer. Tumour Biol 2016;37:5365-74. [PMID: 26561474 DOI: 10.1007/s13277-015-4398-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
428 Kim MK, Min DJ, Wright G, Goldlust I, Annunziata CM. Loss of compensatory pro-survival and anti-apoptotic modulator, IKKε, sensitizes ovarian cancer cells to CHEK1 loss through an increased level of p21. Oncotarget 2014;5:12788-802. [PMID: 25474241 DOI: 10.18632/oncotarget.2665] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
429 Yeddula N, Xia Y, Ke E, Beumer J, Verma IM. Screening for tumor suppressors: Loss of ephrin receptor A2 cooperates with oncogenic KRas in promoting lung adenocarcinoma. Proc Natl Acad Sci U S A 2015;112:E6476-85. [PMID: 26542681 DOI: 10.1073/pnas.1520110112] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
430 Nunan R, Campbell J, Mori R, Pitulescu ME, Jiang WG, Harding KG, Adams RH, Nobes CD, Martin P. Ephrin-Bs Drive Junctional Downregulation and Actin Stress Fiber Disassembly to Enable Wound Re-epithelialization. Cell Rep 2015;13:1380-95. [PMID: 26549443 DOI: 10.1016/j.celrep.2015.09.085] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 5.1] [Reference Citation Analysis]
431 Alam SK, Yadav VK, Bajaj S, Datta A, Dutta SK, Bhattacharyya M, Bhattacharya S, Debnath S, Roy S, Boardman LA. DNA damage-induced ephrin-B2 reverse signaling promotes chemoresistance and drives EMT in colorectal carcinoma harboring mutant p53. Cell Death Differ. 2016;23:707-722. [PMID: 26494468 DOI: 10.1038/cdd.2015.133] [Cited by in Crossref: 42] [Cited by in F6Publishing: 49] [Article Influence: 6.0] [Reference Citation Analysis]
432 Giorgio C, Russo S, Incerti M, Bugatti A, Vacondio F, Barocelli E, Mor M, Pala D, Hassan-Mohamed I, Gioiello A, Rusnati M, Lodola A, Tognolini M. Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis. Biochem Pharmacol 2016;99:18-30. [PMID: 26462575 DOI: 10.1016/j.bcp.2015.10.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
433 Cockbill LM, Murk K, Love S, Hanley JG. Protein interacting with C kinase 1 suppresses invasion and anchorage-independent growth of astrocytic tumor cells. Mol Biol Cell 2015;26:4552-61. [PMID: 26466675 DOI: 10.1091/mbc.E15-05-0270] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
434 Hameetman L, van der Fits L, Zoutman WH, Out-Luiting JJ, Siegal G, de Esch IJ, Vermeer MH, Tensen CP. EPHA4 is overexpressed but not functionally active in Sézary syndrome. Oncotarget 2015;6:31868-76. [PMID: 26376612 DOI: 10.18632/oncotarget.5573] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
435 Lee ST, Wiemels JL. Genome-wide CpG island methylation and intergenic demethylation propensities vary among different tumor sites. Nucleic Acids Res 2016;44:1105-17. [PMID: 26464434 DOI: 10.1093/nar/gkv1038] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 3.9] [Reference Citation Analysis]
436 Vrahnas C, Sims NA. EphrinB2 Signalling in Osteoblast Differentiation, Bone Formation and Endochondral Ossification. Curr Mol Bio Rep 2015;1:148-56. [DOI: 10.1007/s40610-015-0024-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
437 Lee J, Nakajima-Koyama M, Sone M, Koga M, Ebisuya M, Yamamoto T, Nishida E. Secreted Ephrin Receptor A7 Promotes Somatic Cell Reprogramming by Inducing ERK Activity Reduction. Stem Cell Reports 2015;5:480-9. [PMID: 26441306 DOI: 10.1016/j.stemcr.2015.09.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
438 Rota M, Goichberg P, Anversa P, Leri A. Aging Effects on Cardiac Progenitor Cell Physiology. In: Terjung R, editor. Comprehensive Physiology. Wiley; 2011. pp. 1775-814. [DOI: 10.1002/cphy.c140082] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
439 Callegari D, Pala D, Scalvini L, Tognolini M, Incerti M, Rivara S, Mor M, Lodola A. Comparative Analysis of Virtual Screening Approaches in the Search for Novel EphA2 Receptor Antagonists. Molecules 2015;20:17132-51. [PMID: 26393553 DOI: 10.3390/molecules200917132] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
440 Giorgio C, Mena P, Del rio D, Brighenti F, Barocelli E, Hassan-mohamed I, Callegari D, Lodola A, Tognolini M. The ellagitannin colonic metabolite urolithin D selectively inhibits EphA2 phosphorylation in prostate cancer cells. Mol Nutr Food Res 2015;59:2155-67. [DOI: 10.1002/mnfr.201500470] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
441 Singh DR, Ahmed F, King C, Gupta N, Salotto M, Pasquale EB, Hristova K. EphA2 Receptor Unliganded Dimers Suppress EphA2 Pro-tumorigenic Signaling. J Biol Chem 2015;290:27271-9. [PMID: 26363067 DOI: 10.1074/jbc.M115.676866] [Cited by in Crossref: 46] [Cited by in F6Publishing: 36] [Article Influence: 6.6] [Reference Citation Analysis]
442 Pullos AN, Castilho RM, Squarize CH. HPV Infection of the Head and Neck Region and Its Stem Cells. J Dent Res 2015;94:1532-43. [PMID: 26353884 DOI: 10.1177/0022034515605456] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
443 Aparicio LA, Blanco M, Castosa R, Concha Á, Valladares M, Calvo L, Figueroa A. Clinical implications of epithelial cell plasticity in cancer progression. Cancer Letters 2015;366:1-10. [DOI: 10.1016/j.canlet.2015.06.007] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.6] [Reference Citation Analysis]
444 Castelli R, Tognolini M, Vacondio F, Incerti M, Pala D, Callegari D, Bertoni S, Giorgio C, Hassan-Mohamed I, Zanotti I, Bugatti A, Rusnati M, Festuccia C, Rivara S, Barocelli E, Mor M, Lodola A. Δ(5)-Cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system. Eur J Med Chem 2015;103:312-24. [PMID: 26363867 DOI: 10.1016/j.ejmech.2015.08.048] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
445 Sabet O, Stockert R, Xouri G, Brüggemann Y, Stanoev A, Bastiaens PIH. Ubiquitination switches EphA2 vesicular traffic from a continuous safeguard to a finite signalling mode. Nat Commun 2015;6:8047. [PMID: 26292967 DOI: 10.1038/ncomms9047] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 6.4] [Reference Citation Analysis]
446 Dunne PD, Dasgupta S, Blayney JK, McArt DG, Redmond KL, Weir JA, Bradley CA, Sasazuki T, Shirasawa S, Wang T, Srivastava S, Ong CW, Arthur K, Salto-Tellez M, Wilson RH, Johnston PG, Van Schaeybroeck S. EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer. Clin Cancer Res 2016;22:230-42. [PMID: 26283684 DOI: 10.1158/1078-0432.CCR-15-0603] [Cited by in Crossref: 60] [Cited by in F6Publishing: 65] [Article Influence: 8.6] [Reference Citation Analysis]
447 Ćwiek P, Leni Z, Salm F, Dimitrova V, Styp-Rekowska B, Chiriano G, Carroll M, Höland K, Djonov V, Scapozza L, Guiry P, Arcaro A. RNA interference screening identifies a novel role for PCTK1/CDK16 in medulloblastoma with c-Myc amplification. Oncotarget 2015;6:116-29. [PMID: 25402633 DOI: 10.18632/oncotarget.2699] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
448 Laussu J, Khuong A, Gautrais J, Davy A. Beyond boundaries--Eph:ephrin signaling in neurogenesis. Cell Adh Migr 2014;8:349-59. [PMID: 25482631 DOI: 10.4161/19336918.2014.969990] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
449 Pitulescu ME, Adams RH. Regulation of signaling interactions and receptor endocytosis in growing blood vessels. Cell Adh Migr 2014;8:366-77. [PMID: 25482636 DOI: 10.4161/19336918.2014.970010] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
450 Hutchens T, Piston DW. EphA4 Receptor Forward Signaling Inhibits Glucagon Secretion From α-Cells. Diabetes 2015;64:3839-51. [PMID: 26251403 DOI: 10.2337/db15-0488] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
451 Fagotto F, Winklbauer R, Rohani N. Ephrin-Eph signaling in embryonic tissue separation. Cell Adh Migr 2014;8:308-26. [PMID: 25482630 DOI: 10.4161/19336918.2014.970028] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 6.0] [Reference Citation Analysis]
452 Nikolov DB, Xu K, Himanen JP. Homotypic receptor-receptor interactions regulating Eph signaling. Cell Adh Migr 2014;8:360-5. [PMID: 25530219 DOI: 10.4161/19336918.2014.971684] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
453 Ryall KA, Shin J, Yoo M, Hinz TK, Kim J, Kang J, Heasley LE, Tan AC. Identifying kinase dependency in cancer cells by integrating high-throughput drug screening and kinase inhibition data. Bioinformatics 2015;31:3799-806. [PMID: 26206305 DOI: 10.1093/bioinformatics/btv427] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 0.1] [Reference Citation Analysis]
454 Park SH, Park S, Kim DY, Pyo A, Kimura RH, Sathirachinda A, Choy HE, Min JJ, Gambhir SS, Hong Y. Isolation and Characterization of a Monobody with a Fibronectin Domain III Scaffold That Specifically Binds EphA2. PLoS One 2015;10:e0132976. [PMID: 26177208 DOI: 10.1371/journal.pone.0132976] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
455 Ebert K, Wiemer J, Caballero J, Köckerling M, Steinbach J, Pietzsch J, Mamat C. Development of indazolylpyrimidine derivatives as high-affine EphB4 receptor ligands and potential PET radiotracers. Bioorg Med Chem 2015;23:6025-35. [PMID: 26189032 DOI: 10.1016/j.bmc.2015.06.040] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
456 Puttick S, Stringer BW, Day BW, Bruce ZC, Ensbey KS, Mardon K, Cowin GJ, Thurecht KJ, Whittaker AK, Fay M, Boyd AW, Rose S. EphA2 as a Diagnostic Imaging Target in Glioblastoma: A Positron Emission Tomography/Magnetic Resonance Imaging Study. Mol Imaging 2015;14:7290.2015.00008. [DOI: 10.2310/7290.2015.00008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
457 Bai YQ, Zhang JY, Bai CY, Xu XE, Wu JY, Chen B, Wu ZY, Wang SH, Shen J, Shen JH, Yao XD, Gao LZ, Wu B, Gu HL, Liu XH, Li X, Li EM, Xu LY. Low EphA7 Expression Correlated with Lymph Node Metastasis and Poor Prognosis of Patients with Esophageal Squamous Cell Carcinoma. Acta Histochem Cytochem 2015;48:75-81. [PMID: 26160986 DOI: 10.1267/ahc.14054] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
458 Mercurio FA, Di Natale C, Pirone L, Scognamiglio PL, Marasco D, Pedone EM, Saviano M, Leone M. Peptide Fragments of Odin-Sam1: Conformational Analysis and Interaction Studies with EphA2-Sam. ChemBioChem 2015;16:1629-36. [DOI: 10.1002/cbic.201500197] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
459 Thiede-Stan NK, Schwab ME. Attractive and repulsive factors act through multi-subunit receptor complexes to regulate nerve fiber growth. J Cell Sci. 2015;128:2403-2414. [PMID: 26116576 DOI: 10.1242/jcs.165555] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
460 Sobotič B, Vizovišek M, Vidmar R, Van Damme P, Gocheva V, Joyce JA, Gevaert K, Turk V, Turk B, Fonović M. Proteomic Identification of Cysteine Cathepsin Substrates Shed from the Surface of Cancer Cells. Mol Cell Proteomics 2015;14:2213-28. [PMID: 26081835 DOI: 10.1074/mcp.M114.044628] [Cited by in Crossref: 59] [Cited by in F6Publishing: 67] [Article Influence: 8.4] [Reference Citation Analysis]
461 Chu LH, Vijay CG, Annex BH, Bader JS, Popel AS. PADPIN: protein-protein interaction networks of angiogenesis, arteriogenesis, and inflammation in peripheral arterial disease. Physiol Genomics 2015;47:331-43. [PMID: 26058837 DOI: 10.1152/physiolgenomics.00125.2014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
462 Forse GJ, Uson ML, Nasertorabi F, Kolatkar A, Lamberto I, Pasquale EB, Kuhn P. Distinctive Structure of the EphA3/Ephrin-A5 Complex Reveals a Dual Mode of Eph Receptor Interaction for Ephrin-A5. PLoS One 2015;10:e0127081. [PMID: 25993310 DOI: 10.1371/journal.pone.0127081] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
463 Zhao Y, Li H, Wu R, Li S, Wang P, Wang H, Wang J, Zhou J. Antitumor Effects of Oncolytic Adenovirus-Carrying siRNA Targeting Potential Oncogene EphA3. PLoS One 2015;10:e0126726. [PMID: 25978371 DOI: 10.1371/journal.pone.0126726] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
464 Jung YH, Lee SJ, Oh SY, Lee HJ, Ryu JM, Han HJ. Oleic acid enhances the motility of umbilical cord blood derived mesenchymal stem cells through EphB2-dependent F-actin formation. Biochim Biophys Acta. 2015;1853:1905-1917. [PMID: 25962624 DOI: 10.1016/j.bbamcr.2015.05.006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
465 Qi Z, Chen YG. Regulation of intestinal stem cell fate specification. Sci China Life Sci 2015;58:570-8. [PMID: 25951932 DOI: 10.1007/s11427-015-4859-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
466 Kampen KR, Scherpen FJ, Garcia-Manero G, Yang H, Kaspers GJ, Cloos J, Zwaan CM, van den Heuvel-Eibrink MM, Kornblau SM, De Bont ES. EphB1 Suppression in Acute Myelogenous Leukemia: Regulating the DNA Damage Control System. Mol Cancer Res 2015;13:982-92. [PMID: 25944917 DOI: 10.1158/1541-7786.MCR-14-0660-T] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
467 Scholz R, Imami K, Scott NE, Trimble WS, Foster LJ, Finlay BB. Novel Host Proteins and Signaling Pathways in Enteropathogenic E. coli Pathogenesis Identified by Global Phosphoproteome Analysis. Mol Cell Proteomics 2015;14:1927-45. [PMID: 25944883 DOI: 10.1074/mcp.M114.046847] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
468 Luo Q, Liu X, Zheng Y, Zhao Y, Zhu J, Zou L. Ephrin-B2 mediates trophoblast-dependent maternal spiral artery remodeling in first trimester. Placenta 2015;36:567-74. [DOI: 10.1016/j.placenta.2015.02.009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
469 Harada K, Negishi M, Katoh H. HGF-induced serine 897 phosphorylation of EphA2 regulates epithelial morphogenesis of MDCK cells in 3D culture. J Cell Sci 2015;128:1912-21. [PMID: 25908849 DOI: 10.1242/jcs.163790] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
470 Weiss A, Kispert A. Eph/ephrin signaling in the kidney and lower urinary tract. Pediatr Nephrol 2016;31:359-71. [DOI: 10.1007/s00467-015-3112-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
471 Subbarayal P, Karunakaran K, Winkler AC, Rother M, Gonzalez E, Meyer TF, Rudel T. EphrinA2 receptor (EphA2) is an invasion and intracellular signaling receptor for Chlamydia trachomatis. PLoS Pathog 2015;11:e1004846. [PMID: 25906164 DOI: 10.1371/journal.ppat.1004846] [Cited by in Crossref: 73] [Cited by in F6Publishing: 66] [Article Influence: 10.4] [Reference Citation Analysis]
472 Lin B, Yin T, Wu YI, Inoue T, Levchenko A. Interplay between chemotaxis and contact inhibition of locomotion determines exploratory cell migration. Nat Commun 2015;6:6619. [PMID: 25851023 DOI: 10.1038/ncomms7619] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 8.0] [Reference Citation Analysis]
473 Kundu P, Genander M, Strååt K, Classon J, Ridgway RA, Tan EH, Björk J, Martling A, van Es J, Sansom OJ, Clevers H, Pettersson S, Frisén J. An EphB-Abl signaling pathway is associated with intestinal tumor initiation and growth. Sci Transl Med 2015;7:281ra44-281ra44. [DOI: 10.1126/scitranslmed.3010567] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
474 Chen P, Rossi N, Priddy S, Pierson CR, Studebaker AW, Johnson RA. EphB2 activation is required for ependymoma development as well as inhibits differentiation and promotes proliferation of the transformed cell. Sci Rep 2015;5:9248. [PMID: 25801123 DOI: 10.1038/srep09248] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
475 Farshchian M, Nissinen L, Siljamäki E, Riihilä P, Toriseva M, Kivisaari A, Ala-Aho R, Kallajoki M, Veräjänkorva E, Honkanen HK, Heljasvaara R, Pihlajaniemi T, Grénman R, Peltonen J, Peltonen S, Kähäri VM. EphB2 Promotes Progression of Cutaneous Squamous Cell Carcinoma. J Invest Dermatol 2015;135:1882-92. [PMID: 25789706 DOI: 10.1038/jid.2015.104] [Cited by in Crossref: 29] [Cited by in F6Publishing: 38] [Article Influence: 4.1] [Reference Citation Analysis]
476 Smalley KS, Fedorenko IV. Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma. Mol Cell Oncol 2015;2:e1008291. [PMID: 27308505 DOI: 10.1080/23723556.2015.1008291] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
477 Sheleg M, Yochum CL, Richardson JR, Wagner GC, Zhou R. Ephrin-A5 regulates inter-male aggression in mice. Behav Brain Res 2015;286:300-7. [PMID: 25746458 DOI: 10.1016/j.bbr.2015.03.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
478 Magnon C. Role of the autonomic nervous system in tumorigenesis and metastasis. Mol Cell Oncol 2015;2:e975643. [PMID: 27308436 DOI: 10.4161/23723556.2014.975643] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
479 Mertens-Walker I, Lisle JE, Nyberg WA, Stephens CR, Burke L, Rutkowski R, Herington AC, Stephenson SA. EphB4 localises to the nucleus of prostate cancer cells. Exp Cell Res 2015;333:105-15. [PMID: 25724901 DOI: 10.1016/j.yexcr.2015.02.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
480 Lahtela J, Pradhan B, Närhi K, Hemmes A, Särkioja M, Kovanen PE, Brown A, Verschuren EW. The putative tumor suppressor gene EphA3 fails to demonstrate a crucial role in murine lung tumorigenesis or morphogenesis. Dis Model Mech 2015;8:393-401. [PMID: 25713296 DOI: 10.1242/dmm.019257] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
481 Yan Y, Wang Q, Yan XL, Zhang Y, Li W, Tang F, Li X, Yang P. miR-10a controls glioma migration and invasion through regulating epithelial-mesenchymal transition via EphA8. FEBS Lett 2015;589:756-65. [PMID: 25683004 DOI: 10.1016/j.febslet.2015.02.005] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 4.9] [Reference Citation Analysis]
482 Gajadhar AS, Johnson H, Slebos RJ, Shaddox K, Wiles K, Washington MK, Herline AJ, Levine DA, Liebler DC, White FM; Clinical Proteomic Tumor Analysis Consortium. Phosphotyrosine signaling analysis in human tumors is confounded by systemic ischemia-driven artifacts and intra-specimen heterogeneity. Cancer Res 2015;75:1495-503. [PMID: 25670172 DOI: 10.1158/0008-5472.CAN-14-2309] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 5.1] [Reference Citation Analysis]
483 Mohamed ER, Noguchi M, Hamed AR, Eldahshoury MZ, Hammady AR, Salem EE, Itoh K. Reduced expression of erythropoietin-producing hepatocyte B6 receptor tyrosine kinase in prostate cancer. Oncol Lett 2015;9:1672-6. [PMID: 25789021 DOI: 10.3892/ol.2015.2925] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
484 Staquicini FI, Qian MD, Salameh A, Dobroff AS, Edwards JK, Cimino DF, Moeller BJ, Kelly P, Nunez MI, Tang X, Liu DD, Lee JJ, Hong WK, Ferrara F, Bradbury AR, Lobb RR, Edelman MJ, Sidman RL, Wistuba II, Arap W, Pasqualini R. Receptor tyrosine kinase EphA5 is a functional molecular target in human lung cancer. J Biol Chem 2015;290:7345-59. [PMID: 25623065 DOI: 10.1074/jbc.M114.630525] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
485 Uchiyama S, Saeki N, Ogawa K. Aberrant EphB/ephrin-B expression in experimental gastric lesions and tumor cells. World J Gastroenterol 2015; 21(2): 453-464 [PMID: 25593460 DOI: 10.3748/wjg.v21.i2.453] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
486 Graham C, LeBrun DP. Tumor suppressors in follicular lymphoma. Leuk Lymphoma 2015;56:1981-8. [PMID: 25379618 DOI: 10.3109/10428194.2014.982638] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
487 Paraiso KH, Das Thakur M, Fang B, Koomen JM, Fedorenko IV, John JK, Tsao H, Flaherty KT, Sondak VK, Messina JL, Pasquale EB, Villagra A, Rao UN, Kirkwood JM, Meier F, Sloot S, Gibney GT, Stuart D, Tawbi H, Smalley KS. Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype. Cancer Discov 2015;5:264-73. [PMID: 25542447 DOI: 10.1158/2159-8290.CD-14-0293] [Cited by in Crossref: 59] [Cited by in F6Publishing: 59] [Article Influence: 7.4] [Reference Citation Analysis]
488 Lamberto I, Lechtenberg BC, Olson EJ, Mace PD, Dawson PE, Riedl SJ, Pasquale EB. Development and structural analysis of a nanomolar cyclic peptide antagonist for the EphA4 receptor. ACS Chem Biol 2014;9:2787-95. [PMID: 25268696 DOI: 10.1021/cb500677x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
489 Aharon R, Janes PW, Burgess AW, Hamza K, Klebaner F, Lackmann M. A mathematical model for eph/ephrin-directed segregation of intermingled cells. PLoS One 2014;9:e111803. [PMID: 25436892 DOI: 10.1371/journal.pone.0111803] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
490 Maguire LH, Thomas AR, Goldstein AM. Tumors of the neural crest: Common themes in development and cancer. Dev Dyn 2015;244:311-22. [PMID: 25382669 DOI: 10.1002/dvdy.24226] [Cited by in Crossref: 59] [Cited by in F6Publishing: 59] [Article Influence: 7.4] [Reference Citation Analysis]
491 Wei Q, Liu J, Wang N, Zhang X, Jin J, Chin-sang I, Zheng J, Jia Z. Structures of an Eph receptor tyrosine kinase and its potential activation mechanism. Acta Crystallogr D Biol Crystallogr 2014;70:3135-43. [DOI: 10.1107/s1399004714021944] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
492 Danielsen SA, Eide PW, Nesbakken A, Guren T, Leithe E, Lothe RA. Portrait of the PI3K/AKT pathway in colorectal cancer. Biochim Biophys Acta. 2015;1855:104-121. [PMID: 25450577 DOI: 10.1016/j.bbcan.2014.09.008] [Cited by in Crossref: 67] [Cited by in F6Publishing: 145] [Article Influence: 8.4] [Reference Citation Analysis]
493 Herington AC, Mertens-Walker I, Lisle JE, Maharaj M, Stephenson SA. Inhibiting Eph kinase activity may not be "Eph"ective for cancer treatment. Growth Factors 2014;32:207-13. [PMID: 25413947 DOI: 10.3109/08977194.2014.985293] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
494 Ma B, Kolb S, Diprima M, Karna M, Tosato G, Yang Q, Huang Q, Nussinov R. Investigation of the interactions between the EphB2 receptor and SNEW peptide variants. Growth Factors 2014;32:236-46. [PMID: 25410963 DOI: 10.3109/08977194.2014.985786] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
495 Al-ejeh F, Offenhäuser C, Lim YC, Stringer BW, Day BW, Boyd AW. Eph family co-expression patterns define unique clusters predictive of cancer phenotype. Growth Factors 2014;32:254-64. [DOI: 10.3109/08977194.2014.984807] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
496 Wong SS, Kim KM, Ting JC, Yu K, Fu J, Liu S, Cristescu R, Nebozhyn M, Gong L, Yue YG. Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing. Nat Commun. 2014;5:5477. [PMID: 25407104 DOI: 10.1038/ncomms6477] [Cited by in Crossref: 108] [Cited by in F6Publishing: 120] [Article Influence: 13.5] [Reference Citation Analysis]
497 Nakagawa M, Inokuchi M, Takagi Y, Kato K, Sugita H, Otsuki S, Kojima K, Uetake H, Sugihara K. Erythropoietin-Producing Hepatocellular A1 is an Independent Prognostic Factor for Gastric Cancer. Ann Surg Oncol 2015;22:2329-35. [DOI: 10.1245/s10434-014-4231-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
498 Janes PW, Slape CI, Farnsworth RH, Atapattu L, Scott AM, Vail ME. EphA3 biology and cancer. Growth Factors 2014;32:176-89. [PMID: 25391995 DOI: 10.3109/08977194.2014.982276] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
499 Xiao Z, Carrasco R, Kinneer K, Sabol D, Jallal B, Coats S, Tice DA. EphB4 promotes or suppresses Ras/MEK/ERK pathway in a context-dependent manner: Implications for EphB4 as a cancer target. Cancer Biology & Therapy 2014;13:630-7. [DOI: 10.4161/cbt.20080] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 5.0] [Reference Citation Analysis]
500 Shang X, Lin X, Howell SB. Claudin-4 controls the receptor tyrosine kinase EphA2 pro-oncogenic switch through β-catenin. Cell Commun Signal 2014;12:59. [PMID: 25344320 DOI: 10.1186/s12964-014-0059-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
501 Becerikli M, Merwart B, Lam MC, Suppelna P, Rittig A, Mirmohammedsadegh A, Stricker I, Theiss C, Singer BB, Jacobsen F, Steinstraesser L. EPHB4 tyrosine-kinase receptor expression and biological significance in soft tissue sarcoma. Int J Cancer 2015;136:1781-91. [PMID: 25274141 DOI: 10.1002/ijc.29244] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
502 Fagotto F. The cellular basis of tissue separation. Development 2014;141:3303-18. [PMID: 25139853 DOI: 10.1242/dev.090332] [Cited by in Crossref: 95] [Cited by in F6Publishing: 80] [Article Influence: 11.9] [Reference Citation Analysis]
503 Rhoda K, Choonara YE, Kumar P, Bijukumar D, du Toit LC, Pillay V. Potential nanotechnologies and molecular targets in the quest for efficient chemotherapy in ovarian cancer. Expert Opin Drug Deliv 2015;12:613-34. [PMID: 25300775 DOI: 10.1517/17425247.2015.970162] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
504 Pala D, Castelli R, Incerti M, Russo S, Tognolini M, Giorgio C, Hassan-Mohamed I, Zanotti I, Vacondio F, Rivara S, Mor M, Lodola A. Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction. J Chem Inf Model 2014;54:2621-6. [PMID: 25289483 DOI: 10.1021/ci5004619] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
505 Barquilla A, Pasquale EB. Eph receptors and ephrins: therapeutic opportunities. Annu Rev Pharmacol Toxicol 2015;55:465-87. [PMID: 25292427 DOI: 10.1146/annurev-pharmtox-011112-140226] [Cited by in Crossref: 166] [Cited by in F6Publishing: 164] [Article Influence: 20.8] [Reference Citation Analysis]
506 Eriksson O, Ramström M, Hörnaeus K, Bergquist J, Mokhtari D, Siegbahn A. The Eph tyrosine kinase receptors EphB2 and EphA2 are novel proteolytic substrates of tissue factor/coagulation factor VIIa. J Biol Chem 2014;289:32379-91. [PMID: 25281742 DOI: 10.1074/jbc.M114.599332] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
507 Pretze M, Mosch B, Bergmann R, Steinbach J, Pietzsch J, Mamat C. Radiofluorination and first radiopharmacological characterization of a SWLAY peptide-based ligand targeting EphA2: A [ 18 F]SWLAY peptide-based ligand for EphA2 targeting. J Label Compd Radiopharm 2014;57:660-5. [DOI: 10.1002/jlcr.3237] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
508 Lu H, Clauser KR, Tam WL, Fröse J, Ye X, Eaton EN, Reinhardt F, Donnenberg VS, Bhargava R, Carr SA, Weinberg RA. A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages. Nat Cell Biol 2014;16:1105-17. [PMID: 25266422 DOI: 10.1038/ncb3041] [Cited by in Crossref: 241] [Cited by in F6Publishing: 260] [Article Influence: 30.1] [Reference Citation Analysis]
509 Lam S, Wiercinska E, Teunisse AFAS, Lodder K, ten Dijke P, Jochemsen AG. Wild-type p53 inhibits pro-invasive properties of TGF-β3 in breast cancer, in part through regulation of EPHB2, a new TGF-β target gene. Breast Cancer Res Treat 2014;148:7-18. [DOI: 10.1007/s10549-014-3147-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
510 Akada M, Harada K, Negishi M, Katoh H. EphB6 promotes anoikis by modulating EphA2 signaling. Cell Signal 2014;26:2879-84. [PMID: 25239188 DOI: 10.1016/j.cellsig.2014.08.031] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
511 Lim CJ, Oh K, Ha JD, Lee JH, Seo HW, Chae CH, Kim D, Lee M, Lee BH. 4-Substituted quinazoline derivatives as novel EphA2 receptor tyrosine kinase inhibitors. Bioorganic & Medicinal Chemistry Letters 2014;24:4080-3. [DOI: 10.1016/j.bmcl.2014.07.081] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
512 Hassan-Mohamed I, Giorgio C, Incerti M, Russo S, Pala D, Pasquale EB, Zanotti I, Vicini P, Barocelli E, Rivara S, Mor M, Lodola A, Tognolini M. UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. Br J Pharmacol 2014;171:5195-208. [PMID: 24597515 DOI: 10.1111/bph.12669] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
513 Allonby O, El Zawily AM, Freywald T, Mousseau DD, Chlan J, Anderson D, Benmerah A, Sidhu V, Babu M, DeCoteau J, Freywald A. Ligand stimulation induces clathrin- and Rab5-dependent downregulation of the kinase-dead EphB6 receptor preceded by the disruption of EphB6-Hsp90 interaction. Cell Signal 2014;26:2645-57. [PMID: 25152371 DOI: 10.1016/j.cellsig.2014.08.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
514 Mercurio FA, Scognamiglio PL, Di Natale C, Marasco D, Pellecchia M, Leone M. CD and NMR conformational studies of a peptide encompassing the Mid Loop interface of Ship2-Sam: Conformational Studies of a Ship2-Sam Fragment. Biopolymers 2014;101:1088-98. [DOI: 10.1002/bip.22512] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
515 Day BW, Stringer BW, Boyd AW. Eph receptors as therapeutic targets in glioblastoma. Br J Cancer 2014;111:1255-61. [PMID: 25144626 DOI: 10.1038/bjc.2014.73] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 5.8] [Reference Citation Analysis]
516 Chiappalupi S, Riuzzi F, Fulle S, Donato R, Sorci G. Defective RAGE activity in embryonal rhabdomyosarcoma cells results in high PAX7 levels that sustain migration and invasiveness. Carcinogenesis 2014;35:2382-92. [PMID: 25123133 DOI: 10.1093/carcin/bgu176] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
517 Michaelis UR. Mechanisms of endothelial cell migration. Cell Mol Life Sci 2014;71:4131-48. [PMID: 25038776 DOI: 10.1007/s00018-014-1678-0] [Cited by in Crossref: 69] [Cited by in F6Publishing: 77] [Article Influence: 8.6] [Reference Citation Analysis]
518 Giansanti P, Preisinger C, Huber KV, Gridling M, Superti-Furga G, Bennett KL, Heck AJ. Evaluating the promiscuous nature of tyrosine kinase inhibitors assessed in A431 epidermoid carcinoma cells by both chemical- and phosphoproteomics. ACS Chem Biol 2014;9:1490-8. [PMID: 24804581 DOI: 10.1021/cb500116c] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
519 Toma MI, Erdmann K, Diezel M, Meinhardt M, Zastrow S, Fuessel S, Wirth MP, Baretton GB. Lack of ephrin receptor A1 is a favorable independent prognostic factor in clear cell renal cell carcinoma. PLoS One. 2014;9:e102262. [PMID: 25025847 DOI: 10.1371/journal.pone.0102262] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
520 Gómez-Maldonado L, Tiana M, Roche O, Prado-Cabrero A, Jensen L, Fernandez-Barral A, Guijarro-Muñoz I, Favaro E, Moreno-Bueno G, Sanz L, Aragones J, Harris A, Volpert O, Jimenez B, del Peso L. EFNA3 long noncoding RNAs induced by hypoxia promote metastatic dissemination. Oncogene 2015;34:2609-20. [PMID: 25023702 DOI: 10.1038/onc.2014.200] [Cited by in Crossref: 55] [Cited by in F6Publishing: 65] [Article Influence: 6.9] [Reference Citation Analysis]
521 Khansaard W, Techasen A, Namwat N, Yongvanit P, Khuntikeo N, Puapairoj A, Loilome W. Increased EphB2 expression predicts cholangiocarcinoma metastasis. Tumor Biol 2014;35:10031-41. [DOI: 10.1007/s13277-014-2295-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
522 Dai D, Huang Q, Nussinov R, Ma B. Promiscuous and specific recognition among ephrins and Eph receptors. Biochim Biophys Acta 2014;1844:1729-40. [PMID: 25017878 DOI: 10.1016/j.bbapap.2014.07.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
523 Barneh F, Moshayedi M, Mirmohammadsadeghi H, Haghjooy-Javanmard S, Sabzghabaee AM, Badri S. EphB4 tyrosine kinase stimulation inhibits growth of MDA-MB-231 breast cancer cells in a dose and time dependent manner. Dis Markers 2013;35:933-8. [PMID: 24427781 DOI: 10.1155/2013/857895] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
524 Cramer KS, Gabriele ML. Axon guidance in the auditory system: multiple functions of Eph receptors. Neuroscience 2014;277:152-62. [PMID: 25010398 DOI: 10.1016/j.neuroscience.2014.06.068] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
525 Shaw A, Lundin V, Petrova E, Fördős F, Benson E, Al-amin A, Herland A, Blokzijl A, Högberg B, Teixeira AI. Spatial control of membrane receptor function using ligand nanocalipers. Nat Methods 2014;11:841-6. [DOI: 10.1038/nmeth.3025] [Cited by in Crossref: 149] [Cited by in F6Publishing: 153] [Article Influence: 18.6] [Reference Citation Analysis]
526 Liu Y, Lan X, Wu T, Lang J, Jin X, Sun X, Wen Q, An R. 99mTc-labeled SWL specific peptide for targeting EphA2 receptor. Nuclear Medicine and Biology 2014;41:450-6. [DOI: 10.1016/j.nucmedbio.2014.03.020] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
527 Tonna S, Takyar FM, Vrahnas C, Crimeen-Irwin B, Ho PW, Poulton IJ, Brennan HJ, McGregor NE, Allan EH, Nguyen H, Forwood MR, Tatarczuch L, Mackie EJ, Martin TJ, Sims NA. EphrinB2 signaling in osteoblasts promotes bone mineralization by preventing apoptosis. FASEB J 2014;28:4482-96. [PMID: 24982128 DOI: 10.1096/fj.14-254300] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 6.4] [Reference Citation Analysis]
528 Sharma GK, Dhillon VK, Masood R, Maceri DR. Overexpression of EphB4, EphrinB2, and epidermal growth factor receptor in papillary thyroid carcinoma: A pilot study: Differential gene expression in PTC. Head Neck 2015;37:964-9. [DOI: 10.1002/hed.23694] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
529 DU T, Niu H. Inhibitory effect of gene combination in a mouse model of colon cancer with liver metastasis. Exp Ther Med 2014;8:913-8. [PMID: 25120623 DOI: 10.3892/etm.2014.1809] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
530 Gao YF, Shu Y, Yang L, He YC, Li LP, Huang G, Li HP, Jiang Y. A graphic method for identification of novel glioma related genes. Biomed Res Int 2014;2014:891945. [PMID: 25050377 DOI: 10.1155/2014/891945] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
531 Nagano K, Maeda Y, Kanasaki S, Watanabe T, Yamashita T, Inoue M, Higashisaka K, Yoshioka Y, Abe Y, Mukai Y, Kamada H, Tsutsumi Y, Tsunoda S. Ephrin receptor A10 is a promising drug target potentially useful for breast cancers including triple negative breast cancers. J Control Release 2014;189:72-9. [PMID: 24946238 DOI: 10.1016/j.jconrel.2014.06.010] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
532 Sato M, Kadota M, Tang B, Yang HH, Yang YA, Shan M, Weng J, Welsh MA, Flanders KC, Nagano Y, Michalowski AM, Clifford RJ, Lee MP, Wakefield LM. An integrated genomic approach identifies persistent tumor suppressive effects of transforming growth factor-β in human breast cancer. Breast Cancer Res 2014;16:R57. [PMID: 24890385 DOI: 10.1186/bcr3668] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
533 Cadinu D, Hooda J, Alam MM, Balamurugan P, Henke RM, Zhang L. Comparative proteomic analysis reveals characteristic molecular changes accompanying the transformation of nonmalignant to cancer lung cells. EuPA Open Proteomics 2014;3:1-12. [DOI: 10.1016/j.euprot.2014.01.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
534 Pound LD, Comstock SM, Grove KL. Consumption of a Western-style diet during pregnancy impairs offspring islet vascularization in a Japanese macaque model. Am J Physiol Endocrinol Metab 2014;307:E115-23. [PMID: 24844258 DOI: 10.1152/ajpendo.00131.2014] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 4.4] [Reference Citation Analysis]
535 Chen J, Song W, Amato K. Eph receptor tyrosine kinases in cancer stem cells. Cytokine Growth Factor Rev 2015;26:1-6. [PMID: 24933439 DOI: 10.1016/j.cytogfr.2014.05.001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
536 Yu M, Liang W, Wen S, Zhao T, Zhu MX, Li HH, Long Q, Wang M, Cheng X, Liao YH, Yuan J. EphB2 contributes to human naive B-cell activation and is regulated by miR-185. FASEB J 2014;28:3609-17. [PMID: 24803541 DOI: 10.1096/fj.13-247759] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
537 Gucciardo E, Sugiyama N, Lehti K. Eph- and ephrin-dependent mechanisms in tumor and stem cell dynamics. Cell Mol Life Sci 2014;71:3685-710. [PMID: 24794629 DOI: 10.1007/s00018-014-1633-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
538 Lindskog H, Kim YH, Jelin EB, Kong Y, Guevara-Gallardo S, Kim TN, Wang RA. Molecular identification of venous progenitors in the dorsal aorta reveals an aortic origin for the cardinal vein in mammals. Development 2014;141:1120-8. [PMID: 24550118 DOI: 10.1242/dev.101808] [Cited by in Crossref: 52] [Cited by in F6Publishing: 43] [Article Influence: 6.5] [Reference Citation Analysis]
539 Liu C, Huang H, Wang C, Kong Y, Zhang H. Involvement of ephrin receptor A4 in pancreatic cancer cell motility and invasion. Oncol Lett 2014;7:2165-9. [PMID: 24932309 DOI: 10.3892/ol.2014.2011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
540 Barile E, Wang S, Das SK, Noberini R, Dahl R, Stebbins JL, Pasquale EB, Fisher PB, Pellecchia M. Design, synthesis and bioevaluation of an EphA2 receptor-based targeted delivery system. ChemMedChem 2014;9:1403-12. [PMID: 24677792 DOI: 10.1002/cmdc.201400067] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
541 Son AI, Sheleg M, Cooper MA, Sun Y, Kleiman NJ, Zhou R. Formation of persistent hyperplastic primary vitreous in ephrin-A5-/- mice. Invest Ophthalmol Vis Sci 2014;55:1594-606. [PMID: 24550361 DOI: 10.1167/iovs.13-12706] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
542 Kaenel P, Hahnewald S, Wotzkow C, Strange R, Andres AC. Overexpression of EphB4 in the mammary epithelium shifts the differentiation pathway of progenitor cells and promotes branching activity and vascularization. Dev Growth Differ 2014;56:255-75. [PMID: 24635767 DOI: 10.1111/dgd.12126] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
543 Overman RC, Debreczeni JE, Truman CM, McAlister MS, Attwood TK. Completing the structural family portrait of the human EphB tyrosine kinase domains. Protein Sci 2014;23:627-38. [PMID: 24677421 DOI: 10.1002/pro.2445] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
544 Fukai J, Fujita K, Yamoto T, Sasaki T, Uematsu Y, Nakao N. Intracranial extension of adenoid cystic carcinoma: potential involvement of EphA2 expression and epithelial-mesenchymal transition in tumor metastasis: a case report. BMC Res Notes 2014;7:131. [PMID: 24606764 DOI: 10.1186/1756-0500-7-131] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
545 Song W, Ma Y, Wang J, Brantley-Sieders D, Chen J. JNK signaling mediates EPHA2-dependent tumor cell proliferation, motility, and cancer stem cell-like properties in non-small cell lung cancer. Cancer Res 2014;74:2444-54. [PMID: 24607842 DOI: 10.1158/0008-5472.CAN-13-2136] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 5.5] [Reference Citation Analysis]
546 Barton WA, Dalton AC, Seegar TC, Himanen JP, Nikolov DB. Tie2 and Eph receptor tyrosine kinase activation and signaling. Cold Spring Harb Perspect Biol 2014;6:a009142. [PMID: 24478383 DOI: 10.1101/cshperspect.a009142] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
547 Iida J, Clancy R, Dorchak J, Somiari RI, Somiari S, Cutler ML, Mural RJ, Shriver CD. DNA aptamers against exon v10 of CD44 inhibit breast cancer cell migration. PLoS One 2014;9:e88712. [PMID: 24586375 DOI: 10.1371/journal.pone.0088712] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
548 Xi HQ, Wu XS, Wei B, Chen L. Eph receptors and ephrins as targets for cancer therapy. J Cell Mol Med. 2012;16:2894-2909. [PMID: 22862837 DOI: 10.1111/j.1582-4934.2012.01612.x] [Cited by in Crossref: 75] [Cited by in F6Publishing: 73] [Article Influence: 9.4] [Reference Citation Analysis]
549 Li BQ, You J, Huang T, Cai YD. Classification of non-small cell lung cancer based on copy number alterations. PLoS One 2014;9:e88300. [PMID: 24505469 DOI: 10.1371/journal.pone.0088300] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
550 Giaginis C, Tsoukalas N, Bournakis E, Alexandrou P, Kavantzas N, Patsouris E, Theocharis S. Ephrin (Eph) receptor A1, A4, A5 and A7 expression in human non-small cell lung carcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients' survival. BMC Clin Pathol 2014;14:8. [PMID: 24495444 DOI: 10.1186/1472-6890-14-8] [Cited by in Crossref: 36] [Cited by in F6Publishing: 42] [Article Influence: 4.5] [Reference Citation Analysis]
551 Miao H, Gale NW, Guo H, Qian J, Petty A, Kaspar J, Murphy AJ, Valenzuela DM, Yancopoulos G, Hambardzumyan D, Lathia JD, Rich JN, Lee J, Wang B. EphA2 promotes infiltrative invasion of glioma stem cells in vivo through cross-talk with Akt and regulates stem cell properties. Oncogene 2015;34:558-67. [PMID: 24488013 DOI: 10.1038/onc.2013.590] [Cited by in Crossref: 90] [Cited by in F6Publishing: 92] [Article Influence: 11.3] [Reference Citation Analysis]
552 Huang J, Hu W, Bottsford-Miller J, Liu T, Han HD, Zand B, Pradeep S, Roh JW, Thanapprapasr D, Dalton HJ, Pecot CV, Rupaimoole R, Lu C, Fellman B, Urbauer D, Kang Y, Jennings NB, Huang L, Deavers MT, Broaddus R, Coleman RL, Sood AK. Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib. Clin Cancer Res 2014;20:1846-55. [PMID: 24486585 DOI: 10.1158/1078-0432.CCR-13-2141] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
553 Tang H, Wei P, Duell EJ, Risch HA, Olson SH, Bueno-de-Mesquita HB, Gallinger S, Holly EA, Petersen G, Bracci PM, McWilliams RR, Jenab M, Riboli E, Tjønneland A, Boutron-Ruault MC, Kaaks R, Trichopoulos D, Panico S, Sund M, Peeters PH, Khaw KT, Amos CI, Li D. Axonal guidance signaling pathway interacting with smoking in modifying the risk of pancreatic cancer: a gene- and pathway-based interaction analysis of GWAS data. Carcinogenesis 2014;35:1039-45. [PMID: 24419231 DOI: 10.1093/carcin/bgu010] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
554 Keane N, Freeman C, Swords R, Giles FJ. EPHA3 as a novel therapeutic target in the hematological malignancies. Expert Review of Hematology 2014;5:325-40. [DOI: 10.1586/ehm.12.19] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
555 Molina-Vila MA, Nabau-Moretó N, Tornador C, Sabnis AJ, Rosell R, Estivill X, Bivona TG, Marino-Buslje C. Activating mutations cluster in the "molecular brake" regions of protein kinases and do not associate with conserved or catalytic residues. Hum Mutat 2014;35:318-28. [PMID: 24323975 DOI: 10.1002/humu.22493] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
556 Boyd AW, Bartlett PF, Lackmann M. Therapeutic targeting of EPH receptors and their ligands. Nat Rev Drug Discov 2014;13:39-62. [DOI: 10.1038/nrd4175] [Cited by in Crossref: 229] [Cited by in F6Publishing: 218] [Article Influence: 25.4] [Reference Citation Analysis]
557 Reungwetwattana T, Dy GK. Targeted therapies in development for non-small cell lung cancer. J Carcinog 2013;12:22. [PMID: 24574860 DOI: 10.4103/1477-3163.123972] [Cited by in Crossref: 46] [Cited by in F6Publishing: 50] [Article Influence: 5.1] [Reference Citation Analysis]
558 Falivelli G, Lisabeth EM, Rubio de la Torre E, Perez-Tenorio G, Tosato G, Salvucci O, Pasquale EB. Attenuation of eph receptor kinase activation in cancer cells by coexpressed ephrin ligands. PLoS One 2013;8:e81445. [PMID: 24348920 DOI: 10.1371/journal.pone.0081445] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 4.4] [Reference Citation Analysis]
559 Tognolini M, Hassan-Mohamed I, Giorgio C, Zanotti I, Lodola A. Therapeutic perspectives of Eph-ephrin system modulation. Drug Discov Today 2014;19:661-9. [PMID: 24291785 DOI: 10.1016/j.drudis.2013.11.017] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
560 Han X, Xu Y, Yang Y, Xi J, Tian W, Duggineni S, Huang Z, An J. Discovery and characterization of a novel cyclic peptide that effectively inhibits ephrin binding to the EphA4 receptor and displays anti-angiogenesis activity. PLoS One 2013;8:e80183. [PMID: 24265799 DOI: 10.1371/journal.pone.0080183] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
561 Rud AK, Boye K, Oijordsbakken M, Lund-Iversen M, Halvorsen AR, Solberg SK, Berge G, Helland A, Brustugun OT, Mælandsmo GM. Osteopontin is a prognostic biomarker in non-small cell lung cancer. BMC Cancer 2013;13:540. [PMID: 24215488 DOI: 10.1186/1471-2407-13-540] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
562 Tian R. Exploring intercellular signaling by proteomic approaches. Proteomics 2014;14:498-512. [DOI: 10.1002/pmic.201300259] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
563 Russo S, Incerti M, Tognolini M, Castelli R, Pala D, Hassan-Mohamed I, Giorgio C, De Franco F, Gioiello A, Vicini P, Barocelli E, Rivara S, Mor M, Lodola A. Synthesis and structure-activity relationships of amino acid conjugates of cholanic acid as antagonists of the EphA2 receptor. Molecules 2013;18:13043-60. [PMID: 24152675 DOI: 10.3390/molecules181013043] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
564 Goichberg P, Kannappan R, Cimini M, Bai Y, Sanada F, Sorrentino A, Signore S, Kajstura J, Rota M, Anversa P, Leri A. Age-associated defects in EphA2 signaling impair the migration of human cardiac progenitor cells. Circulation 2013;128:2211-23. [PMID: 24141256 DOI: 10.1161/CIRCULATIONAHA.113.004698] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 3.7] [Reference Citation Analysis]
565 Boissier P, Chen J, Huynh-Do U. EphA2 signaling following endocytosis: role of Tiam1. Traffic 2013;14:1255-71. [PMID: 24112471 DOI: 10.1111/tra.12123] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
566 Mori T, Maeda N, Inoue K, Sekimoto R, Tsushima Y, Matsuda K, Yamaoka M, Suganami T, Nishizawa H, Ogawa Y, Funahashi T, Shimomura I. A novel role for adipose ephrin-B1 in inflammatory response. PLoS One 2013;8:e76199. [PMID: 24098442 DOI: 10.1371/journal.pone.0076199] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
567 Nekrasova OV, Sharonov GV, Tikhonov RV, Kolosov PM, Astapova MV, Yakimov SA, Tagvey AI, Korchagina AA, Bocharova OV, Wulfson AN, Feofanov AV, Kirpichnikov MP. Receptor-binding domain of ephrin-A1: production in bacterial expression system and activity. Biochemistry (Mosc) 2012;77:1387-94. [PMID: 23244735 DOI: 10.1134/S0006297912120073] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
568 Posthumadeboer J, Piersma SR, Pham TV, van Egmond PW, Knol JC, Cleton-Jansen AM, van Geer MA, van Beusechem VW, Kaspers GJ, van Royen BJ, Jiménez CR, Helder MN. Surface proteomic analysis of osteosarcoma identifies EPHA2 as receptor for targeted drug delivery. Br J Cancer 2013;109:2142-54. [PMID: 24064975 DOI: 10.1038/bjc.2013.578] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 3.2] [Reference Citation Analysis]
569 Tognolini M, Incerti M, Pala D, Russo S, Castelli R, Hassan-Mohamed I, Giorgio C, Lodola A. Target hopping as a useful tool for the identification of novel EphA2 protein-protein antagonists. ChemMedChem 2014;9:67-72. [PMID: 24115725 DOI: 10.1002/cmdc.201300305] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
570 Strimpakos A, Pentheroudakis G, Kotoula V, De Roock W, Kouvatseas G, Papakostas P, Makatsoris T, Papamichael D, Andreadou A, Sgouros J, Zizi-Sermpetzoglou A, Kominea A, Televantou D, Razis E, Galani E, Pectasides D, Tejpar S, Syrigos K, Fountzilas G. The prognostic role of ephrin A2 and endothelial growth factor receptor pathway mediators in patients with advanced colorectal cancer treated with cetuximab. Clin Colorectal Cancer 2013;12:267-274.e2. [PMID: 24050852 DOI: 10.1016/j.clcc.2013.07.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
571 Theocharis S, Klijanienko J, Giaginis C, Alexandrou P, Patsouris E, Sastre-Garau X. Ephrin receptor (Eph) -A1, -A2, -A4 and -A7 expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival. Pathol Oncol Res 2014;20:277-84. [PMID: 24022400 DOI: 10.1007/s12253-013-9692-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
572 Yamada T, Yuasa M, Masaoka T, Taniyama T, Maehara H, Torigoe I, Yoshii T, Shinomiya K, Okawa A, Sotome S. After repeated division, bone marrow stromal cells express inhibitory factors with osteogenic capabilities, and EphA5 is a primary candidate. Bone 2013;57:343-54. [PMID: 24029132 DOI: 10.1016/j.bone.2013.08.028] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
573 Song Y, Zhao XP, Song K, Shang ZJ. Ephrin-A1 is up-regulated by hypoxia in cancer cells and promotes angiogenesis of HUVECs through a coordinated cross-talk with eNOS. PLoS One 2013;8:e74464. [PMID: 24040255 DOI: 10.1371/journal.pone.0074464] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
574 Hang TC, Tedford NC, Reddy RJ, Rimchala T, Wells A, White FM, Kamm RD, Lauffenburger DA. Vascular endothelial growth factor (VEGF) and platelet (PF-4) factor 4 inputs modulate human microvascular endothelial signaling in a three-dimensional matrix migration context. Mol Cell Proteomics 2013;12:3704-18. [PMID: 24023389 DOI: 10.1074/mcp.M113.030528] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
575 Nishimura M, Jung EJ, Shah MY, Lu C, Spizzo R, Shimizu M, Han HD, Ivan C, Rossi S, Zhang X. Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discov. 2013;3:1302-1315. [PMID: 24002999 DOI: 10.1158/2159-8290.cd-13-0159] [Cited by in Crossref: 103] [Cited by in F6Publishing: 107] [Article Influence: 11.4] [Reference Citation Analysis]
576 Lisabeth EM, Falivelli G, Pasquale EB. Eph receptor signaling and ephrins. Cold Spring Harb Perspect Biol 2013;5:a009159. [PMID: 24003208 DOI: 10.1101/cshperspect.a009159] [Cited by in Crossref: 214] [Cited by in F6Publishing: 225] [Article Influence: 23.8] [Reference Citation Analysis]
577 Dave A, Laurie K, Staffieri SE, Taranath D, Mackey DA, Mitchell P, Wang JJ, Craig JE, Burdon KP, Sharma S. Mutations in the EPHA2 gene are a major contributor to inherited cataracts in South-Eastern Australia. PLoS One 2013;8:e72518. [PMID: 24014202 DOI: 10.1371/journal.pone.0072518] [Cited by in Crossref: 20] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
578 Fujiwara H, Nishioka Y, Matsumoto H, Suginami K, Horie A, Tani H, Matsumura N, Baba T, Sato Y, Araki Y, Konishi I. Eph-ephrin A system regulates human choriocarcinoma-derived JEG-3 cell invasion. Int J Gynecol Cancer 2013;23:576-82. [PMID: 23429488 DOI: 10.1097/IGC.0b013e3182849e36] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
579 Kuusisto KM, Akinrinade O, Vihinen M, Kankuri-Tammilehto M, Laasanen SL, Schleutker J. copy number variation analysis in familial BRCA1/2-negative Finnish breast and ovarian cancer. PLoS One 2013;8:e71802. [PMID: 23967248 DOI: 10.1371/journal.pone.0071802] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
580 Sáinz-Jaspeado M, Huertas-Martinez J, Lagares-Tena L, Martin Liberal J, Mateo-Lozano S, de Alava E, de Torres C, Mora J, Del Muro XG, Tirado OM. EphA2-induced angiogenesis in ewing sarcoma cells works through bFGF production and is dependent on caveolin-1. PLoS One 2013;8:e71449. [PMID: 23951165 DOI: 10.1371/journal.pone.0071449] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
581 Guo C, Shao R, Correa AM, Behrens C, Johnson FM, Raso MG, Prudkin L, Solis LM, Nunez MI, Fang B, Roth JA, Wistuba II, Swisher SG, Lin T, Pataer A. Prognostic significance of combinations of RNA-dependent protein kinase and EphA2 biomarkers for NSCLC. J Thorac Oncol 2013;8:301-8. [PMID: 23370317 DOI: 10.1097/JTO.0b013e318282def7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
582 Liu Q, Zhou JP, Li B, Huang ZC, Dong HY, Li GY, Zhou K, Nie SL. Basic transcription factor 3 is involved in gastric cancer development and progression. World J Gastroenterol 2013; 19(28): 4495-4503 [PMID: 23901224 DOI: 10.3748/wjg.v19.i28.4495] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
583 Tiwari A, Schneider M, Fiorino A, Haider R, Okoniewski MJ, Roschitzki B, Uzozie A, Menigatti M, Jiricny J, Marra G. Early insights into the function of KIAA1199, a markedly overexpressed protein in human colorectal tumors. PLoS One. 2013;8:e69473. [PMID: 23936024 DOI: 10.1371/journal.pone.0069473] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 3.9] [Reference Citation Analysis]
584 Sonoda A, Mukaisho K, Nakayama T, Diem VT, Hattori T, Andoh A, Fujiyama Y, Sugihara H. Genetic lineages of undifferentiated-type gastric carcinomas analysed by unsupervised clustering of genomic DNA microarray data. BMC Med Genomics. 2013;6:25. [PMID: 23866769 DOI: 10.1186/1755-8794-6-25] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
585 Wu B, Zhang Z, Noberini R, Barile E, Giulianotti M, Pinilla C, Houghten RA, Pasquale EB, Pellecchia M. HTS by NMR of combinatorial libraries: a fragment-based approach to ligand discovery. Chem Biol 2013;20:19-33. [PMID: 23352136 DOI: 10.1016/j.chembiol.2012.10.015] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 6.1] [Reference Citation Analysis]
586 Barrett CW, Singh K, Motley AK, Lintel MK, Matafonova E, Bradley AM, Ning W, Poindexter SV, Parang B, Reddy VK. Dietary selenium deficiency exacerbates DSS-induced epithelial injury and AOM/DSS-induced tumorigenesis. PLoS One. 2013;8:e67845. [PMID: 23861820 DOI: 10.1371/journal.pone.0067845] [Cited by in Crossref: 55] [Cited by in F6Publishing: 63] [Article Influence: 6.1] [Reference Citation Analysis]
587 Ferguson BD, Liu R, Rolle CE, Tan YH, Krasnoperov V, Kanteti R, Tretiakova MS, Cervantes GM, Hasina R, Hseu RD, Iafrate AJ, Karrison T, Ferguson MK, Husain AN, Faoro L, Vokes EE, Gill PS, Salgia R. The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target. PLoS One 2013;8:e67668. [PMID: 23844053 DOI: 10.1371/journal.pone.0067668] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 4.4] [Reference Citation Analysis]
588 Park JE, Son AI, Zhou R. Roles of EphA2 in Development and Disease. Genes (Basel) 2013;4:334-57. [PMID: 24705208 DOI: 10.3390/genes4030334] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
589 Seiradake E, Schaupp A, del Toro Ruiz D, Kaufmann R, Mitakidis N, Harlos K, Aricescu AR, Klein R, Jones EY. Structurally encoded intraclass differences in EphA clusters drive distinct cell responses. Nat Struct Mol Biol 2013;20:958-64. [PMID: 23812375 DOI: 10.1038/nsmb.2617] [Cited by in Crossref: 64] [Cited by in F6Publishing: 56] [Article Influence: 7.1] [Reference Citation Analysis]
590 Kim Y, Park E, Noh H, Park S. Expression of EphA8-Fc in transgenic mouse embryos induces apoptosis of neural epithelial cells during brain development. Dev Neurobiol 2013;73:702-12. [PMID: 23696555 DOI: 10.1002/dneu.22092] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
591 Vermeer PD, Colbert PL, Wieking BG, Vermeer DW, Lee JH. Targeting ERBB receptors shifts their partners and triggers persistent ERK signaling through a novel ERBB/EFNB1 complex. Cancer Res 2013;73:5787-97. [PMID: 23811940 DOI: 10.1158/0008-5472.CAN-13-0760] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
592 Suksaweang S, Jiang TX, Roybal P, Chuong CM, Widelitz R. Roles of EphB3/ephrin-B1 in feather morphogenesis. Int J Dev Biol 2012;56:719-28. [PMID: 23319347 DOI: 10.1387/ijdb.120021rw] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
593 Makarov A, Ylivinkka I, Nyman TA, Hyytiäinen M, Keski-Oja J. Ephrin-As, Eph receptors and integrin α3 interact and colocalise at membrane protrusions of U251MG glioblastoma cells. Cell Biol Int 2013;37:1080-8. [PMID: 23686814 DOI: 10.1002/cbin.10134] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
594 Lohmüller T, Xu Q, Groves JT. Nanoscale obstacle arrays frustrate transport of EphA2-Ephrin-A1 clusters in cancer cell lines. Nano Lett 2013;13:3059-64. [PMID: 23668885 DOI: 10.1021/nl400874v] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
595 Dong P, Kaneuchi M, Konno Y, Watari H, Sudo S, Sakuragi N. Emerging therapeutic biomarkers in endometrial cancer. Biomed Res Int 2013;2013:130362. [PMID: 23819113 DOI: 10.1155/2013/130362] [Cited by in Crossref: 19] [Cited by in F6Publishing: 34] [Article Influence: 2.1] [Reference Citation Analysis]
596 Vasileiou I, Adamakis I, Patsouris E, Theocharis S. Ephrins and pain. Expert Opinion on Therapeutic Targets 2013;17:879-87. [DOI: 10.1517/14728222.2013.801456] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
597 Overman RC, Debreczeni JE, Truman CM, McAlister MS, Attwood TK. Biochemical and biophysical characterization of four EphB kinase domains reveals contrasting thermodynamic, kinetic and inhibition profiles. Biosci Rep 2013;33:e00040. [PMID: 23627399 DOI: 10.1042/BSR20130028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
598 Miyazaki K, Inokuchi M, Takagi Y, Kato K, Kojima K, Sugihara K. EphA4 is a prognostic factor in gastric cancer. BMC Clin Pathol. 2013;13:19. [PMID: 23738943 DOI: 10.1186/1472-6890-13-19] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
599 Schmitt F, Nguyen PH, Gupta N, Mayer D. Eph receptor B4 is a regulator of estrogen receptor alpha in breast cancer cells. J Recept Signal Transduct Res 2013;33:244-8. [PMID: 23725356 DOI: 10.3109/10799893.2013.795971] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
600 Rooney M, Devarakonda S, Govindan R. Genomics of squamous cell lung cancer. Oncologist 2013;18:707-16. [PMID: 23728941 DOI: 10.1634/theoncologist.2013-0063] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
601 Resnier P, Montier T, Mathieu V, Benoit JP, Passirani C. A review of the current status of siRNA nanomedicines in the treatment of cancer. Biomaterials 2013;34:6429-43. [PMID: 23727262 DOI: 10.1016/j.biomaterials.2013.04.060] [Cited by in Crossref: 139] [Cited by in F6Publishing: 139] [Article Influence: 15.4] [Reference Citation Analysis]
602 Jordan NV, Prat A, Abell AN, Zawistowski JS, Sciaky N, Karginova OA, Zhou B, Golitz BT, Perou CM, Johnson GL. SWI/SNF chromatin-remodeling factor Smarcd3/Baf60c controls epithelial-mesenchymal transition by inducing Wnt5a signaling. Mol Cell Biol 2013;33:3011-25. [PMID: 23716599 DOI: 10.1128/MCB.01443-12] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 4.0] [Reference Citation Analysis]
603 Jellinghaus S, Poitz DM, Ende G, Augstein A, Weinert S, Stütz B, Braun-Dullaeus RC, Pasquale EB, Strasser RH. Ephrin-A1/EphA4-mediated adhesion of monocytes to endothelial cells. Biochim Biophys Acta 2013;1833:2201-11. [PMID: 23707953 DOI: 10.1016/j.bbamcr.2013.05.017] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 3.9] [Reference Citation Analysis]
604 Ieguchi K, Tomita T, Omori T, Komatsu A, Deguchi A, Masuda J, Duffy SL, Coulthard MG, Boyd A, Maru Y. ADAM12-cleaved ephrin-A1 contributes to lung metastasis. Oncogene 2014;33:2179-90. [DOI: 10.1038/onc.2013.180] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 5.0] [Reference Citation Analysis]
605 Oricchio E, Wendel HG. Functional genomics lead to new therapies in follicular lymphoma. Ann N Y Acad Sci 2013;1293:18-24. [PMID: 23676193 DOI: 10.1111/nyas.12120] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
606 Ferluga S, Hantgan R, Goldgur Y, Himanen JP, Nikolov DB, Debinski W. Biological and structural characterization of glycosylation on ephrin-A1, a preferred ligand for EphA2 receptor tyrosine kinase. J Biol Chem 2013;288:18448-57. [PMID: 23661698 DOI: 10.1074/jbc.M113.464008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
607 Dai C, Brissova M, Reinert RB, Nyman L, Liu EH, Thompson C, Shostak A, Shiota M, Takahashi T, Powers AC. Pancreatic islet vasculature adapts to insulin resistance through dilation and not angiogenesis. Diabetes 2013;62:4144-53. [PMID: 23630302 DOI: 10.2337/db12-1657] [Cited by in Crossref: 79] [Cited by in F6Publishing: 79] [Article Influence: 8.8] [Reference Citation Analysis]
608 Nikolov DB, Xu K, Himanen JP. Eph/ephrin recognition and the role of Eph/ephrin clusters in signaling initiation. Biochim Biophys Acta 2013;1834:2160-5. [PMID: 23628727 DOI: 10.1016/j.bbapap.2013.04.020] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 7.1] [Reference Citation Analysis]
609 Binda E, Visioli A, Giani F, Lamorte G, Copetti M, Pitter KL, Huse JT, Cajola L, Zanetti N, DiMeco F, De Filippis L, Mangiola A, Maira G, Anile C, De Bonis P, Reynolds BA, Pasquale EB, Vescovi AL. The EphA2 receptor drives self-renewal and tumorigenicity in stem-like tumor-propagating cells from human glioblastomas. Cancer Cell 2012;22:765-80. [PMID: 23238013 DOI: 10.1016/j.ccr.2012.11.005] [Cited by in Crossref: 134] [Cited by in F6Publishing: 132] [Article Influence: 14.9] [Reference Citation Analysis]
610 Guijarro-Muñoz I, Sánchez A, Martínez-Martínez E, García JM, Salas C, Provencio M, Alvarez-Vallina L, Sanz L. Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab. Med Oncol 2013;30:572. [PMID: 23579861 DOI: 10.1007/s12032-013-0572-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
611 Villar-Cerviño V, Molano-Mazón M, Catchpole T, Valdeolmillos M, Henkemeyer M, Martínez LM, Borrell V, Marín O. Contact repulsion controls the dispersion and final distribution of Cajal-Retzius cells. Neuron 2013;77:457-71. [PMID: 23395373 DOI: 10.1016/j.neuron.2012.11.023] [Cited by in Crossref: 70] [Cited by in F6Publishing: 65] [Article Influence: 7.8] [Reference Citation Analysis]
612 Rood BR, Leprince D. Deciphering HIC1 control pathways to reveal new avenues in cancer therapeutics. Expert Opin Ther Targets 2013;17:811-27. [PMID: 23566242 DOI: 10.1517/14728222.2013.788152] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
613 Pretze M, Kuchar M, Bergmann R, Steinbach J, Pietzsch J, Mamat C. An efficient bioorthogonal strategy using CuAAC click chemistry for radiofluorinations of SNEW peptides and the role of copper depletion. ChemMedChem 2013;8:935-45. [PMID: 23559494 DOI: 10.1002/cmdc.201300053] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
614 Day BW, Stringer BW, Al-Ejeh F, Ting MJ, Wilson J, Ensbey KS, Jamieson PR, Bruce ZC, Lim YC, Offenhäuser C, Charmsaz S, Cooper LT, Ellacott JK, Harding A, Leveque L, Inglis P, Allan S, Walker DG, Lackmann M, Osborne G, Khanna KK, Reynolds BA, Lickliter JD, Boyd AW. EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme. Cancer Cell 2013;23:238-48. [PMID: 23410976 DOI: 10.1016/j.ccr.2013.01.007] [Cited by in Crossref: 137] [Cited by in F6Publishing: 139] [Article Influence: 15.2] [Reference Citation Analysis]
615 Prokopiou EM, Ryder SA, Walsh JJ. Tumour vasculature targeting agents in hybrid/conjugate drugs. Angiogenesis 2013;16:503-24. [DOI: 10.1007/s10456-013-9347-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
616 Coyle MP, Xu Q, Chiang S, Francis MB, Groves JT. DNA-mediated assembly of protein heterodimers on membrane surfaces. J Am Chem Soc 2013;135:5012-6. [PMID: 23530555 DOI: 10.1021/ja3101215] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
617 Incerti M, Tognolini M, Russo S, Pala D, Giorgio C, Hassan-Mohamed I, Noberini R, Pasquale EB, Vicini P, Piersanti S, Rivara S, Barocelli E, Mor M, Lodola A. Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. J Med Chem 2013;56:2936-47. [PMID: 23489211 DOI: 10.1021/jm301890k] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 4.4] [Reference Citation Analysis]
618 Villaflor VM, Salgia R. Targeted agents in non-small cell lung cancer therapy: What is there on the horizon? J Carcinog 2013;12:7. [PMID: 23599689 DOI: 10.4103/1477-3163.109253] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
619 Arthur A, Panagopoulos RA, Cooper L, Menicanin D, Parkinson IH, Codrington JD, Vandyke K, Zannettino AC, Koblar SA, Sims NA, Matsuo K, Gronthos S. EphB4 enhances the process of endochondral ossification and inhibits remodeling during bone fracture repair. J Bone Miner Res 2013;28:926-35. [DOI: 10.1002/jbmr.1821] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 4.2] [Reference Citation Analysis]
620 Barderas R, Mendes M, Torres S, Bartolomé RA, López-Lucendo M, Villar-Vázquez R, Peláez-García A, Fuente E, Bonilla F, Casal JI. In-depth characterization of the secretome of colorectal cancer metastatic cells identifies key proteins in cell adhesion, migration, and invasion. Mol Cell Proteomics 2013;12:1602-20. [PMID: 23443137 DOI: 10.1074/mcp.M112.022848] [Cited by in Crossref: 78] [Cited by in F6Publishing: 82] [Article Influence: 8.7] [Reference Citation Analysis]
621 Lisle JE, Mertens-Walker I, Rutkowski R, Herington AC, Stephenson SA. Eph receptors and their ligands: promising molecular biomarkers and therapeutic targets in prostate cancer. Biochim Biophys Acta 2013;1835:243-57. [PMID: 23396052 DOI: 10.1016/j.bbcan.2013.01.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 18] [Article Influence: 0.6] [Reference Citation Analysis]
622 Duggineni S, Mitra S, Lamberto I, Han X, Xu Y, An J, Pasquale EB, Huang Z. Design and Synthesis of Potent Bivalent Peptide Agonists Targeting the EphA2 Receptor. ACS Med Chem Lett 2013;4. [PMID: 24167659 DOI: 10.1021/ml3004523] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
623 Whitsett TG, Loftus JC, Winkles JA, Tran NL. New insights into the functional consequences of ephrin A3 mutations in non-small cell lung cancer. Transl Lung Cancer Res 2013;2:3-5. [PMID: 25806199 DOI: 10.3978/j.issn.2218-6751.2012.10.05] [Reference Citation Analysis]
624 Xue G, Hemmings BA. PKB/Akt-Dependent Regulation of Cell Motility. JNCI Journal of the National Cancer Institute 2013;105:393-404. [DOI: 10.1093/jnci/djs648] [Cited by in Crossref: 163] [Cited by in F6Publishing: 174] [Article Influence: 18.1] [Reference Citation Analysis]
625 Kawai H, Kobayashi M, Hiramoto-Yamaki N, Harada K, Negishi M, Katoh H. Ephexin4-mediated promotion of cell migration and anoikis resistance is regulated by serine 897 phosphorylation of EphA2. FEBS Open Bio 2013;3:78-82. [PMID: 23772378 DOI: 10.1016/j.fob.2013.01.002] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
626 Lahtela J, Corson LB, Hemmes A, Brauer MJ, Koopal S, Lee J, Hunsaker TL, Jackson PK, Verschuren EW. A high-content cellular senescence screen identifies candidate tumor suppressors, including EPHA3. Cell Cycle 2013;12:625-34. [PMID: 23324396 DOI: 10.4161/cc.23515] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
627 Miura K, Wakayama Y, Tanino M, Orba Y, Sawa H, Hatakeyama M, Tanaka S, Sabe H, Mochizuki N. Involvement of EphA2-mediated tyrosine phosphorylation of Shp2 in Shp2-regulated activation of extracellular signal-regulated kinase. Oncogene 2013;32:5292-301. [DOI: 10.1038/onc.2012.571] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]
628 Ståhl S, Kaminskyy VO, Efazat G, Hyrslova Vaculova A, Rodriguez-Nieto S, Moshfegh A, Lewensohn R, Viktorsson K, Zhivotovsky B. Inhibition of Ephrin B3-mediated survival signaling contributes to increased cell death response of non-small cell lung carcinoma cells after combined treatment with ionizing radiation and PKC 412. Cell Death Dis 2013;4:e454. [PMID: 23303128 DOI: 10.1038/cddis.2012.188] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
629 Shao Z, Zhu F, Song K, Zhang H, Liu K, Shang Z. EphA2/ephrinA1 mRNA expression and protein production in adenoid cystic carcinoma of salivary gland. J Oral Maxillofac Surg 2013;71:869-78. [PMID: 23298804 DOI: 10.1016/j.joms.2012.10.026] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
630 Buensuceso AV, Deroo BJ. The Ephrin Signaling Pathway Regulates Morphology and Adhesion of Mouse Granulosa Cells In Vitro1. Biology of Reproduction 2013;88. [DOI: 10.1095/biolreprod.112.100123] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
631 Naumann U, Harter P, Rubel J, Ilina E, Blank A, Esteban H, Mittelbronn M. Glioma cell migration and invasion as potential target for novel treatment strategies. Translational Neuroscience 2013;4. [DOI: 10.2478/s13380-013-0126-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
632 Etheridge SL, Brooke MA, Kelsell DP, Blaydon DC. Rhomboid proteins: a role in keratinocyte proliferation and cancer. Cell Tissue Res 2013;351:301-7. [DOI: 10.1007/s00441-012-1542-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
633 Duggineni S, Mitra S, Noberini R, Han X, Lin N, Xu Y, Tian W, An J, Pasquale EB, Huang Z. Design, synthesis and characterization of novel small molecular inhibitors of ephrin-B2 binding to EphB4. Biochem Pharmacol 2013;85:507-13. [PMID: 23253822 DOI: 10.1016/j.bcp.2012.12.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
634 Nordberg J, Mpindi JP, Iljin K, Pulliainen AT, Kallajoki M, Kallioniemi O, Elenius K, Elenius V. Systemic analysis of gene expression profiles identifies ErbB3 as a potential drug target in pediatric alveolar rhabdomyosarcoma. PLoS One 2012;7:e50819. [PMID: 23227212 DOI: 10.1371/journal.pone.0050819] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
635 Bulk E, Yu J, Hascher A, Koschmieder S, Wiewrodt R, Krug U, Timmermann B, Marra A, Hillejan L, Wiebe K, Berdel WE, Schwab A, Müller-Tidow C. Mutations of the EPHB6 receptor tyrosine kinase induce a pro-metastatic phenotype in non-small cell lung cancer. PLoS One 2012;7:e44591. [PMID: 23226491 DOI: 10.1371/journal.pone.0044591] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
636 Miller MA, Chin-Sang ID. Eph receptor signaling in C. elegans. WormBook 2012;:1-17. [PMID: 23197476 DOI: 10.1895/wormbook.1.151.1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
637 Chen W, Sin SH, Wen KW, Damania B, Dittmer DP. Hsp90 inhibitors are efficacious against Kaposi Sarcoma by enhancing the degradation of the essential viral gene LANA, of the viral co-receptor EphA2 as well as other client proteins. PLoS Pathog 2012;8:e1003048. [PMID: 23209418 DOI: 10.1371/journal.ppat.1003048] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 4.0] [Reference Citation Analysis]
638 Palomares K, Vigant F, Van Handel B, Pernet O, Chikere K, Hong P, Sherman SP, Patterson M, An DS, Lowry WE, Mikkola HK, Morizono K, Pyle AD, Lee B. Nipah virus envelope-pseudotyped lentiviruses efficiently target ephrinB2-positive stem cell populations in vitro and bypass the liver sink when administered in vivo. J Virol 2013;87:2094-108. [PMID: 23192877 DOI: 10.1128/JVI.02032-12] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
639 Rettew AN, Young ED, Lev DC, Kleinerman ES, Abdul-Karim FW, Getty PJ, Greenfield EM. Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines. Oncogenesis 2012;1:e34. [PMID: 23552467 DOI: 10.1038/oncsis.2012.34] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
640 Wang S, Noberini R, Stebbins JL, Das S, Zhang Z, Wu B, Mitra S, Billet S, Fernandez A, Bhowmick NA, Kitada S, Pasquale EB, Fisher PB, Pellecchia M. Targeted delivery of paclitaxel to EphA2-expressing cancer cells. Clin Cancer Res 2013;19:128-37. [PMID: 23155185 DOI: 10.1158/1078-0432.CCR-12-2654] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 4.0] [Reference Citation Analysis]
641 Soskis MJ, Ho HY, Bloodgood BL, Robichaux MA, Malik AN, Ataman B, Rubin AA, Zieg J, Zhang C, Shokat KM, Sharma N, Cowan CW, Greenberg ME. A chemical genetic approach reveals distinct EphB signaling mechanisms during brain development. Nat Neurosci 2012;15:1645-54. [PMID: 23143520 DOI: 10.1038/nn.3249] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
642 Atapattu L, Saha N, Llerena C, Vail ME, Scott AM, Nikolov DB, Lackmann M, Janes PW. Antibodies binding the ADAM10 substrate recognition domain inhibit Eph function. J Cell Sci 2012;125:6084-93. [PMID: 23108669 DOI: 10.1242/jcs.112631] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
643 Li Y, Nie Y, Cao J, Tu S, Lin Y, Du Y, Li Y. G-A variant in miR-200c binding site of EFNA1 alters susceptibility to gastric cancer. Mol Carcinog. 2014;53:219-229. [PMID: 23065816 DOI: 10.1002/mc.21966] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
644 Mamat C, Mosch B, Neuber C, Köckerling M, Bergmann R, Pietzsch J. Fluorine-18 Radiolabeling and Radiopharmacological Characterization of a Benzodioxolylpyrimidine-based Radiotracer Targeting the Receptor Tyrosine Kinase EphB4. ChemMedChem 2012;7:1991-2003. [DOI: 10.1002/cmdc.201200264] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
645 Zozulya SA, Udovichenko IP. [Eph family receptors as therapeutic targets]. Bioorg Khim 2012;38:267-79. [PMID: 22997698 DOI: 10.1134/s106816201203017x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
646 Park E, Kim Y, Noh H, Lee H, Yoo S, Park S. EphA/ephrin-A signaling is critically involved in region-specific apoptosis during early brain development. Cell Death Differ 2013;20:169-80. [PMID: 22976838 DOI: 10.1038/cdd.2012.121] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.1] [Reference Citation Analysis]
647 Salvucci O, Tosato G. Essential roles of EphB receptors and EphrinB ligands in endothelial cell function and angiogenesis. Adv Cancer Res 2012;114:21-57. [PMID: 22588055 DOI: 10.1016/B978-0-12-386503-8.00002-8] [Cited by in Crossref: 94] [Cited by in F6Publishing: 57] [Article Influence: 9.4] [Reference Citation Analysis]
648 Van den Broeck A, Vankelecom H, Van Eijsden R, Govaere O, Topal B. Molecular markers associated with outcome and metastasis in human pancreatic cancer. J Exp Clin Cancer Res 2012;31:68. [PMID: 22925330 DOI: 10.1186/1756-9966-31-68] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 4.5] [Reference Citation Analysis]
649 Ziyad S, Iruela-Arispe ML. Molecular mechanisms of tumor angiogenesis. Genes Cancer. 2011;2:1085-1096. [PMID: 22866200 DOI: 10.1177/1947601911432334] [Cited by in Crossref: 101] [Cited by in F6Publishing: 108] [Article Influence: 10.1] [Reference Citation Analysis]
650 Lamberto I, Qin H, Noberini R, Premkumar L, Bourgin C, Riedl SJ, Song J, Pasquale EB. Distinctive binding of three antagonistic peptides to the ephrin-binding pocket of the EphA4 receptor. Biochem J 2012;445:47-56. [PMID: 22489865 DOI: 10.1042/BJ20120408] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 3.0] [Reference Citation Analysis]
651 Giannoni E, Taddei ML, Parri M, Bianchini F, Santosuosso M, Grifantini R, Fibbi G, Mazzanti B, Calorini L, Chiarugi P. EphA2-mediated mesenchymal-amoeboid transition induced by endothelial progenitor cells enhances metastatic spread due to cancer-associated fibroblasts. J Mol Med (Berl). 2013;91:103-115. [PMID: 22903544 DOI: 10.1007/s00109-012-0941-9] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 3.0] [Reference Citation Analysis]
652 Petty A, Myshkin E, Qin H, Guo H, Miao H, Tochtrop GP, Hsieh JT, Page P, Liu L, Lindner DJ. A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo. PLoS One. 2012;7:e42120. [PMID: 22916121 DOI: 10.1371/journal.pone.0042120] [Cited by in Crossref: 81] [Cited by in F6Publishing: 80] [Article Influence: 8.1] [Reference Citation Analysis]
653 Ronchi CL, Leich E, Sbiera S, Weismann D, Rosenwald A, Allolio B, Fassnacht M. Single nucleotide polymorphism microarray analysis in cortisol-secreting adrenocortical adenomas identifies new candidate genes and pathways. Neoplasia 2012;14:206-18. [PMID: 22496620 DOI: 10.1593/neo.111758] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
654 Bailey CM, Morrison JA, Kulesa PM. Melanoma revives an embryonic migration program to promote plasticity and invasion. Pigment Cell Melanoma Res 2012;25:573-83. [PMID: 22681858 DOI: 10.1111/j.1755-148X.2012.01025.x] [Cited by in Crossref: 68] [Cited by in F6Publishing: 59] [Article Influence: 6.8] [Reference Citation Analysis]
655 Rud AK, Lund-Iversen M, Berge G, Brustugun OT, Solberg SK, Mælandsmo GM, Boye K. Expression of S100A4, ephrin-A1 and osteopontin in non-small cell lung cancer. BMC Cancer 2012;12:333. [PMID: 22853000 DOI: 10.1186/1471-2407-12-333] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
656 Zhuang G, Song W, Amato K, Hwang Y, Lee K, Boothby M, Ye F, Guo Y, Shyr Y, Lin L, Carbone DP, Brantley-Sieders DM, Chen J. Effects of cancer-associated EPHA3 mutations on lung cancer. J Natl Cancer Inst 2012;104:1182-97. [PMID: 22829656 DOI: 10.1093/jnci/djs297] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 3.9] [Reference Citation Analysis]
657 Saintigny P, Peng S, Zhang L, Sen B, Wistuba II, Lippman SM, Girard L, Minna JD, Heymach JV, Johnson FM. Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion. Mol Cancer Ther 2012;11:2021-32. [PMID: 22807579 DOI: 10.1158/1535-7163.MCT-12-0030] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 3.9] [Reference Citation Analysis]
658 Wang J, Ma J, Dong Y, Shen Z, Ma H, Wang X, Shi S, Wu J, Lu G, Peng L, Zhoud X. High expression of EphA1 in esophageal squamous cell carcinoma is associated with lymph node metastasis and advanced disease. APMIS 2013;121:30-7. [PMID: 23030051 DOI: 10.1111/j.1600-0463.2012.02941.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
659 Tandon M, Vemula SV, Sharma A, Ahi YS, Mittal S, Bangari DS, Mittal SK. EphrinA1-EphA2 interaction-mediated apoptosis and FMS-like tyrosine kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth in a breast cancer mouse model. J Gene Med 2012;14:77-89. [PMID: 22228563 DOI: 10.1002/jgm.1649] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
660 Sakamoto A, Kawashiri M, Ishibashi-Ueda H, Sugamoto Y, Yoshimuta T, Higashikata T, Ogino H, Tada H, Konno T, Hayashi K, Yamagishi M. Expression and Function of Ephrin-B1 and Its Cognate Receptor EphB2 in Human Abdominal Aortic Aneurysm. Int J Vasc Med 2012;2012:127149. [PMID: 22830028 DOI: 10.1155/2012/127149] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
661 Noberini R, Koolpe M, Lamberto I, Pasquale EB. Inhibition of Eph receptor-ephrin ligand interaction by tea polyphenols. Pharmacol Res 2012;66:363-73. [PMID: 22750215 DOI: 10.1016/j.phrs.2012.05.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
662 Sikkema AH, den Dunnen WF, Hulleman E, van Vuurden DG, Garcia-Manero G, Yang H, Scherpen FJ, Kampen KR, Hoving EW, Kamps WA, Diks SH, Peppelenbosch MP, de Bont ES. EphB2 activity plays a pivotal role in pediatric medulloblastoma cell adhesion and invasion. Neuro Oncol 2012;14:1125-35. [PMID: 22723427 DOI: 10.1093/neuonc/nos130] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
663 Pandiri AR, Sills RC, Ziglioli V, Ton TV, Hong HH, Lahousse SA, Gerrish KE, Auerbach SS, Shockley KR, Bushel PR, Peddada SD, Hoenerhoff MJ. Differential transcriptomic analysis of spontaneous lung tumors in B6C3F1 mice: comparison to human non-small cell lung cancer. Toxicol Pathol 2012;40:1141-59. [PMID: 22688403 DOI: 10.1177/0192623312447543] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
664 Tan P, Liu Y, Yu C, Su Z, Li G, Zhou X, Huang D, Zhang X, Qiu Y, Tian Y. EphA2 silencing in nasopharyngeal carcinoma leads to decreased proliferation, invasion and increased sensitization to paclitaxel. Oncol Lett 2012;4:429-34. [PMID: 23741245 DOI: 10.3892/ol.2012.746] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
665 Guo H, Nairn A, dela Rosa M, Nagy T, Zhao S, Moremen K, Pierce M. Transcriptional regulation of the protocadherin β cluster during Her-2 protein-induced mammary tumorigenesis results from altered N-glycan branching. J Biol Chem 2012;287:24941-54. [PMID: 22665489 DOI: 10.1074/jbc.M112.369355] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
666 Son AI, Park JE, Zhou R. The role of Eph receptors in lens function and disease. Sci China Life Sci 2012;55:434-43. [PMID: 22645087 DOI: 10.1007/s11427-012-4318-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
667 Casaletto JB, McClatchey AI. Spatial regulation of receptor tyrosine kinases in development and cancer. Nat Rev Cancer 2012;12:387-400. [PMID: 22622641 DOI: 10.1038/nrc3277] [Cited by in Crossref: 199] [Cited by in F6Publishing: 193] [Article Influence: 19.9] [Reference Citation Analysis]
668 Ho E, Dagnino L. Emerging role of ILK and ELMO2 in the integration of adhesion and migration pathways. Cell Adh Migr 2012;6:168-72. [PMID: 22568984 DOI: 10.4161/cam.20399] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
669 Tognolini M, Incerti M, Hassan-Mohamed I, Giorgio C, Russo S, Bruni R, Lelli B, Bracci L, Noberini R, Pasquale EB, Barocelli E, Vicini P, Mor M, Lodola A. Structure-activity relationships and mechanism of action of Eph-ephrin antagonists: interaction of cholanic acid with the EphA2 receptor. ChemMedChem 2012;7:1071-83. [PMID: 22529030 DOI: 10.1002/cmdc.201200102] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
670 Jin Y, Jakobsson L. The dynamics of developmental and tumor angiogenesis-a comparison. Cancers (Basel) 2012;4:400-19. [PMID: 24213317 DOI: 10.3390/cancers4020400] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
671 Nettersheim D, Westernströer B, Haas N, Leinhaas A, Brüstle O, Schlatt S, Schorle H. Establishment of a versatile seminoma model indicates cellular plasticity of germ cell tumor cells. Genes Chromosomes Cancer 2012;51:717-26. [PMID: 22489004 DOI: 10.1002/gcc.21958] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
672 Dömling A, Wang W, Wang K. Chemistry and biology of multicomponent reactions. Chem Rev 2012;112:3083-135. [PMID: 22435608 DOI: 10.1021/cr100233r] [Cited by in Crossref: 1512] [Cited by in F6Publishing: 1032] [Article Influence: 151.2] [Reference Citation Analysis]
673 Tognolini M, Giorgio C, Hassan Mohamed I, Barocelli E, Calani L, Reynaud E, Dangles O, Borges G, Crozier A, Brighenti F, Del Rio D. Perturbation of the EphA2–EphrinA1 System in Human Prostate Cancer Cells by Colonic (Poly)phenol Catabolites. J Agric Food Chem 2012;60:8877-84. [DOI: 10.1021/jf205305m] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
674 Oricchio E, Wendel HG. Mining the cancer genome uncovers therapeutic activity of EphA7 against lymphoma. Cell Cycle 2012;11:1076-80. [PMID: 22356769 DOI: 10.4161/cc.11.6.19451] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
675 Koes D, Khoury K, Huang Y, Wang W, Bista M, Popowicz GM, Wolf S, Holak TA, Dömling A, Camacho CJ. Enabling large-scale design, synthesis and validation of small molecule protein-protein antagonists. PLoS One 2012;7:e32839. [PMID: 22427896 DOI: 10.1371/journal.pone.0032839] [Cited by in Crossref: 81] [Cited by in F6Publishing: 73] [Article Influence: 8.1] [Reference Citation Analysis]
676 Mercurio FA, Marasco D, Pirone L, Pedone EM, Pellecchia M, Leone M. Solution structure of the first Sam domain of Odin and binding studies with the EphA2 receptor. Biochemistry 2012;51:2136-45. [PMID: 22332920 DOI: 10.1021/bi300141h] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
677 Arvanitis DN, Davy A. Regulation and misregulation of Eph/ephrin expression. Cell Adh Migr 2012;6:131-7. [PMID: 22568953 DOI: 10.4161/cam.19690] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
678 Noberini R, Rubio de la Torre E, Pasquale EB. Profiling Eph receptor expression in cells and tissues: a targeted mass spectrometry approach. Cell Adh Migr 2012;6:102-12. [PMID: 22568954 DOI: 10.4161/cam.19620] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 3.7] [Reference Citation Analysis]
679 Mosch B, Pietzsch D, Pietzsch J. Irradiation affects cellular properties and Eph receptor expression in human melanoma cells. Cell Adh Migr 2012;6:113-25. [PMID: 22568947 DOI: 10.4161/cam.20655] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [